


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update August 10 - August 16, 2020,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 33 2020 804 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

Mainstream Media

New York Times - Corona update

Coronavirus Vaccine Tracker

Coronavirus Drug and Treatment Tracker

To Fight Covid-19, Don't Neglect Immunity and Inflammation

Looking at Masks and Respiratory Health

Coronavirus Doctors Battle Another Scourge: Misinformation

What if 'Herd Immunity' Is Closer Than Scientists Thought?

Scientists See Signs of Lasting Immunity to Covid-19, Even After Mild Infections

Washington Post - Corona update

Halfway through the year, the pandemic is only intensifying in many states

Where states reopened and cases spiked after the U.S. shutdown

Italy shuts nightclubs, mandates masks as coronavirus case numbers rise

We could control the coronavirus by winter if we start using rapid tests

Coronavirus infections are rising in children, CDC says

People who recover from covid-19 don't need to be retested for 3 months, CDC says

Guardian - Corona update

South Korea on brink of new Covid crisis as church linked to outbreak

Covid-19 and children: it should be safe to reopen English schools

Covid-19 ethics: digital contact tracing

Trump calls out New Zealand's 'terrible' Covid surge, on day it records 9 cases

alarm over Covid case rates in 19 European countries

Sweden's Covid-19 strategist under fire over herd immunity emails

Key Articles

1. **Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19.** Cell 2020; Sekine T, Perez-Potti A, Rivera-Ballesteros O *et al.*

One of the many "million-dollar" COVID-19 questions is how long does immunity last after infection. There have been reports suggesting that cured patients can get re-infected. It is unclear if these positive test results were damaged virus particles that were still lingering or reflecting a new infection. This Cell paper provides some reassurance that even a SARS-CoV-2 infection with modest symptoms elicits robust, broad, and highly functional memory T cell responses, suggesting that natural exposure or infection may prevent recurrent episodes of severe COVID-19

2. **Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.** Curr Atheroscler Rep 2020; 22:48Moriarty PM, Gorby LK, Stroes ES *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32710255>

An enigmatic clinical features of COVID-19 is the frequently observed coagulopathy. Manifesting as microthrombi as well as venous thromboembolisms followed by (fatal) pulmonary. In this brief review, the authors

suggest that Lp(a) is a potential marker for increased risk of developing serious CVD complications. Lp(a) has both pro-inflammatory properties as well as anti-fibrinolytic activity. An elevated Lp(a) in COVID-19 patients could, therefore, prompt for initiating systemic anticoagulation as well as interventions to lower this lipoprotein. Further research is suggested to test this hypothesis

3. **Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-Cov-2 infection: a multicenter cohort study (PREDI-CO study).** Clin Microbiol Infect 2020; Bartoletti M, Giannella M, Scudeller L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781244>

Predicting at admission, which COVID-19 patient will end up in intensive care and need ventilation, could prompt for more a more personalized therapy to prevent these serious sequelae from manifesting. Based on data collected in 11 Italian hospitals and 1119 patients, the PREDI-CO score was developed; 644 patients were randomly assigned to the derivation cohort, and 469 used as the validation cohort. The score was based on the following parameters, age (>70 years), obesity, temperature, respiratory rate, lymphocytes, creatinine, CRP, and LDH. The area under the receiver operator curve was 0.89 in the derivation cohort and 0.84 in the validation group. Based on their findings the authors suggested that the PREDI-CO score can be used to allocate resources and prioritize treatments

4. **A Scoping Review of Registered Clinical Trials of Convalescent Plasma for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence (FAST Evidence).** Transfus Med Rev 2020; Zheng K, Liao G, Lalu MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771272>
5. **COVID-19: a cardiological point-of-view.** Deutsche medizinische Wochenschrift (1946) 2020; 145:1063-1067 Weckbach LT, Kellnar A, Stremmel C *et al.*
6. **Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19).** Biomed J 2020; Verma HK, Merchant N, Verma MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792167>
7. **Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis.** J Med Virol 2020; Sarkar S, Soni KD, Khanna P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776573>
8. **COVID-19 and pregnancy: A review of clinical characteristics, obstetric outcomes and vertical transmission.** Aust N Z J Obstet Gynaecol 2020; Pettiroso E, Giles M, Cole S, Rees M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779193>
9. **A multicenter study on epidemiological and clinical characteristics of 125 newborns born to women infected with COVID-19 by Turkish Neonatal Society.** Eur. J. Pediatr. 2020; Oncel MY, Akın IM, Kanburoglu MK

et al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776309>

10. **Epidemiology of COVID-19: A Systematic Review and Meta-analysis of Clinical Characteristics, Risk factors and Outcomes.** J Med Virol 2020; Li J, Huang DQ, Zou B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790106>
11. **COVID-19: A review of the proposed pharmacological treatments.** Eur. J. Pharmacol. 2020:173451 Lam S, Lombardi A, Ouanounou A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768505>
12. **COVID-19: Questions and answers from infectiology.** Deutsche medizinische Wochenschrift (1946) 2020; 145:1051-1056 Khatamzas E, Rothe C, Kroidl I.
13. **Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study.** The Lancet Diabetes & Endocrinology 2020; Holman N, Knighton P, Kar P *et al.*
14. **Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection.** Diabetes Metab Syndr 2020; 14:1463-1465 Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771919>
15. **Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.** Eur. J. Clin. Pharmacol. 2020:1-12 Chen C, Pan K, Wu B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780229>

Basic Science (53 articles)

1. **SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs.** Am J Physiol Lung Cell Mol Physiol 2020; Bartoszewski R, Dabrowski M, Jakiela B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32755307>
2. **The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.** Antiviral Res 2020:104902 Okamoto M, Toyama M, Baba M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32739404>
3. **Expansion of Single Cell Transcriptomics Data of SARS-CoV Infection in Human Bronchial Epithelial Cells to COVID-19.** Biol. Proced. Online 2020; 22:16 Zolfaghari Emameh R, Nosrati H, Eftekhari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32754004>
4. **The SARS-CoV-2 main protease as drug target.** Bioorg. Med. Chem. Lett. 2020; 30:127377 Ullrich S, Nitsche C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32738988>
5. **Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy.** bioRxiv 2020; Barone SM, Paul AGA, Muehling LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32766581>
6. **Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2.** bioRxiv 2020; Onabajo OO, Banday AR, Yan W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32743577>
7. **Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M(pro) and cathepsin L.** bioRxiv 2020; Sacco MD, Ma C, Lagarias P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32766590>
8. **Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.** bioRxiv 2020; Zhao P, Praissman JL, Grant OC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32743578>
9. **Application of Bayesian phylogenetic inference modelling for evolutionary genetic analysis and dynamic changes in 2019-nCoV.** Brief. Bioinform. 2020; Shao T, Wang W, Duan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32743639>

10. **Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19.** *Cell Stress Chaperones* 2020; Marino Gammazza A, Légaré S, Lo Bosco G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32754823>
11. **In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy.** *Chin J Integr Med* 2020; Wei TZ, Wang H, Wu XQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32740825>
12. **Potential mechanism prediction of Cold-Damp Plague Formula against COVID-19 via network pharmacology analysis and molecular docking.** *Chin. Med.* 2020; 15:78Han L, Wei XX, Zheng YJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32754224>
13. **Management of epigenomic networks entailed in coronavirus infections and COVID-19.** *Clin. Epigenetics* 2020; 12:118El Baba R, Herbein G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32758273>
14. **Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking Screening.** *Comb. Chem. High Throughput Screen.* 2020; Chtita S, Belhassan A, Aouidate A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32748740>
15. **Genus-specific pattern of intrinsically disordered central regions in the nucleocapsid protein of coronaviruses.** *Comput Struct Biotechnol J* 2020; 18:1884-1890Barik S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32765822>
16. **Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19.** *Crit Care* 2020; 24:484Nakamura H, Kinjo T, Arakaki W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32753065>
17. **Using Virus Sequencing to Determine Source of SARS-CoV-2 Transmission for Healthcare Worker.** *Emerg Infect Dis* 2020; 26:Safdar N, Moreno GK, Braun KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32758345>
18. **Small Particle Aerosol Exposure of African Green Monkeys to MERS-CoV as a Model for Highly Pathogenic Coronavirus Infection.** *Emerg Infect Dis* 2020; 26:Tutura A, Livingston V, Frick O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32744989>
19. **In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.** *Eur. J. Pharmacol.* 2020:173430Deshpande RR, Tiwari AP, Nyayanit N, Modak M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32758569>
20. **Epigenetic Regulator miRNA Pattern Differences Among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 World-Wide Isolates Delineated the Mystery Behind the Epic Pathogenicity and Distinct Clinical Characteristics of Pandemic COVID-19.** *Front Genet* 2020; 11:765Khan MA, Sany MRU, Islam MS, Islam A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32765592>
21. **Natural Polymorphisms Are Present in the Furin Cleavage Site of the SARS-CoV-2 Spike Glycoprotein.** *Front Genet* 2020; 11:783Xing Y, Li X, Gao X, Dong Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32765596>
22. **Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach.** *Front. Immunol.* 2020; 11:1664Choudhary S, Malik YS, Tomar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32754161>
23. **Pathological Aspects of COVID-19 as a Conformational Disease and the Use of Pharmacological Chaperones as a Potential Therapeutic Strategy.** *Front. Pharmacol.* 2020; 11:1095Aoe T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32754041>
24. **SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study.** *Heliyon* 2020; 6:e04502Ahmad J, Ikram S, Ahmad F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32754651>
25. **Role of key point Mutations in Receptor Binding Domain of SARS-CoV-2 Spike Glycoprotein.** *Infect Disord Drug Targets* 2020; Singh B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32753027>
26. **Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2.** *Infect Genet Evol* 2020:104490Kaur N, Singh R, Dar Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32745811>
27. **Bioinformatic Analysis of Correlation between Immune Infiltration and COVID-19 in Cancer Patients.** *Int J Biol Sci* 2020; 16:2464-2476Huang X, He C, Hua X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32760213>
28. **Use of Whole Genome Sequencing Data for a First in Silico Specificity Evaluation of the RT-qPCR Assays Used for SARS-CoV-2 Detection.** *Int J Mol Sci* 2020; 21:Gand M, Vanneste K, Thomas I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32759818>
29. **COVID-19 Solution.** *Int. J. Prev. Med.* 2020; 11:73Menicagli R, Limodio M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32742617>
30. **Roles of nurses and National Nurses Associations in combating COVID-19: Taiwan experience.** *Int Nurs Rev* 2020; Huang LH, Chen CM, Chen SF, Wang HH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32761608>
31. **Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us.** *Int. Rev. Immunol.* 2020:1-49Kumar V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32744465>
32. **In silico virtual screening, characterization, docking and molecular dynamics studies of crucial SARS-CoV-2 proteins.** *J Biomol Struct Dyn* 2020:1-11Alazmi M, Motwalli O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32762537>
33. **In silico investigation of phytoconstituents from Indian medicinal herb 'Tinospora cordifolia (giloy)' against SARS-CoV-2 (COVID-19) by molecular dynamics approach.** *J Biomol Struct Dyn* 2020:1-18Chowdhury P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32762511>
34. **Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.** *J Biomol Struct Dyn* 2020:1-13Fakhar Z, Faramarzi B, Pacifico S, Faramarzi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32741312>
35. **Identification of polyphenols from Broussonetia papyrifera as SARS CoV-2 main protease inhibitors using in silico docking and molecular dynamics simulation approaches.** *J Biomol Struct Dyn* 2020:1-14Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32762411>
36. **Predictive modeling by deep learning, virtual screening and molecular dynamics study of natural compounds against SARS-CoV-2 main protease.** *J Biomol Struct Dyn* 2020:1-19Joshi T, Joshi T, Pundir H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32752947>
37. **Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2.** *J Biomol Struct Dyn* 2020:1-11Sharma P, Vijayan V, Pant P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32741313>

38. **Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2.** *J Biomol Struct Dyn* 2020:1-14 Siddiqui AJ, Jahan S, Ashraf SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32752944>
39. **Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.** *J Biomol Struct Dyn* 2020:1-15 Vijayan V, Pant P, Vikram N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32741322>
40. **Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer.** *J. Cancer* 2020; 11:5289-5292 Zhang H, Quek K, Chen R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32742475>
41. **Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.** *J. Clin. Invest.* 2020; Skendros P, Mitsios A, Chrysanthopoulou A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32759504>
42. **Polyacylated anthocyanins constructively network with catalytic dyad residues of 3CL(pro) of 2019-nCoV than monomeric anthocyanins: A structural-relationship activity study with 10 anthocyanins using in-silico approaches.** *J. Mol. Graph. Model.* 2020; 100:107690 Khalifa I, Nawaz A, Sobhy R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32745925>
43. **In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation.** *J Thromb Haemost* 2020; Blasi A, von Meijenfeldt FA, Adelmeijer J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32762118>
44. **Can COVID-19 induce glioma tumorigenesis through binding cell receptors?** *Med. Hypotheses* 2020; 144:110009 Khan I, Hatiboglu MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32758869>
45. **Single-cell RNA sequencing analysis of human kidney reveals the presence of ACE2 receptor: A potential pathway of COVID-19 infection.** *Mol Genet Genomic Med* 2020:e1442 He Q, Mok TN, Yun L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32744436>
46. **In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19.** *OMICS* 2020; Sachdeva C, Wadhwa A, Kumari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32757981>
47. **Newcastle Disease Virus as a Vaccine Vector for SARS-CoV-2.** *Pathogens* 2020; 9 Shirvani E, Samal SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32751194>
48. **Understanding genomic diversity, pan-genome, and evolution of SARS-CoV-2.** *PeerJ* 2020; 8:e9576 Parlikar A, Kalia K, Sinha S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32742815>
49. **Presence of mismatches between diagnostic PCR assays and coronavirus SARS-CoV-2 genome.** *R Soc Open Sci* 2020; 7:200636 Khan KA, Cheung P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32742701>
50. **Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.** *Ssrn* 2020:3639618 Zhou T, Teng IT, Ollia AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32742241>
51. **Physiological Relevance of Angiotensin Converting Enzyme 2 As a Metabolic Linker and Therapeutic Implication of Mesenchymal Stem Cells in COVID-19 and Hypertension.** *Stem Cell Rev Rep* 2020; Saha S, Chakrabarti S, Singh PK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32748331>
52. **ACE2 isoform diversity predicts the host susceptibility of SARS-CoV-2.** *Transbound Emerg Dis* 2020; Gao S, Luan J, Cui H, Zhang L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32757470>
53. **SARS-CoV-2 jumping the species barrier: zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus.** *Travel Med Infect Dis* 2020:101830 Dhama K, Patel SK, Sharun K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32755673>

Biomarkers - Genetics (65 articles)

1. **The Role of Chest Radiograph, Procalcitonin and Moxifloxacin in Diagnosis and Management of Breast Cancer Patients with COVID-19.** *Acta Med Indones* 2020; 52:163-171 Rinaldi I, Muthalib A, Astowo P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778631>
2. **A cross-sectional study of immune seroconversion to SARS-CoV-2 in frontline maternity health professionals.** *Anaesthesia* 2020; Bampoe S, Lucas DN, Neall G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777861>
3. **Evaluation of coagulation status using viscoelastic testing in intensive care patients with coronavirus disease 2019 (COVID-19): An observational point prevalence cohort study.** *Aust. Crit. Care* 2020; Collett LW, Gluck S, Strickland RM, Reddi BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773357>
4. **Laboratory markers included in the Corona Score can identify false negative results on COVID-19 RT-PCR in the emergency room.** *Biochem. Med. (Zagreb)* 2020; 30:030402 Assandri R, Canetta C, Viganò G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774118>
5. **SARS-CoV-2 - a new challenge for laboratory medicine.** *Biochem. Med. (Zagreb)* 2020; 30:030503 Dodig S, Čepelak I, Čepelak Dodig D, Laškaj R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774121>
6. **Rate of re-positive RT-PCR test among patients recovered from COVID-19.** *Biochem. Med. (Zagreb)* 2020; 30:030401 Habibzadeh P, Sajadi MM, Emami A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774117>
7. **Strategies and perspectives to develop SARS-CoV-2 detection methods and diagnostics.** *Biomed. Pharmacother.* 2020; 129:110446 Jalandra R, Yadav AK, Verma D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768943>
8. **A diagnostic genomic signal processing (GSP)-based system for automatic feature analysis and detection of COVID-19.** *Brief. Bioinform.* 2020; Naeem SM, Mabrouk MS, Marzouk SY, Eldosoky MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793981>
9. **Profiling of Initial Available SARS-CoV-2 Sequences from Iranian Related COVID-19 Patients.** *Cell J* 2020; 22:148-150 Salehi N, Amiri-Yekta A, Totonchi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779445>
10. **Method comparison of SARS-CoV-2 serology assays involving three commercially available platforms and a novel in-house developed enzyme-linked immunosorbent assay.** *Clin. Biochem.* 2020; Seegmiller JC, Kokkaiser EL, Story SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791053>
11. **ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: An epidemiological study in the Asian population.** *Clin Chim Acta* 2020; Pati A, Mahto H, Padhi S, Panda AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791137>

12. **Usability and acceptability of home-based self-testing for SARS-CoV-2 antibodies for population surveillance.** *Clin Infect Dis* 2020; Atchison C, Pristerà P, Cooper E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785665>
13. **Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.** *Comput. Biol. Chem.* 2020; 88:107351Meyer-Almes FJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769050>
14. **Persistence of Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Positivity in COVID-19 Recovered Patients: A Call for Revised Hospital Discharge Criteria.** *Cureus* 2020; 12:e9048Jameel T, Baig M, Gazzaz ZJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782867>
15. **Assessment of sample pooling for SARS-CoV-2 molecular testing for screening of asymptomatic persons in Tunisia.** *Diagn. Microbiol. Infect. Dis.* 2020; 98:115125Abid S, Ferjani S, El Moussi A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768876>
16. **Preliminary Post-Mortem COVID-19 Evidence of Endothelial Injury and Factor VIII Hyperexpression.** *Diagnostics (Basel)* 2020; 10Cipolloni L, Sessa F, Bertozzi G *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784826>
17. **A specialized clinical laboratory center for the coronavirus disease 2019 (COVID-19) in Wuhan Leishenshan Hospital during the COVID-19 outbreak.** *Disaster Med Public Health Prep* 2020:1-11Xie Y, Wu W, Xie W *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782047>
18. **Characteristics of peripheral blood differential counts in hospitalized patients with COVID-19.** *Eur. J. Haematol.* 2020; Pakos I, Lo KB, Salacup G *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794205>
19. **Association Between ABO Blood Group System and COVID-19 Susceptibility in Wuhan.** *Front Cell Infect Microbiol* 2020; 10:404Fan Q, Zhang W, Li B *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793517>
20. **Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:431Boregowda U, Aloysius MM, Perisetti A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793616>
21. **Geographic and Genomic Distribution of SARS-CoV-2 Mutations.** *Front. Microbiol.* 2020; 11:1800Mercatelli D, Giorgi FM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793182>
22. **ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.** *Hypertension* 2020; 76:651-661Sharma RK, Stevens BR, Obukhov AG *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783758>
23. **Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.** *Immunity* 2020; Atyeo C, Fischinger S, Zohar T *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783920>
24. **Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients.** *Immunity* 2020; Zhu L, Yang P, Zhao Y *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783921>
25. **Guidelines for various laboratory sections in view of COVID-19: Recommendations from the Indian Association of Pathologists and Microbiologists.** *Indian J. Pathol. Microbiol.* 2020; 63:350-357Misra V, Agrawal R, Kumar H *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769321>
26. **Re-Testing for SARS-CoV-2: Patterns of Testing from a Large U.S. Healthcare System.** *Infect Control Hosp Epidemiol* 2020:1-7Kennedy AJ, Hilmes MK, Waddell L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772941>
27. **Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection.** *Infect Genet Evol* 2020:104498Klaassen K, Stankovic B, Zucic B *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771700>
28. **Increased Complement Receptor-3 levels in monocytes and granulocytes distinguish COVID-19 patients with pneumonia from those with mild symptoms.** *Int J Infect Dis* 2020; Gupta R, Gant VA, Williams B, Enver T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771640>
29. **Evaluating the efficacy of RT-qPCR SARS-CoV-2 direct approaches in comparison to RNA extraction.** *Int J Infect Dis* 2020; Israeli O, Beth-Din A, Paran N *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791207>
30. **Ferritin levels in patients with COVID-19: A poor predictor of mortality and hemophagocytic lymphohistiocytosis.** *Int. J. Lab. Hematol.* 2020; Feld J, Tremblay D, Thibaud S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790918>
31. **Is neutrophilia associated with mortality in COVID-19 patients? A meta-analysis and meta-regression.** *Int. J. Lab. Hematol.* 2020; Shi L, Wang Y, Liang X *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779881>
32. **Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review.** *Int. J. Lab. Hematol.* 2020; Wagner J, DuPont A, Larson S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779838>
33. **Clinical and hematological characteristics of 88 patients with COVID-19.** *Int. J. Lab. Hematol.* 2020; Zhang H, Cao X, Kong M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779860>
34. **Development and Evaluation of Novel and Highly Sensitive Single-Tube Nested Real-Time RT-PCR Assays for SARS-CoV-2 Detection.** *Int J Mol Sci* 2020; 21Yip CC, Sridhar S, Leung KH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784770>
35. **COVID-19 severity associates with pulmonary redistribution of CD1c+ DC and inflammatory transitional and nonclassical monocytes.** *J. Clin. Invest.* 2020; Sánchez-Cerrillo I, Landete P, Aldave B *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784290>
36. **Comparison of different serological assays for SARS-CoV-2 in real life.** *J Clin Virol* 2020; 130:104569Brochot E, Demey B, Handala L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769023>
37. **Clinical predictors and timing of cessation of viral RNA shedding in patients with COVID-19.** *J Clin Virol* 2020; 130:104577Corsini Campioli C, Cano Cevallos E, Assi M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777762>
38. **Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays.** *J Clin Virol* 2020; 130:104578Mostafa HH, Hardick J, Morehead E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777761>
39. **Multicenter evaluation of the NeuMoDx™ SARS-CoV-2 Test.** *J Clin Virol* 2020; 130:104583Mostafa HH, Lamson DM, Uhteg K *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791382>
40. **Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2.** *J Clin Virol* 2020; 130:104573Wirlden M, Feghoul L, Bertine M *et al*.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769025>
41. **Serial serum SARS-CoV-2 RNA results in two COVID-19 cases with severe respiratory failure.** *J Infect Chemother* 2020; Kodama T, Kouzaki Y, Kawano S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792249>
 42. **Spectrum of neonatal COVID-19 in Iran: 19 infants with SARS-CoV-2 perinatal infections with varying test results, clinical findings and outcomes.** *J Matern Fetal Neonatal Med* 2020:1-10Schwartz DA, Mohagheghi P, Beigi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783494>
 43. **COVID-19 diagnostics for resource-limited settings: Evaluation of "unextracted" qRT-PCR.** *J Med Virol* 2020; Adams NM, Leelawong M, Benton A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779772>
 44. **Consecutive false-negative rRT-PCR test results for SARS-CoV-2 in patients after clinical recovery from COVID-19.** *J Med Virol* 2020; Wang G, Yu N, Xiao W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779765>
 45. **Analysis of the application value of serum antibody detection for staging of COVID-19 infection.** *J Med Virol* 2020; Zheng Y, Yan M, Wang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779744>
 46. **Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations.** *J Thromb Haemost* 2020; Hardy M, Douxfils J, Bareille M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790951>
 47. **Exploring alternative swabs for use in SARS-CoV-2 detection from the oropharynx and anterior nares.** *J. Virol. Methods* 2020:113948Patriquin G, Davis I, Heinstein C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783913>
 48. **COVID-19 Viral Load in the Severity of and Recovery from Olfactory and Gustatory Dysfunction.** *Laryngoscope* 2020; Cho RH, To ZW, Yeung ZW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794209>
 49. **Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review.** *Life Sci* 2020:118207Mahendiratta S, Batra G, Sarma P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777301>
 50. **Clinical Characteristics of confirmed and clinically diagnosed patients with 2019 novel coronavirus pneumonia: a single-center, retrospective, case-control study.** *Med Clin (Barc)* 2020; Ke C, Yu C, Yue D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782109>
 51. **Pandemic printing: a novel 3D-printed swab for detecting SARS-CoV-2.** *Med. J. Aust.* 2020; Williams E, Bond K, Isles N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772375>
 52. **Vascular endothelial injury exacerbates coronavirus disease 2019: The role of endothelial glycocalyx protection.** *Microcirculation* 2020:e12654Okada H, Yoshida S, Hara A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791568>
 53. **Preliminary report of COVID-19 testing: experience of the clinical microbiology laboratory Universitas Indonesia, Jakarta, Indonesia.** *New Microbes New Infect* 2020; 37:100733Ibrahim F, Natasha A, Saharman YR, Sudarmono P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793354>
 54. **Outcomes of Coronavirus Disease 2019 Drive-Through Screening at an Academic Military Medical Center.** *Open Forum Infect Dis* 2020; 7:ofaa306Lindholm DA, Kiley JL, Jansen NK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782913>
 55. **Genome sequencing and the diagnosis of novel coronavirus (SARS-COV-2) in Africa: how far are we?** *Pan Afr. Med. J.* 2020; 36:80Shey M, Okeibunor JC, Yahaya AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774639>
 56. **Abnormal liver-related biomarkers in COVID-19 patients and the role of prealbumin.** *Saudi J. Gastroenterol.* 2020; Li T, Guo Y, Zhuang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769260>
 57. **First environmental surveillance for the presence of SARS-CoV-2 RNA in wastewater and river water in Japan.** *Sci Total Environ* 2020; 737:140405Haramoto E, Malla B, Thakali O, Kitajima M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783878>
 58. **First proof of the capability of wastewater surveillance for COVID-19 in India through detection of genetic material of SARS-CoV-2.** *Sci Total Environ* 2020; 746:141326Kumar M, Patel AK, Shah AV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768790>
 59. **Primary concentration - The critical step in implementing the wastewater based epidemiology for the COVID-19 pandemic: A mini-review.** *Sci Total Environ* 2020; 747:141245Lu D, Huang Z, Luo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768768>
 60. **Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry.** *Stroke* 2020:Strokeaha120031208Ntaios G, Michel P, Georgiopoulos G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787707>
 61. **The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?** *Thromb Res* 2020; 194:192-194Previtali G, Seghezzi M, Moioli V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788116>
 62. **Coronavirus Disease 2019: Hematological Anomalies and Antithrombotic Therapy.** *Tohoku J. Exp. Med.* 2020; 251:327-336Ornelas-Ricardo D, Jaloma-Cruz AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788506>
 63. **Testing wastewater to detect severe acute respiratory syndrome coronavirus 2 in communities.** *Trans. R. Soc. Trop. Med. Hyg.* 2020; Harries AD, Dar Berger S, Satyanarayana S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780856>
 64. **Investigation of SARS-CoV-2 in Semen of Patients in the Acute Stage of COVID-19 Infection.** *Urol. Int.* 2020:1-6Kayaaslan B, Korukluoglu G, Hasanoglu I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781456>
 65. **SARS-CoV-2 RNA Extraction Using Magnetic Beads for Rapid Large-Scale Testing by RT-qPCR and RT-LAMP.** *Viruses* 2020; 12Klein S, Müller TG, Khalid D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784757>

Children (22 articles)

1. **Imaging findings of SARS-CoV-2 infection in pediatrics: A systematic review of coronavirus disease 2019 (COVID-19) in 850 patients.** *Acad Radiol* 2020; Katal S, Johnston SK, Johnston JH, Gholamrezanezhad A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773328>

2. **SARS-CoV2 coronavirus: so far polite with children. Debatable immunological and non-immunological evidence.** *Allergol. Immunopathol. (Madr.)* 2020; Álvarez F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771236>
3. **Children with SARS-CoV-2 infection during an epidemic in China (outside of Hubei province).** *Ann Transl Med* 2020; 8:849Xiao F, Chen B, Xiao T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793693>
4. **COVID-19-associated apnea and circumoral cyanosis in a 3-week-old.** *BMC Pediatr.* 2020; 20:382Needleman JS, Hanson AE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787956>
5. **Cerebrospinal fluid features in SARS-CoV-2 RT-PCR positive patients.** *Clin Infect Dis* 2020; Bellon M, Schwebelin C, Lambeng N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770235>
6. **Pediatric neuropsychological evaluation via telehealth: Novel models of care.** *Clin. Neuropsychol.* 2020:1-13Pritchard AE, Sweeney K, Salorio CF, Jacobson LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787508>
7. **Pediatric transplantation in Europe during the COVID-19 pandemic: early impact on activity and healthcare.** *Clin. Transplant.* 2020:e14063Doná D, Torres Canizales J, Benetti E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32786120>
8. **Cardiac involvement in a pediatric patient with COVID-19: Looking beyond the nonspecific global cardiac injury.** *Echocardiography* 2020; Bhansali S, Minocha P, Phoon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770794>
9. **Dynamic changes of throat swabs RNA and serum antibodies for SARS-CoV-2 and their diagnostic performances in patients with COVID-19.** *Emerg Microbes Infect* 2020:1-33Qiu X, Xiang Y, Sun J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787527>
10. **The Perioperative Surgical Home in Pediatrics: Improve Patient Outcomes, Decrease Cancellations, Improve HealthCare Spending and Allocation of Resources during the COVID-19 Pandemic.** *Healthcare (Basel)* 2020; 8Hasan A, Zimmerman R, Gillock K, Parrish RH, 2nd. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784549>
11. **COVID -19 pandemic and paediatric population with special reference to congenital heart disease.** *Indian Heart J.* 2020; 72:141-144Malviya A, Yadav R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768011>
12. **Parents' Knowledge and Attitude towards COVID-19 in Children: A Jordanian Study.** *Int J Clin Pract* 2020:e13671Abuhammad S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780560>
13. **Children's Anxiety and Factors Related to the COVID-19 Pandemic: An Exploratory Study Using the Children's Anxiety Questionnaire and the Numerical Rating Scale.** *Int J Environ Res Public Health* 2020; 17Garcia de Avila MA, Hamamoto Filho PT, Jacob F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784898>
14. **All that glisters is not COVID: low prevalence of seroconversion against SARS-CoV-2 in a pediatric cohort of patients with Chilblain-like lesions.** *J Am Acad Dermatol* 2020; Denina M, Pellegrino F, Morotti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781180>
15. **Unique challenges in pediatric anesthesia created by COVID-19.** *J. Anesth.* 2020; Gai N, Maynes JT, Aoyama K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770277>
16. **Editorial Perspective: COVID-19 pandemic-related psychopathology in children and adolescents with mental illness.** *J. Child Psychol. Psychiatry* 2020; Jepsen OH, Rohde C, Nørremark B, Østergaard SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779748>
17. **Pediatric patients with COVID-19 admitted to intensive care units in Brazil: a prospective multicenter study.** *J. Pediatr. (Rio J.)* 2020; Prata-Barbosa A, Lima-Setta F, Santos GRD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781034>
18. **Burden of illness in households with SARS-CoV-2 infected children.** *J Pediatric Infect Dis Soc* 2020; Teherani MF, Kao CM, Camacho-Gonzalez A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780809>
19. **Multi-System Inflammatory Syndrome in a Child Mimicking Kawasaki Disease.** *J. Trop. Pediatr.* 2020; Gupta A, Gill A, Sharma M, Garg M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778886>
20. **Prevention of COVID-19 infection in a pediatric oncology ward in Wuhan.** *Pediatr Blood Cancer* 2020:e28424Zhang A, Hu Q, Liu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779822>
21. **Ten key points about COVID-19 in children: the shadows on the wall.** *Pediatr Pulmonol* 2020; Escosa-García L, Aguilera-Alonso D, Calvo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790245>
22. **Delayed acute bronchiolitis in infants hospitalized for COVID-19.** *Pediatr Pulmonol* 2020; 55:2211-2212Grimaud E, Challiol M, Guilbaud C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779885>

Clinical Features (44 articles)

1. **A Family Cluster of Coronavirus Disease (COVID-19) Infection with Different Clinical Manifestations.** *Acta Med Indones* 2020; 52:155-162Soedarsono S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778630>
2. **Coronavirus-19 and malaria: The great mimics.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3Kusotera T, Nhengu TG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787398>
3. **Direct COVID-19 Infection of Enterocytes: The Role of Hypochlorhydria.** *Am. J. Infect. Control* 2020; Dibner JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791258>
4. **Dermatological Manifestations in Patients With SARS-CoV-2: A Systematic Review.** *Cureus* 2020; 12:e9446Almutairi A, Alfaleh M, Alasheikh M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775112>
5. **Maculopapular eruptions associated to COVID-19: a subanalysis of the COVID-Piel study.** *Dermatol Ther* 2020; Català A, Galván-Casas C, Carretero-Hernández G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779280>
6. **Cutaneous, skin histopathological manifestations and relationship to COVID-19 infection patients.** *Dermatol Ther* 2020:e14157Li H, Zhao Y, Zhou L, Hu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770717>
7. **Familial Clustering of COVID-19 Skin Manifestations.** *Dermatol Ther* 2020:e14181Tatu AL, Nadasdy T, Bujoreanu FC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794366>
8. **The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea.** *Diabetes Metab. J.* 2020; Kim MK, Jeon JH, Kim SW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794386>
9. **Investigation and Analysis of 108 Cases of Home Isolated Patients with Mild COVID-19.** *Disaster Med Public Health Prep* 2020:1-13Li H, Peng YY, Lu JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782040>

10. **Symptomatology of COVID-19 from the otorhinolaryngology perspective: a survey of 223 SARS-CoV-2 RNA-positive patients.** *Eur Arch Otorhinolaryngol* 2020; Salepci E, Turk B, Ozcan SN *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794002>
11. **COVID-19 and Vitamin D: A lesson from the skin.** *Exp. Dermatol.* 2020; Slominski RM, Stefan J, Athar M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779213>
12. **COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:459Nasiri MJ, Haddadi S, Tahvildari A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793620>
13. **Persistent headache and persistent anosmia associated with COVID-19.** *Headache* 2020; Sampaio Rocha-Filho PA, Voss L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790179>
14. **Case series of headache characteristics in COVID-19; Headache can be an isolated symptom.** *Headache* 2020; Toptan T, Aktan Ç, Başarı A, Bolay H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790216>
15. **Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.** *Immunity* 2020; Atyeo C, Fischinger S, Zohar T *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783920>
16. **Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India.** *Indian J Med Res* 2020; Mohan A, Tiwari P, Bhatnagar S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773414>
17. **Atypical COVID-19: preventing transmission from unexpected cases.** *Infect Control Hosp Epidemiol* 2020;1-9Chow A, Htun HL, Mar Kyaw W *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787979>
18. **Comparison of COVID-19 Health Risks With Other Viral Occupational Hazards.** *Int J Health Serv* 2020;20731420946590Unger JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772627>
19. **Clinical Characteristics of Asymptomatic Patients with COVID-19: A Nationwide Cohort Study in South Korea.** *Int J Infect Dis* 2020; Jung CY, Park H, Kim DW *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771632>
20. **Clinical and hematological characteristics of 88 patients with COVID-19.** *Int. J. Lab. Hematol.* 2020; Zhang H, Cao X, Kong M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779860>
21. **All that glisters is not COVID: low prevalence of seroconversion against SARS-CoV-2 in a pediatric cohort of patients with Chilblain-like lesions.** *J Am Acad Dermatol* 2020; Denina M, Pellegrino F, Morotti F *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781180>
22. **Review of adverse cutaneous reactions of pharmacologic interventions for coronavirus disease 2019 (COVID-19): a guide for the dermatologist.** *J Am Acad Dermatol* 2020; Martinez-Lopez A, Cuenca-Barrales C, Montero-Vilchez T *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777318>
23. **Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series.** *J. Clin. Endocrinol. Metab.* 2020; Brancatella A, Ricci D, Cappellani D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780854>
24. **Urticaria and COVID-19 infection: a critical appraisal.** *J Dermatolog Treat* 2020;1-4Pathania YS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772600>
25. **COVID-19 in Renal Transplant Patient Presenting With Active Typical Symptoms and Resolved Atypical Symptoms.** *J Investig Med High Impact Case Rep* 2020; 8:2324709620949307Adapa S, Konala VM, Naramala S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779481>
26. **Hilar lymphadenopathy, a novel finding in the setting of coronavirus disease (COVID-19): a case report.** *J Med Case Rep* 2020; 14:124Mughal MS, Rehman R, Osman R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771058>
27. **Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study.** *J. Med. Microbiol.* 2020; Khan M, Khan H, Khan S, Nawaz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783802>
28. **Epidemiology of COVID-19: A Systematic Review and Meta-analysis of Clinical Characteristics, Risk factors and Outcomes.** *J Med Virol* 2020; Li J, Huang DQ, Zou B *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790106>
29. **Ocular findings in patients with coronavirus disease 2019 (COVID-19) in an outbreak hospital.** *J Med Virol* 2020; Öncül H, Öncül FY, Alakus MF *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776614>
30. **Clinical Characteristics of Moderate COVID-19 Patients Aggravation in Wuhan Stadium Cabin Hospital: A 571 Cases of Retrospective Cohort Study.** *J Med Virol* 2020; Shu L, Wang X, Li M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779760>
31. **A COVID-19 patient with intense burning pain.** *J. Neurovirol.* 2020; Aksan F, Nelson EA, Swedish KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779108>
32. **Reticular skin eruption as the initial sign of coronavirus disease 2019 infection.** *JAAD Case Rep* 2020; 6:790-792Strom MA, Trager MH, Geskin LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775588>
33. **Epidemiological, Clinical, and Immunological Features of a Cluster of COVID-19-Contracted Hemodialysis Patients.** *Kidney Int Rep* 2020; 5:1333-1341Ma Y, Diao B, Lv X *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775837>
34. **Clinical Characteristics of confirmed and clinically diagnosed patients with 2019 novel coronavirus pneumonia: a single-center, retrospective, case-control study.** *Med Clin (Barc)* 2020; Ke C, Yu C, Yue D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782109>
35. **COVID-19 in an asymptomatic patient undergoing FDG PET/CT.** *Radiol Case Rep* 2020; 15:1809-1812Johnson LN, Vesselle H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788945>
36. **Anosmia: A marker of infection by the new corona virus.** *Respir Med Case Rep* 2020; 31:101129Daher VB, Soares Oliveira DS, Daher Júnior MF *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775188>
37. **Anosmia: a missing link in the neuroimmunology of coronavirus disease 2019 (COVID-19).** *Rev. Neurosci.* 2020; Yazdanpanah N, Saghazadeh A, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776905>
38. **[Coronavirus disease 2019 (COVID-19) and headaches].** *Rinsho Shinkeigaku.* 2020; Suzuki K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779603>
39. **COVID-19: Clinical aspects and therapeutics responses.** *Saudi Pharm J* 2020; 28:1004-1008Khan S, Ali A, Shi H *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788835>
40. **Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry.** *Stroke* 2020;Strokeaha120031208Ntaios G, Michel P, Georgiopoulos G *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787707>

41. **Coronavirus Disease 2019: Hematological Anomalies and Antithrombotic Therapy.** *Tohoku J. Exp. Med.* 2020; 251:327-336Ornelas-Ricardo D, Jaloma-Cruz AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788506>
42. **[Ocular manifestations of coronavirus infection COVID-19 (clinical observation)].** *Vestn. Oftalmol.* 2020; 136:118-123Maychuk DY, Atlas SN, Loshkareva AO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779465>
43. **Epidemiological and clinical differences of coronavirus disease 2019 patients with distinct viral exposure history.** *Virulence* 2020; 11:1015-1023Gao Y, Ma X, Bi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787496>
44. **Clinical characteristics of patients with COVID-19 presenting with gastrointestinal symptoms as initial symptoms: Retrospective case series.** *World J Clin Cases* 2020; 8:2950-2958Yang TY, Li YC, Wang SC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775377>

CNS (30 articles)

1. **Fragile Endothelium and Brain Dysregulated Neurochemical Activity in COVID-19.** *ACS Chem Neurosci* 2020; 11:2159-2162Alharthy A, Faqih F, Memish ZA, Karakitsos D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32786343>
2. **Acute Cerebellar Strokes with Anoxic Brain Injury After a Cardiopulmonary Arrest in SARS-CoV-2 Patient.** *Acta Med Indones* 2020; 52:177-178Janjua T, Moscote-Salazar LR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778633>
3. **Generalized Status Epilepticus as a Possible Manifestation of COVID-19.** *Acta Neurol. Scand.* 2020; Abdulsalam MA, Abdulsalam AJ, Shehab D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779768>
4. **Towards Neuro-CoViD-19.** *Bioinformation* 2020; 16:288-292Chiappelli F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773986>
5. **Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?** *Cell. Mol. Neurobiol.* 2020; Romero A, Ramos E, López-Muñoz F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772307>
6. **Cerebrospinal fluid features in SARS-CoV-2 RT-PCR positive patients.** *Clin Infect Dis* 2020; Bellon M, Schwebelin C, Lambeng N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770235>
7. **Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients.** *Crit Care* 2020; 24:491Helms J, Kremer S, Merdji H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771053>
8. **Noteworthy Neurological Manifestations Associated With COVID-19 Infection.** *Cureus* 2020; 12:e8992Elkhouly A, Kaplan AC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775074>
9. **Neurological emergencies associated with COVID-19: stroke and beyond.** *Emerg Radiol* 2020; Agarwal A, Pinho M, Raj K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778985>
10. **Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement.** *Eur. J. Neurol.* 2020; Senel M, Abu-Rumeileh S, Michel D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781484>
11. **Neurology practice during the COVID-19 outbreak and post-pandemic era: experiences and challenges.** *Eur. J. Neurol.* 2020; Tang Y, Xing Y, Cui L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779848>
12. **Neuromuscular diseases and Covid-19: Advices from scientific societies and early observations in Italy.** *Eur. J. Transl. Myol.* 2020; 30:9032Angelini C, Siciliano G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782765>
13. **The Consequences of Coronavirus-Induced Cytokine Storm Are Associated With Neurological Diseases, Which May Be Preventable.** *Front. Neurol.* 2020; 11:745Isacson O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793108>
14. **Persistent headache and persistent anosmia associated with COVID-19.** *Headache* 2020; Sampaio Rocha-Filho PA, Voss L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790179>
15. **Case series of headache characteristics in COVID-19; Headache can be an isolated symptom.** *Headache* 2020; Toptan T, Aktan Ç, Başarı A, Bolay H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790216>
16. **Meningoencephalitis from SARS-CoV-2 infection.** *IDCases* 2020; 21:e00919Hafizi F, Kherani S, Shams M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775207>
17. **The impact of COVID-19 pandemic on congenital heart surgery practice: An alarming change in demographics.** *J. Card. Surg.* 2020; Korun O, Yurdakök O, Arslan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789953>
18. **Potential impact and challenges associated with Parkinson's disease patient care amidst the COVID-19 global pandemic.** *J Clin Mov Disord* 2020; 7:7Elbeddini A, To A, Tayefehchamani Y, Wen C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782815>
19. **SARS-CoV-2 associated Guillain-Barré syndrome.** *J. Neurol.* 2020; Pelea T, Reuter U, Schmidt C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770414>
20. **COVID-19 Viral Load in the Severity of and Recovery from Olfactory and Gustatory Dysfunction.** *Laryngoscope* 2020; Cho RH, To ZW, Yeung ZW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794209>
21. **Impact of COVID-19 pandemic on cognition in Parkinson's disease.** *Mov Disord* 2020; Palermo G, Tommasini L, Baldacci F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776602>
22. **Impact of COVID-19 Pandemic on Parkinson's Disease: A Cross-sectional Survey of 568 Spanish Patients.** *Mov Disord* 2020; Santos García D, Oreiro M, Pérez P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776601>
23. **Perceived Worsening of Tics in Adult Patients with Tourette Syndrome after the COVID-19 Outbreak.** *Mov Disord Clin Pract* 2020; 7:725-726Mataix-Cols D, Ringberg H, Fernández de la Cruz L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775530>
24. **Virtual Parkinson's Disease Support Groups in the COVID-19 Era: Social Connection in the Time of Social Distancing.** *Mov Disord Clin Pract* 2020; 7:739-740Subramanian I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775536>
25. **Multiple sclerosis management during the COVID-19 pandemic.** *Mult. Scler.* 2020;1352458520948231Moss BP, Mahajan KR, Bermel RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775536>

- term=32772807
26. **Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.** *Mult Scler Relat Disord* 2020; 45:102442Iannetta M, Cesta N, Stingone C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777745>
 27. **COVID-19 infection recurrence presenting with meningoencephalitis.** *New Microbes New Infect* 2020; 37:100732Mardani M, Nadji SA, Sarhangipor KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789020>
 28. **Anosmia: A marker of infection by the new corona virus.** *Respir Med Case Rep* 2020; 31:101129Daher VB, Soares Oliveira DS, Daher Júnior MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775188>
 29. **Anosmia: a missing link in the neuroimmunology of coronavirus disease 2019 (COVID-19).** *Rev. Neurosci.* 2020; Yazdanpanah N, Saghadzadeh A, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776905>
 30. **[Coronavirus disease 2019 (COVID-19) and headaches].** *Rinsho Shinkeigaku.* 2020; Suzuki K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779603>

Coagulation (35 articles)

1. **The clinical impact of COVID-19 epidemic in the hematologic setting.** *Adv Biol Regul* 2020; 77:100742Finelli C, Parisi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773103>
2. **Thromboembolic events and Covid-19.** *Adv Biol Regul* 2020; 77:100735Ribes A, Vardon-Bounes F, Mémier V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773098>
3. **Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19.** *Am. J. Health Syst. Pharm.* 2020; Sagardia LM, Daniels LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780853>
4. **Development of pulmonary embolism in a nonhospitalized patient with COVID-19 who did not receive venous thromboembolism prophylaxis.** *Am. J. Health Syst. Pharm.* 2020; Uppuluri EM, Shapiro NL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780839>
5. **Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection.** *Am. J. Med.* 2020; McCullough PA, Kelly RJ, Ruocco G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771461>
6. **Evaluation of coagulation status using viscoelastic testing in intensive care patients with coronavirus disease 2019 (COVID-19): An observational point prevalence cohort study.** *Aust. Crit. Care* 2020; Collett LW, Gluck S, Strickland RM, Reddi BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773357>
7. **SARS-CoV-2 - a new challenge for laboratory medicine.** *Biochem. Med. (Zagreb)* 2020; 30:030503Dodig S, Čepelak I, Čepelak Dodig D, Laškaj R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774121>
8. **Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19.** *Br. J. Haematol.* 2020; Chistolini A, Ruberto F, Alessandri F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779783>
9. **Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study.** *Circulation* 2020; 142:611-614Masi P, Hékimian G, Lejeune M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776849>
10. **Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.** *Clin Immunol* 2020:108555Laurence J, Mulvey JJ, Seshadri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771488>
11. **Percutaneous Mechanical Pulmonary Thrombectomy in a Patient With Pulmonary Embolism as a First Presentation of COVID-19.** *Cureus* 2020; 12:e9506Holat GJ, Durer C, Durer S, Gupta P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775114>
12. **Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.** *Curr Atheroscler Rep* 2020; 22:48Moriarty PM, Gorby LK, Stroes ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710255>
13. **Neurological emergencies associated with COVID-19: stroke and beyond.** *Emerg Radiol* 2020; Agarwal A, Pinho M, Raj K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778985>
14. **A Peculiar Case of Priapism: The Hypercoagulable State in Patients with Severe COVID-19 Infection.** *Eur J Case Rep Intern Med* 2020; 7:001779Lam G, McCarthy R, Haider R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789142>
15. **Severe immune thrombocytopenia in a critically ill COVID-19 patient.** *Int J Infect Dis* 2020; Martincic Z, Skopec B, Renner K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771636>
16. **Infiltrative Shadows in COVID-19: Pneumonia or Pulmonary Embolism?** *Intern Med* 2020; Nagai H, Yamamoto S, Saito M, Adachi E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788547>
17. **Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19.** *J Am Coll Cardiol* 2020; 76:122-124Paranjpe I, Fuster V, Lala A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32387623>
18. **Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports.** *J Artif Organs* 2020; Bidar F, Hékimian G, Martin-Toutain I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789604>
19. **Response to Letter: "Reply to 'High frequency of Antiphospholipid Antibodies in Critically-ill COVID19 patients: a Link with Hypercoagulability?'".** *J Intern Med* 2020; Pineton de Chambrun M, Frere C, Miyara M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772406>
20. **Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression.** *J Med Virol* 2020; Khinda J, Janjua NZ, Cheng S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776551>
21. **COVID-19 as a Blood Clotting Disorder Masquerading as a Respiratory Illness: A Cerebrovascular Perspective and Therapeutic Implications for Stroke Thrombectomy.** *J. Neuroimaging* 2020; Janardhan V, Janardhan V, Kalousek V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776617>
22. **Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis.** *J. Neurol.* 2020; Patel U, Malik P, Shah D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770412>

23. **Liver abnormality may develop cerebral venous sinus thrombosis in COVID-19.** *J Neurol Sci* 2020; 417:117076Neshin SAS, Basirjafari S, Saberi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791424>
24. **Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations.** *J Thromb Haemost* 2020; Hardy M, Douxfils J, Bareille M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790951>
25. **In vivo demonstration of microvascular thrombosis in severe COVID-19.** *J. Thromb. Thrombolysis* 2020; do Espirito Santo DA, Lemos ACB, Miranda CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789730>
26. **Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.** *J. Thromb. Thrombolysis* 2020; Mattioli M, Benfaremo D, Mancini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794132>
27. **Reticular skin eruption as the initial sign of coronavirus disease 2019 infection.** *JAAD Case Rep* 2020; 6:790-792Strom MA, Trager MH, Geskin LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775588>
28. **Hyper- and hypocoagulability in COVID-19 as assessed by thromboelastometry. Two case reports.** *Korean J Anesthesiol* 2020; Kong R, Hutchinson N, Görlinger K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773727>
29. **Incidental and simultaneous finding of pulmonary thrombus and COVID-19 pneumonia in a cancer patient derived to (18)F-FDG PET/CT. New pathophysiological insights from hybrid imaging.** *Radiol Case Rep* 2020; 15:1803-1805Ferrando-Castagnetto F, Wakfie-Corieh CG, Garcia AMB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788944>
30. **The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management.** *Thromb Res* 2020; 194:101-115Abou-Ismael MY, Diamond A, Kapoor S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788101>
31. **Portal vein thrombosis in a patient with COVID-19.** *Thromb Res* 2020; 194:150-152Franco-Moreno A, Piniella-Ruiz E, Montoya-Adarraga J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788107>
32. **The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?** *Thromb Res* 2020; 194:192-194Previtali G, Seghezzi M, Moiola V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788116>
33. **Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study.** *Thromb Res* 2020; 194:209-215Stessel B, Vanvuchelen C, Bruckers L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788120>
34. **D-dimer level is associated with the severity of COVID-19.** *Thromb Res* 2020; 195:219-225Yu HH, Qin C, Chen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777639>
35. **Coronavirus Disease 2019: Hematological Anomalies and Antithrombotic Therapy.** *Tohoku J. Exp. Med.* 2020; 251:327-336Ornelas-Ricardo D, Jaloma-Cruz AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788506>

Complications (72 articles)

1. **Acute Cerebellar Strokes with Anoxic Brain Injury After a Cardiopulmonary Arrest in SARS-CoV-2 Patient.** *Acta Med Indones* 2020; 52:177-178Janjua T, Moscote-Salazar LR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778633>
2. **Generalized Status Epilepticus as a Possible Manifestation of COVID-19.** *Acta Neurol. Scand.* 2020; Abdulsalam MA, Abdulsalam AJ, Shehab D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779768>
3. **Veno-venous extracorporeal membrane oxygenation and prone ventilation for therapeutic management of COVID-19.** *Acute Med Surg* 2020; 7:e546Kasai T, Bunya N, Wada K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793357>
4. **Thromboembolic events and Covid-19.** *Adv Biol Regul* 2020; 77:100735Ribes A, Vardon-Boues F, Mémier V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773098>
5. **Ventilators are not the answer in Africa.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3Madzimbamuto FD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787397>
6. **Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19.** *Am. J. Health Syst. Pharm.* 2020; Sagardia LM, Daniels LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780853>
7. **Development of pulmonary embolism in a nonhospitalized patient with COVID-19 who did not receive venous thromboembolism prophylaxis.** *Am. J. Health Syst. Pharm.* 2020; Uppuluri EM, Shapiro NL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780839>
8. **Haemodynamic Monitoring and Management in COVID-19 Intensive Care Patients: An International Survey.** *Anaesth Crit Care Pain Med* 2020; Michard F, Malbrain ML, Martin GS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781167>
9. **Acute lower limb ischemia as clinical presentation of COVID-19 infection.** *Ann. Vasc. Surg.* 2020; Mietto C, Salice V, Ferraris M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791191>
10. **The microbial coinfection in COVID-19.** *Appl. Microbiol. Biotechnol.* 2020:1-9Chen X, Liao B, Cheng L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780290>
11. **The absorbing filter Oxiris in severe COVID-19 patients: A case series.** *Artif. Organs* 2020; Fengmin S, Zhang H, Zhu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779737>
12. **COVID-19-associated apnea and circumoral cyanosis in a 3-week-old.** *BMC Pediatr.* 2020; 20:382Needleman JS, Hanson AE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787956>
13. **Liver transplantation and COVID-19: a case report and cross comparison between two identical twins with COVID-19.** *BMC Surg.* 2020; 20:181Nikoupour H, Arasteh P, Gholami S, Nikeghbalian S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770973>
14. **Hazardous mismatch between pulmonary pathogens and antibiotic treatments in COVID-19 patients.** *Br J Anaesth* 2020; Coppola S, Ciabattini A, Pozzi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792137>
15. **Co-Reactivation of Human Herpesvirus alpha Subfamily (HSV I and VZV) in Critically Ill Patient with COVID-19.** *Br. J. Dermatol.* 2020; Xu R, Zhou Y, Cai L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790074>
16. **Weather the Cytokine Storm: A Report of Successful Management of a Colon Cancer Survivor and a Critically Ill Patient with COVID-19.** *Case Rep. Oncol.* 2020; 13:754-759Khalid M, Dernaika T, Jacob L *et*

- al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774271>
17. **COVID-19 in Patients With Renal Cell Carcinoma in the Russian Federation.** *Clin. Genitourin. Cancer* 2020; Tsimafeyeu I, Alekseeva G, Berkut M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792300>
 18. **Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19.** *Clin Infect Dis* 2020; Nelson BC, Laracy J, Shoucri S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772069>
 19. **Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients.** *Crit Care* 2020; 24:491 Helms J, Kremer S, Merdji H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771053>
 20. **COVID-19 as a Possible Cause of Functional Exhaustion of CD4 and CD8 T-cells and Persistent Cause of Methicillin-Sensitive Staphylococcus aureus Bacteremia.** *Cureus* 2020; 12:e9000 Choudhury I, Han H, Manthani K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775080>
 21. **COVID-19 Complicated by Spontaneous Pneumothorax.** *Cureus* 2020; 12:e9104 Mallick T, Dinesh A, Engdahl R, Sabado M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789049>
 22. **Novel coronavirus 2019 (COVID-19) and epidermolysis bullosa: report of three cases.** *Dermatol Ther* 2020:e14194 Abdollahimajd F, Youssefian L, Pourani MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794270>
 23. **Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab.** *Dermatol Ther* 2020:e14186 Kiss N, Lórinicz K, Medvecz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794375>
 24. **Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection.** *Diabetes Metab Syndr* 2020; 14:1463-1465 Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771919>
 25. **Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature.** *Diabetes Metab Syndr* 2020; 14:1459-1462 Reddy PK, Kuchay MS, Mehta Y, Mishra SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771918>
 26. **Neurological emergencies associated with COVID-19: stroke and beyond.** *Emerg Radiol* 2020; Agarwal A, Pinho M, Raj K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778985>
 27. **[Comment] The challenges of planetary mental health in the COVID-19 era.** *Exp. Ther. Med.* 2020; 20:1843-1844 Tsamakis K, Dimitrakakis G, Stefanadi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782492>
 28. **The Consequences of Coronavirus-Induced Cytokine Storm Are Associated With Neurological Diseases, Which May Be Preventable.** *Front. Neurol.* 2020; 11:745 Isacson O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793108>
 29. **Early de-escalation of DAPT after PCI: implications of the latest randomized trials in the COVID era.** *Indian Heart J.* 2020; 72:209-211 Mahajan K, Batra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768026>
 30. **Re-emergence of TIVA in COVID times.** *Indian J. Anaesth.* 2020; 64:S125-s131 Chokshi T, Channabasappa S, Verghese DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773851>
 31. **All India difficult airway association (AIDAA) consensus guidelines for airway management in the operating room during the COVID-19 pandemic.** *Indian J. Anaesth.* 2020; 64:S107-s115 Patwa A, Shah A, Garg R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773848>
 32. **Indian Resuscitation Council (IRC) suggested guidelines for Comprehensive Cardiopulmonary Life Support (CCLS) for suspected or confirmed coronavirus disease (COVID-19) patient.** *Indian J. Anaesth.* 2020; 64:S91-s96 Singh B, Garg R, Chakra Rao SSC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773845>
 33. **Simultaneous circulation of COVID-19 and flu in Italy: potential combined effects on the risk of death?** *Int J Infect Dis* 2020; Capone A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768696>
 34. **Severe immune thrombocytopenia in a critically ill COVID-19 patient.** *Int J Infect Dis* 2020; Martincic Z, Skopec B, Renner K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771636>
 35. **Bacterial co-infections with SARS-CoV-2.** *IUBMB Life* 2020; Mirzaei R, Goodarzi P, Asadi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770825>
 36. **COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases.** *J Am Acad Dermatol* 2020; Kasperkiewicz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781181>
 37. **Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19.** *J Am Coll Cardiol* 2020; 76:122-124 Paranjpe I, Fuster V, Lala A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32387623>
 38. **Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports.** *J Artif Organs* 2020; Bidar F, Hékimian G, Martin-Toutain I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789604>
 39. **Cardiac tamponade in COVID-19 patients: Management and outcomes.** *J. Card. Surg.* 2020; Hakmi H, Sohail A, Brathwaite C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790006>
 40. **Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit - High mortality rate in infected patients with haematologic malignancies.** *J Clin Virol* 2020; 130:104574 Biernat MM, Zińczuk A, Biernat P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769026>
 41. **Knowledge and Behaviors of Adults with Underlying Health Conditions During the Onset of the COVID-19 U.S. Outbreak: The Chicago COVID-19 Comorbidities Survey.** *J. Community Health* 2020:1-9 O'Connor R, Opsasnick L, Benavente JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780294>
 42. **What every Intensivist should know about COVID-19 associated acute kidney injury.** *J Crit Care* 2020; 60:91-95 Ostermann M, Lumlertgul N, Forni LG, Hoste E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777758>
 43. **Severe COVID-19 outcomes in patients with psoriasis.** *J Eur Acad Dermatol Venereol* 2020; Lima XT, Cueva MA, Lopes EM, Alora MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780905>
 44. **COVID-19 and comorbidities: Deleterious impact on infected patients.** *J Infect Public Health* 2020; Ejaz H, Alsrhani A, Zafar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788073>
 45. **Response to Letter: "Reply to 'High frequency of Antiphospholipid Antibodies in Critically-ill COVID19 patients: a Link with Hypercoagulability?'".** *J Intern Med* 2020; Pineton de Chambrun M, Frere C, Miyara M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772406>
 46. **Epstein-Barr Virus Versus Novel Coronavirus-Induced Hemophagocytic Lymphohistocytosis: The Uncharted Waters.** *J Investig Med High Impact Case Rep* 2020; 8:2324709620950107 Amir R, Kichloo A, Singh J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787459>

47. **Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression.** *J Med Virol* 2020; Khinda J, Janjua NZ, Cheng S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776551>
48. **COVID-19 and AIDS: outcomes from the co-existence of two global pandemics and the importance of chronic antiretroviral therapy.** *J Med Virol* 2020; Patel RH, Acharya A, Mohan M, Byrareddy SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779740>
49. **The Outcome of COVID-19 in Patients with Hematological Malignancy.** *J Med Virol* 2020; Yigenoglu TN, Ata N, Altuntas F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776581>
50. **SARS-CoV-2 associated Guillain-Barré syndrome.** *J. Neurol.* 2020; Pelea T, Reuter U, Schmidt C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770414>
51. **Liver abnormality may develop cerebral venous sinus thrombosis in COVID-19.** *J Neurol Sci* 2020; 417:117076Neshin SAS, Basirjafari S, Saberi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791424>
52. **Pediatric patients with COVID-19 admitted to intensive care units in Brazil: a prospective multicenter study.** *J. Pediatr. (Rio J.)* 2020; Prata-Barbosa A, Lima-Setta F, Santos GRD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781034>
53. **In vivo demonstration of microvascular thrombosis in severe COVID-19.** *J. Thromb. Thrombolysis* 2020; do Espírito Santo DA, Lemos ACB, Miranda CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789730>
54. **SARS-CoV-2 Causes a Specific Dysfunction of the Kidney Proximal Tubule.** *Kidney Int* 2020; Werion A, Belkhir L, Perrot M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791255>
55. **Hyper- and hypocoagulability in COVID-19 as assessed by thromboelastometry. Two case reports.** *Korean J Anesthesiol* 2020; Kong R, Hutchinson N, Görlinger K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773727>
56. **The Unrecognized Threat of Secondary Bacterial Infections with COVID-19.** *mBio* 2020; 11 Vaillancourt M, Jorth P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769090>
57. **Cardiovascular comorbidities and complications associated with coronavirus disease 2019.** *Med J Armed Forces India* 2020; 76:253-260Mahajan K, Chandra KS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773926>
58. **“Hybrid tracheostomy”: a low risk procedure for tracheostomy in COVID-19 patients.** *Medizinische Klinik - Intensivmedizin und Notfallmedizin* 2020; Nibbe L, Jungehülsing M, Röber S *et al.*
59. **Vascular endothelial injury exacerbates coronavirus disease 2019: The role of endothelial glycocalyx protection.** *Microcirculation* 2020:e12654Okada H, Yoshida S, Hara A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791568>
60. **The Face of COVID-19: Facial Pressure Wounds Related to Prone Positioning in Patients Undergoing Ventilation in the Intensive Care Unit.** *Otolaryngol Head Neck Surg* 2020:194599820951470Jiang ST, Fang CH, Chen JT, Smith RV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779961>
61. **Implications of COVID-19 infections in sickle cell disease.** *Pan Afr. Med. J.* 2020; 36:81John NA, John JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774640>
62. **Delayed acute bronchiolitis in infants hospitalized for COVID-19.** *Pediatr Pulmonol* 2020; 55:2211-2212Grimaud E, Chailion M, Guilbaud C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779885>
63. **The course of COVID-19 in a 55-year-old patient diagnosed with severe idiopathic pulmonary arterial hypertension.** *Pulm Circ* 2020; 10:2045894020936659Mandler D, Lichtblau M, Ulrich S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782784>
64. **Incidental and simultaneous finding of pulmonary thrombus and COVID-19 pneumonia in a cancer patient derived to (18)F-FDG PET/CT. New pathophysiological insights from hybrid imaging.** *Radiol Case Rep* 2020; 15:1803-1805Ferrando-Castagnetto F, Wakiie-Corieh CG, García AMB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788944>
65. **Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.** *Rheumatol. Int.* 2020; Montero F, Martínez-Barrio J, Serrano-Benavente B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794113>
66. **Delayed COVID Respiratory Failure: What every front line healthcare worker needs to know.** *Rom. J. Intern. Med.* 2020; Hedges MS, Jackson KD, Matcha GV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780717>
67. **History of Stroke Is Independently Associated With In-Hospital Death in Patients With COVID-19.** *Stroke* 2020:Strokeaha120030685Kummer BR, Klang E, Stein LK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772679>
68. **Portal vein thrombosis in a patient with COVID-19.** *Thromb Res* 2020; 194:150-152Franco-Moreno A, Piniella-Ruiz E, Montoya-Adaraga J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788107>
69. **D-dimer level is associated with the severity of COVID-19.** *Thromb Res* 2020; 195:219-225Yu HH, Qin C, Chen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777639>
70. **COVID-19 clinical manifestations and treatment strategies among solid-organ recipients: a systematic review of cases.** *Transpl Infect Dis* 2020:e13427Moosavi SA, Mashhadiagha A, Motazedian N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779820>
71. **COVID-19 in solid organ transplant recipients: No difference in survival compared to general population.** *Transpl Infect Dis* 2020:e13421Rinaldi M, Bartoletti M, Bussini L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779808>
72. **Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques.** *Zool Res* 2020:1-10Song TZ, Zheng HY, Han JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772513>

Cured – Recovered (3 articles)

1. **Modified rehabilitation exercises for mild cases of COVID-19.** *Ann Palliat Med* 2020; Zha L, Xu X, Wang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787373>
2. **Persistence of Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Positivity in COVID-19 Recovered Patients: A Call for Revised Hospital Discharge Criteria.** *Cureus* 2020; 12:e9048Jameel T, Baig M, Gazzaz ZJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782867>

3. **COVID-19 infection recurrence presenting with meningoencephalitis.** *New Microbes New Infect* 2020; 37:100732Mardani M, Nadji SA, Sarhangipor KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789020>

Cardiovascular disease (63 articles)

1. **Thromboembolic events and Covid-19.** *Adv Biol Regul* 2020; 77:100735Ribes A, Vardon-Bounes F, Mémier V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773098>
2. **Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19.** *Am. J. Health Syst. Pharm.* 2020; Sagardia LM, Daniels LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780853>
3. **Development of pulmonary embolism in a nonhospitalized patient with COVID-19 who did not receive venous thromboembolism prophylaxis.** *Am. J. Health Syst. Pharm.* 2020; Uppuluri EM, Shapiro NL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780839>
4. **Role of the renin angiotensin system in the development of severe COVID-19 in hypertensive patients.** *Am J Physiol Lung Cell Mol Physiol* 2020; Silva-Aguiar RP, Peruchetti DB, Rocco PRM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783619>
5. **Acute lower limb ischemia as clinical presentation of COVID-19 infection.** *Ann. Vasc. Surg.* 2020; Mietto C, Salice V, Ferraris M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791191>
6. **Aerosol-generating procedures in thoracic surgery in the COVID-19 era in Malaysia.** *Asian Cardiovasc. Thorac. Ann.* 2020:218492320950898Sathiamurthy N, Balasubbiah N, Dharmaraj B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787442>
7. **Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19.** *Br. J. Haematol.* 2020; Chistolini A, Ruberto F, Alessandri F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779783>
8. **Cardiovascular disease during the COVID-19 pandemic: Think ahead, protect hearts, reduce mortality.** *Cardiol J* 2020; Li G, Saguner AM, An J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789839>
9. **Analysis of cardiopulmonary findings in COVID-19 fatalities: High incidence of pulmonary artery thrombi and acute suppurative bronchopneumonia.** *Cardiovasc. Pathol.* 2020; 49:107263Grosse C, Grosse A, Salzer HJF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784110>
10. **Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study.** *Circulation* 2020; 142:611-614Masi P, Hékimian G, Lejeune M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776849>
11. **COVID-19 among heart transplant recipients in Germany: a multicenter survey.** *Clin Res Cardiol* 2020; Rivinius R, Kaya Z, Schramm R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783099>
12. **Multiple Lacunar Cerebral Infarcts as the Initial Presentation of COVID-19.** *Cureus* 2020; 12:e9638Elshereye A, Erdinc B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789103>
13. **Percutaneous Mechanical Pulmonary Thrombectomy in a Patient With Pulmonary Embolism as a First Presentation of COVID-19.** *Cureus* 2020; 12:e9506Hoilat GJ, Durer C, Durer S, Gupta P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775114>
14. **Angiotensin-converting Enzyme 2 roles in the Pathogenesis of COVID-19.** *Curr. Hypertens. Rev.* 2020; Kenarkoohi A, Maleki M, Safari T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778033>
15. **COVID-19: a cardiological point-of-view.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:1063-1067Weckbach LT, Kellnar A, Stremmel C *et al.*
16. **Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection.** *Diabetes Metab Syndr* 2020; 14:1463-1465Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771919>
17. **SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.** *EBioMedicine* 2020; 58:102907Chung MK, Karnik S, Saef J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771682>
18. **Cardiac involvement in a pediatric patient with COVID-19: Looking beyond the nonspecific global cardiac injury.** *Echocardiography* 2020; Bhansali S, Minocha P, Phoon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770794>
19. **Neurological emergencies associated with COVID-19: stroke and beyond.** *Emerg Radiol* 2020; Agarwal A, Pinho M, Raj K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778985>
20. **Non-Bacterial Thrombotic Endocarditis: A Presentation of COVID-19.** *Eur J Case Rep Intern Med* 2020; 7:001811Balata D, Mellergård J, Ekqvist D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789144>
21. **A Peculiar Case of Priapism: The Hypercoagulable State in Patients with Severe COVID-19 Infection.** *Eur J Case Rep Intern Med* 2020; 7:001779Lam G, McCarthy R, Haider R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789142>
22. **COVID-19 Associated Pneumonia and Pleural Effusion Masquerading as Heart Failure in Rheumatic Heart Disease.** *Eur J Case Rep Intern Med* 2020; 7:001842Malik J, Javed N, Naeem H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789145>
23. **Effects of the COVID-19 pandemic on myocardial perfusion imaging for ischemic heart disease.** *Eur J Nucl Med Mol Imaging* 2020; Nappi C, Megna R, Acampa W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778930>
24. **Impact of myocardial injury on mortality in patients with COVID-19: a meta-analysis.** *Hellenic J. Cardiol.* 2020; Sanz-Sánchez J, Vrachatis DA, Reimers B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781301>
25. **ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.** *Hypertension* 2020; 76:651-661Sharma RK, Stevens BR, Obukhov AG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783758>
26. **Will the hidden specter of acute coronary syndrome (ACS) and ST-segment elevation myocardial infarction (STEMI) emerge from the avalanche of COVID-19?** *Indian Heart J.* 2020; 72:192-193Kapoor A, Yadav R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768020>
27. **COVID -19 pandemic and paediatric population with special reference to congenital heart disease.** *Indian Heart J.* 2020; 72:141-144Malviya A, Yadav R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768011>

28. **Outcomes of patients diagnosed with COVID-19 in the early postoperative period following cardiac surgery.** *Interact. Cardiovasc. Thorac. Surg.* 2020; Yates MT, Balmforth D, Lopez-Marco A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791519>
29. **The association between cardiac injury and outcomes in hospitalized patients with COVID-19.** *Intern Emerg Med* 2020; Karbalai Saleh S, Oraii A, Soleimani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772283>
30. **Infiltrative Shadows in COVID-19: Pneumonia or Pulmonary Embolism?** *Intern Med* 2020; Nagai H, Yamamoto S, Saito M, Adachi E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788547>
31. **Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19.** *J Am Coll Cardiol* 2020; 76:122-124Paranjpe I, Fuster V, Lala A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32387623>
32. **Syncope, Brugada syndrome, and COVID-19 lung disease.** *J Arrhythm* 2020; 36:768-770Pasquetto G, Conti GB, Susana A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778849>
33. **Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports.** *J Artif Organs* 2020; Bidar F, Hékimian G, Martin-Toutain I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789604>
34. **Early respiratory outcomes following cardiac surgery in patients with COVID-19.** *J. Card. Surg.* 2020; Barkhordari K, Khajavi MR, Bagheri J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789988>
35. **International study on impact of COVID-19 on cardiac and thoracic aortic aneurysm surgery.** *J. Card. Surg.* 2020; Idhrees M, Bashir M, Mousavizadeh M, Hosseini S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789915>
36. **The impact of COVID-19 pandemic on congenital heart surgery practice: An alarming change in demographics.** *J. Card. Surg.* 2020; Korun O, Yurdakök O, Arslan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789953>
37. **Clinical and Imaging Characteristics in Patients with SARS-CoV-2 Infection and Acute Intracranial Hemorrhage.** *J Clin Med* 2020; 9Nawabi J, Morotti A, Wildgruber M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781623>
38. **Response to Letter: "Reply to 'High frequency of Antiphospholipid Antibodies in Critically-ill COVID19 patients: a Link with Hypercoagulability?'".** *J Intern Med* 2020; Pineton de Chambrun M, Frere C, Miyara M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772406>
39. **Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus.** *J. Mol. Cell. Cardiol.* 2020; Knowlton KU. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771409>
40. **COVID-19 as a Blood Clotting Disorder Masquerading as a Respiratory Illness: A Cerebrovascular Perspective and Therapeutic Implications for Stroke Thrombectomy.** *J. Neuroimaging* 2020; Janardhan V, Janardhan V, Kalousek V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776617>
41. **Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis.** *J. Neurol.* 2020; Patel U, Malik P, Shah D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770412>
42. **Kawasaki disease fact check: Myths, misconceptions and mysteries.** *J. Paediatr. Child Health* 2020; Butters C, Curtis N, Burgner DP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770807>
43. **Cardiac surgery in North America and coronavirus disease 2019 (COVID-19): Regional variability in burden and impact.** *J. Thorac. Cardiovasc. Surg.* 2020; Ad N, Luc JGY, Nguyen TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768300>
44. **Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations.** *J Thromb Haemost* 2020; Hardy M, Douxfils J, Bareille M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790951>
45. **In vivo demonstration of microvascular thrombosis in severe COVID-19.** *J. Thromb. Thrombolysis* 2020; do Espírito Santo DA, Lemos ACB, Miranda CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789730>
46. **Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.** *J. Thromb. Thrombolysis* 2020; Mattioli M, Benfaremo D, Mancini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794132>
47. **Multi-System Inflammatory Syndrome in a Child Mimicking Kawasaki Disease.** *J. Trop. Pediatr.* 2020; Gupta A, Gill A, Sharma M, Garg M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778886>
48. **CMR in the Era of COVID-19: Evaluation of Myocarditis in the Subacute Phase.** *JACC Cardiovasc. Imaging* 2020; Salerno M, Kwong RY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771570>
49. **Hyper- and hypocoagulability in COVID-19 as assessed by thromboelastometry. Two case reports.** *Korean J Anesthesiol* 2020; Kong R, Hutchinson N, Görlinger K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773727>
50. **Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection.** *Med Clin (Barc)* 2020; Martínez-Del Río J, Piqueras-Flores J, Nieto-Sandoval Martín de la Sierra P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782110>
51. **Cardiovascular comorbidities and complications associated with coronavirus disease 2019.** *Med J Armed Forces India* 2020; 76:253-260Mahajan K, Chandra KS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773926>
52. **Association of Coronavirus Disease 2019 and Stroke: A Rising Concern.** *Neuroepidemiology* 2020;1-5Kolikonda MK, Jandrasupalli KK, Lippmann S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791504>
53. **Defining heart disease risk for death in COVID-19 infection.** *QJM* 2020; Li J, Guo T, Dong D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790836>
54. **Incidental and simultaneous finding of pulmonary thrombus and COVID-19 pneumonia in a cancer patient derived to (18)F-FDG PET/CT. New pathophysiological insights from hybrid imaging.** *Radiol Case Rep* 2020; 15:1803-1805Ferrando-Castagnetto F, Waktie-Corieh CG, García AMB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788944>
55. **The renin angiotensin aldosterone system and COVID-19.** *Saudi Pharm J* 2020; 28:977-984Alsufyani HA, Docherty JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788834>
56. **History of Stroke Is Independently Associated With In-Hospital Death in Patients With COVID-19.** *Stroke* 2020;Strokeaha120030685Kummer BR, Klang E, Stein LK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772679>

57. **Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry.** *Stroke* 2020;Strokeaha120031208Ntaios G, Michel P, Georgiopoulos G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787707>
58. **The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management.** *Thromb Res* 2020; 194:101-115Abou-Ismael MY, Diamond A, Kapoor S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788101>
59. **Portal vein thrombosis in a patient with COVID-19.** *Thromb Res* 2020; 194:150-152Franco-Moreno A, Piniella-Ruiz E, Montoya-Adarraga J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788107>
60. **The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?** *Thromb Res* 2020; 194:192-194Previdali G, Seghezzi M, Moioli V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788116>
61. **Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study.** *Thromb Res* 2020; 194:209-215Stessel B, Vanvuchelen C, Bruckers L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788120>
62. **D-dimer level is associated with the severity of COVID-19.** *Thromb Res* 2020; 195:219-225Yu HH, Qin C, Chen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777639>
63. **Coronavirus Disease 2019: Hematological Anomalies and Antithrombotic Therapy.** *Tohoku J. Exp. Med.* 2020; 251:327-336Ornelas-Ricardo D, Jaloma-Cruz AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788506>

Diagnosis (10 articles)

1. **The Role of Chest Radiograph, Procalcitonin and Moxifloxacin in Diagnosis and Management of Breast Cancer Patients with COVID-19.** *Acta Med Indones* 2020; 52:163-171Rinaldi I, Muthalib A, Astowo P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778631>
2. **A Family Cluster of Coronavirus Disease (COVID-19) Infection with Different Clinical Manifestations.** *Acta Med Indones* 2020; 52:155-162Soedarsono S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778630>
3. **Pulmonary vascular enlargement on thoracic CT for diagnosis and differential diagnosis of COVID-19: a systematic review and meta-analysis.** *Ann Transl Med* 2020; 8:878Lv H, Chen T, Pan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793722>
4. **Laboratory markers included in the Corona Score can identify false negative results on COVID-19 RT-PCR in the emergency room.** *Biochem. Med. (Zagreb)* 2020; 30:030402Assandri R, Canetta C, Viganò G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774118>
5. **A diagnostic genomic signal processing (GSP)-based system for automatic feature analysis and detection of COVID-19.** *Brief. Bioinform.* 2020; Naeem SM, Mabrouk MS, Marzouk SY, Eldosoky MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793981>
6. **Validation of the Corona-Score for rapid identification of SARS-CoV-2 infections in patients seeking emergency department care in the United States.** *Clin Chem Lab Med* 2020; Lippi G, Henry BM, Hoehn J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776894>
7. **Cardiac tamponade in COVID-19 patients: Management and outcomes.** *J. Card. Surg.* 2020; Hakmi H, Sohail A, Brathwaite C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790006>
8. **COVID-19 diagnostics for resource-limited settings: Evaluation of "unextracted" qRT-PCR.** *J Med Virol* 2020; Adams NM, Leelawong M, Benton A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779772>
9. **Clinical and Radiological Diagnosis of Non-SARS-CoV-2 Viruses in the Era of Covid-19 Pandemic.** *J Med Virol* 2020; Alpaydin AO, Gezer NS, Simsek GO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770738>
10. **Deep-COVID: Predicting COVID-19 from chest X-ray images using deep transfer learning.** *Med. Image Anal.* 2020; 65:101794Minaee S, Kafieh R, Sonka M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781377>

DM-MS-Obesity (15 articles)

1. **Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study.** *The Lancet Diabetes & Endocrinology* 2020; Barron E, Bakhai C, Kar P *et al.*
2. **Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study.** *The Lancet Diabetes & Endocrinology* 2020; Holman N, Knighton P, Kar P *et al.*
3. **Obesity as a contributor to immunopathology in pregnant and non-pregnant adults with COVID-19.** *Am. J. Reprod. Immunol.* 2020:e13320McCartney SA, Kachikis A, Huebner EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779790>
4. **Expression Profile of SARS-CoV-2 Host Receptors in Human Pancreatic Islets Revealed Upregulation of ACE2 in Diabetic Donors.** *Biology (Basel)* 2020; 9Taneera J, El-Huneidi W, Hamad M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784802>
5. **The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea.** *Diabetes Metab. J.* 2020; Kim MK, Jeon JH, Kim SW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794386>
6. **Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection.** *Diabetes Metab Syndr* 2020; 14:1463-1465Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771919>
7. **Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature.** *Diabetes Metab Syndr* 2020; 14:1459-1462Reddy PK, Kuchay MS, Mehta Y, Mishra SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771918>
8. **Intervention Delivery Matters: What Mothers at High Risk for Type 2 Diabetes Want in a Diabetes Prevention Program-Results from a Comparative Effectiveness Trial.** *Diabetes Ther.* 2020; Palmer KNB, Garr Barry VE, Marrero DG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770443>

9. **Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review.** *Endocrine* 2020; Lisco G, De Tullio A, Giagulli VA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779091>
10. **Is obesity the missing link between COVID-19 severity and air pollution?** *Environ Pollut* 2020; 266:115327Lubrano C, Risi R, Masi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771867>
11. **A Territory-wide Study on the Impact of COVID-19 on Diabetes-Related Acute Care.** *J Diabetes Investig* 2020; Lui DTW, Lee CH, Chow WS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779868>
12. **Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy.** *J. Endocrinol. Invest.* 2020; Ciardullo S, Zerbini F, Perra S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776197>
13. **Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity.** *Obes Facts* 2020:1-14Goossens GH, Dicker D, Farpour-Lambert NJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791497>
14. **Coronavirus (SARS-CoV-2) and the risk of obesity for critically illness and ICU admitted: Meta-analysis of the epidemiological evidence.** *Obes. Res. Clin. Pract.* 2020; Sales-Peres SHC, de Azevedo-Silva LJ, Bonato RCS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773297>
15. **Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom.** *Proc Natl Acad Sci U S A* 2020; Hamer M, Gale CR, Kivimäki M, Batty GD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788355>

Education and training and science (30 articles)

1. **A bibliometric analysis using VOSviewer of publications on COVID-19.** *Ann Transl Med* 2020; 8:816Yu Y, Li Y, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793661>
2. **Experience with online lectures about endoscopic sinus surgery using an video conferencing app.** *Auris Nasus Larynx* 2020; Maeda Y, Takeda K, Hayama M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792117>
3. **Flattening the curve of COVID-19 for medical education in psychiatry and addiction medicine.** *Australas Psychiatry* 2020:1039856220946647Looi JC, Bonner D, Maguire P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772702>
4. **COVID-19 and the mental well-being of Australian medical students: impact, concerns and coping strategies used.** *Australas Psychiatry* 2020:1039856220947945Lyons Z, Wilcox H, Leung L, Dearsley O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772729>
5. **A hybrid flipped-classroom approach for online teaching of biochemistry in developing countries during Covid-19 crisis.** *Biochem Mol Biol Educ* 2020; Singh S, Arya A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790218>
6. **COVID-19 pandemic may fuel academic bullying.** *Bioimpacts* 2020; 10:139-140Mahmoudi M, Keashly L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793435>
7. **A four-step strategy for handling missing outcome data in randomised trials affected by a pandemic.** *BMC Med. Res. Methodol.* 2020; 20:208Cro S, Morris TP, Kahan BC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787782>
8. **A training programme on basic mechanical ventilation for novel trainees during the COVID-19 outbreak.** *Br J Anaesth* 2020; Sela Y, Weiniger CF, Arnon M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792140>
9. **Impact of the COVID-19 pandemic on anaesthesia trainees and their training.** *Br J Anaesth* 2020; Sneyd JR, Mathoulin SE, O'Sullivan EP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773215>
10. **Covid-19 pandemic research opportunity: Is the Middle East & North Africa (MENA) missing out?** *Contemp Clin Trials* 2020:106106Ibrahim H, Kamour AM, Harhara T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781230>
11. **COVID-19 disparities: An urgent call for race reporting and representation in clinical research.** *Contemp Clin Trials Commun* 2020; 19:100630Borno HT, Zhang S, Gomez S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789282>
12. **Holistic Analysis of Coronavirus Literature: A Scientometric Study of the Global Publications Relevant to SARS-CoV-2 (COVID-19), MERS-CoV (MERS) and SARS-CoV (SARS).** *Disaster Med Public Health Prep* 2020:1-15Şenel E, Topal FE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787980>
13. **Evaluation of technology-based learning by dental students during the pandemic outbreak of Corona virus disease 2019.** *Eur. J. Dent. Educ.* 2020; Al-Taweel FB, Abdulkareem AA, Gul SS, Alshami ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789943>
14. **Training Program in Gastroenterology: How Can It Survive the Pandemic?** *GE Port J Gastroenterol* 2020; 27:224-226Brandão C, Gorjão R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775542>
15. **University Lecturers and Students Could Help in Community Education About SARS-CoV-2 Infection in Uganda.** *Health Serv Insights* 2020; 13:1178632920944167Echoru I, Kasozi KI, Usman IM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782429>
16. **Effectiveness of simulation based teaching of ventilatory management among non-anaesthesiology residents to manage COVID 19 pandemic - A Quasi experimental cross sectional pilot study.** *Indian J. Anaesth.* 2020; 64:S136-s140Mouli TC, Davuluri A, Vijaya S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773853>
17. **A COVID-19 human viral challenge model. Learning from experience.** *Influenza Other Respir Viruses* 2020; Lambkin-Williams R, DeVincenzo JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790065>
18. **Bibliometric Studies and Worldwide Research Trends on Global Health.** *Int J Environ Res Public Health* 2020; 17Salmerón-Manzano E, Manzano-Agugliaro F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784825>
19. **The role of Korean Medicine in the post-COVID-19 era: an online panel discussion part 2 - basic research and education.** *Integr Med Res* 2020; 9:100488Park S, Hahm DH, Joo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789108>
20. **Enhancement in virtual learning cannot substitute for hands-on training in cardiothoracic surgery.** *J. Card. Surg.* 2020; Villamizar N, Nguyen DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789917>

21. **Overcoming Challenges in Coronavirus Disease 19 Translational Research.** *J Infect Dis* 2020; Li JZ, Yu XG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772113>
22. **Medical conferences in the era of environmental conscientiousness and a global health crisis: The carbon footprint of presenter flights to pre-COVID pediatric urology conferences and a consideration of future options.** *J. Pediatr. Surg.* 2020; Milford K, Rickard M, Chua M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782130>
23. **Surgical Residents in the Battle Against COVID-19.** *J Surg Educ* 2020; Obaid O, Zimmermann J, Ares G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792325>
24. **How do we teach surgical residents in the COVID-19 era?** *J Surg Educ* 2020; Okland TS, Pepper JP, Valdez TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773336>
25. **Surgical Education in the Time of COVID: Understanding the Early Response of Surgical Training Programs to the Novel Coronavirus Pandemic.** *J Surg Educ* 2020; White EM, Shaughnessy MP, Esposito AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768380>
26. **The infodemics of COVID-19 amongst healthcare professionals in India.** *Med J Armed Forces India* 2020; 76:276-283 Datta R, Yadav AK, Singh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773929>
27. **Physicians' knowledge of potential covid-19 drug-drug interactions: An online survey in turkey.** *Postgrad. Med.* 2020; Sürmelioglu N, Yalçın N, Kuşçu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780961>
28. **The fear of COVID-19 scale: Validation in spanish university students.** *Psychiatry Res* 2020; 293:113350 Martínez-Lorca M, Martínez-Lorca A, Criado-Álvarez JJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777619>
29. **Impact of the COVID-19 pandemic on core surgical training.** *Scott. Med. J.* 2020:36933020949217 Khan KS, Keay R, McLellan M, Mahmud S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772846>
30. **Positive impact of COVID-19 on career choice in pediatric medical students: a longitudinal study.** *Transl Pediatr* 2020; 9:243-252 Hu L, Wu H, Zhou W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775243>

Elderly (7 articles)

1. **Recommendations for a national Coronavirus disease 2019 response guideline for the care of older persons in Nigeria during and post-pandemic: A family physician's perspective.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3 Olagundoye O, Enema O, Adebowale A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787399>
2. **Association of Frailty with Mortality in Older Inpatients with Covid-19: A Cohort Study.** *Age Ageing* 2020; Aw D, Woodrow L, Ogliari G, Harwood R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778870>
3. **Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population.** *Arch. Gerontol. Geriatr.* 2020; 91:104204 Mostaza JM, García-Iglesias F, González-Alegre T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771883>
4. **When COVID-19 affects muscle: effects of quarantine in older adults.** *Eur. J. Transl. Myol.* 2020; 30:9069 Moro T, Paoli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782767>
5. **Modern Senicide in the Face of a Pandemic: An Examination of Public Discourse and Sentiment about Older Adults and COVID-19 Using Machine Learning.** *J. Gerontol. B Psychol. Sci. Soc. Sci.* 2020; Xiang X, Lu X, Halavanau A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785620>
6. **A Geroscience Approach to Preventing Pathologic Consequences of COVID-19.** *J. Interferon Cytokine Res.* 2020; Dou Y, Fatemi S, Darvas M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790488>
7. **A human circulating immune cell landscape in aging and COVID-19.** *Protein Cell* 2020:1-31 Zheng Y, Liu X, Le W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780218>

Epidemiology (64 articles)

1. **SARS-CoV-2 pandemic: An overview.** *Adv Biol Regul* 2020; 77:100736 Acuti Martellucci C, Flacco ME, Cappadona R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773099>
2. **Outbreak of COVID-19: An emerging global pandemic threat.** *Biomed. Pharmacother.* 2020; 129:110499 Peng M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768974>
3. **Importations of COVID-19 into African countries and risk of onward spread.** *BMC Infect. Dis.* 2020; 20:598 Sun H, Dickens BL, Cook AR, Clapham HE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791999>
4. **COVID-19: Concerns and behaviours in Croatia.** *Br. J. Health Psychol.* 2020; Lauri Korajlija A, Jokic-Begic N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779816>
5. **ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: An epidemiological study in the Asian population.** *Clin Chim Acta* 2020; Pati A, Mahto H, Padhi S, Panda AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791137>
6. **When infections don't reflect infectiousness: interpreting contact investigation data with care.** *Clin Infect Dis* 2020; Kendall EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770232>
7. **Homeless people hospitalized with COVID-19 in Brussels.** *Clin Microbiol Infect* 2020; Schrooyen L, Delforge M, Lebout F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777362>
8. **Stigma at the time of the COVID-19 pandemic.** *Clin Microbiol Infect* 2020; Villa S, Jaramillo E, Mangioni D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777361>
9. **The effect of preventing subclinical transmission on the containment of COVID-19: Mathematical modeling and experience in Taiwan.** *Contemp Clin Trials* 2020:106101 Tsou HH, Cheng YC, Yuan HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771432>
10. **Data for understanding trust in varied information sources, use of news media, and perception of misinformation regarding COVID-19 in Pakistan.** *Data Brief* 2020; 32:106091 Ejaz W, Ittefaq M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789157>
11. **The hidden Markov chain modelling of the COVID-19 spreading using Moroccan dataset.** *Data Brief* 2020; 32:106067 Marfak A, Achak D, Azizi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789156>
12. **Keep distance! Fewer COVID-19 cases due to social distancing.** *Deutsche Apotheker Zeitung* 2020; 160 Jungmayr P.

13. **Being there together for one another: Social commitment in times of corona.** Deutsche Apotheker Zeitung 2020; 160Leuffen AB.
14. **National Preferred Interpersonal Distance Curbs the Spread of COVID-19: A Cross-country Analysis.** Disaster Med Public Health Prep 2020;1-15Gokmen Y, Turen U, Erdem H, Tokmak İ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782051>
15. **"Does the prosperity of a country play a role in COVID-19 outcomes?".** Disaster Med Public Health Prep 2020;1-20Khorram-Manesh A, Carlström E, Hertelendy AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782059>
16. **The Episode of National Lockdown in the Pandemic: Air Traffic Restriction as the Control Strategy and Its Impact on Existing Cases and Recovery Rate of COVID-19 in Megacities of China.** Disaster Med Public Health Prep 2020;1-11Li J, Wang Z, Yuan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782050>
17. **Epidemiology of SARS-CoV-2 in Egypt.** East Mediterr Health J 2020; 26:768-773Radwan GN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794161>
18. **Outbreak investigation: transmission of COVID-19 starting from a spa facility in a local community in Korea.** Epidemiol Health 2020:e2020056Han T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777883>
19. **The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.** Front. Immunol. 2020; 11:1817Frederiksen LSF, Zhang Y, Foged C, Thakur A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793245>
20. **Optimal control on a mathematical model to pattern the progression of coronavirus disease 2019 (COVID-19) in Indonesia.** Glob Health Res Policy 2020; 5:38Sasmita NR, Ikhwan M, Suyanto S, Chongsuivatwong V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775696>
21. **Exploring the impact of COVID-19 pandemic lockdown on informal settlements in Tshwane Gauteng Province, South Africa.** Glob Public Health 2020;1-11Nyashanu M, Simbanegavi P, Gibson L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780633>
22. **COVID-19's Impact on the African American Community: A Stakeholder Engagement Approach to Increase Public Awareness Through Virtual Town Halls.** Health Equity 2020; 4:320-325Fletcher FE, Allen S, Vickers SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775941>
23. **A family cluster of diagnosed coronavirus disease 2019 (COVID-19) kidney transplant recipient in Thailand.** Immun Inflamm Dis 2020; Sakulkonkij P, Bruminhent J, Pankongngam C, Chalermphunchai N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770646>
24. **Massive migration promotes the early spread of COVID-19 in China: a study based on a scale-free network.** Infect Dis Poverty 2020; 9:109Song WY, Zang P, Ding ZX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778160>
25. **An Examination on the Transmission of COVID-19 and the Effect of Response Strategies: A Comparative Analysis.** Int J Environ Res Public Health 2020; 17Chen YT, Yen YF, Yu SH, Su EC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781669>
26. **COVID-19 Lockdown, Food Systems and Urban-Rural Partnership: Case of Nagpur, India.** Int J Environ Res Public Health 2020; 17Sukhwani V, Deshkar S, Shaw R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784648>
27. **COVID-19 response strategies: considering inequalities between and within countries.** Int J Equity Health 2020; 19:137Lau LL, Hung N, Wilson K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787914>
28. **A multimethod approach for county-scale geospatial analysis of emerging infectious diseases: a cross-sectional case study of COVID-19 incidence in Germany.** Int J Health Geogr 2020; 19:32Scarpone C, Brinkmann ST, Große T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791994>
29. **Rural communities in Africa should not be forgotten in responses to COVID-19.** Int. J. Health Plann. Manage. 2020; Ogunkola IO, Adebisi YA, Imo UF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790138>
30. **Estimating COVID-19-Related Infections, Deaths, and Hospitalizations in Iran Under Different Physical Distancing and Isolation Scenarios.** Int J Health Policy Manag 2020; Sharifi H, Jahani Y, Mirzazadeh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772007>
31. **The Health of Indigenous Populations in South Asia: A Critical Review in a Critical Time.** Int J Health Serv 2020;20731420946588Thresia CU, Srinivas PN, Mohindra KS, Jagadeesan CK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787539>
32. **Simultaneous circulation of COVID-19 and flu in Italy: potential combined effects on the risk of death?** Int J Infect Dis 2020; Capone A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768696>
33. **Transmission onset distribution of COVID-19.** Int J Infect Dis 2020; Chun JY, Baek G, Kim Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771633>
34. **Is Colombia an example of successful containment of the COVID-19 2020 pandemic? A critical analysis of the epidemiological data. March to July 2020.** Int J Infect Dis 2020; la Hoz-Restrepo F, Alvis-Zakzuk NJ, la Hoz-Gomez JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791206>
35. **Cluster infections play important roles in the rapid evolution of COVID-19 transmission: a systematic review.** Int J Infect Dis 2020; Liu T, Gong D, Xiao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768702>
36. **Diagnostic serial interval as a novel indicator for contact tracing effectiveness exemplified with the SARS-CoV-2/COVID-19 outbreak in South Korea.** Int J Infect Dis 2020; Mettler SK, Kim J, Maathuis MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771634>
37. **COVID-19: Lessons for Chile.** Int J Integr Care 2020; 20:4Artaza O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774194>
38. **The impact of sheltering-in-place during the COVID-19 pandemic on older adults' social and mental well-being.** J. Gerontol. B Psychol. Sci. Soc. Sci. 2020; Krendl AC, Perry BL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778899>
39. **A retrospective cross-national examination of COVID-19 outbreak in 175 countries: a multiscale geographically weighted regression analysis (January 11-June 28, 2020).** J Infect Public Health 2020; Iyanda AE, Adeleke R, Lu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773211>
40. **Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study.** J. Med. Microbiol. 2020; Khan M, Khan H, Khan S, Nawaz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783802>
41. **COVID-19 Prediction Models and Unexploited Data.** J Med Syst 2020; 44:170Santosh KC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794042>

42. **Low post-pandemic wave SARS-CoV-2 seroprevalence in Kuala Lumpur and Selangor, Malaysia.** *J Med Virol* 2020; Sam IC, Chong YM, Tan CW, Chan YF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790206>
43. **National Disparities in COVID-19 Outcomes between Black and White Americans.** *J. Natl. Med. Assoc.* 2020; Poulson M, Geary A, Annesi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778445>
44. **Impact of COVID-19 outbreak by income: hitting hardest the most deprived.** *J Public Health (Oxf)* 2020; Baena-Díez JM, Barroso M, Cordeiro-Coelho SI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776102>
45. **A medicalized hotel as a public health resource for the containment of Covid-19: more than a place for quarantining.** *J Public Health (Oxf)* 2020; Ramírez-Cervantes KL, Romero-Pardo V, Pérez-Tovar C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776147>
46. **Black and Minority Ethnic (BAME) Alliance Against COVID-19: One Step Forward.** *J Racial Ethn Health Disparities* 2020; Ahmed MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789564>
47. **Prevalence of Comorbidities and Risks Associated with COVID-19 Among Black and Hispanic Populations in New York City: an Examination of the 2018 New York City Community Health Survey.** *J Racial Ethn Health Disparities* 2020; Arasteh K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794024>
48. **Tracking the spread of COVID-19 in India via social networks in the early phase of the pandemic.** *J Travel Med* 2020; Azad S, Devi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776124>
49. **Epidemiological, Clinical, and Immunological Features of a Cluster of COVID-19-Contracted Hemodialysis Patients.** *Kidney Int Rep* 2020; 5:1333-1341 Ma Y, Diao B, Lv X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775837>
50. **COVID-19 has caught us all off guard.** *Klinikarzt* 2020; 49:233-235 Leschke M.
51. **Minimizing disease spread on a quarantined cruise ship: A model of COVID-19 with asymptomatic infections.** *Math. Biosci.* 2020:108442 Batista B, Dickenson D, Gurski K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777227>
52. **Projections for novel coronavirus (COVID-19) and evaluation of epidemic response strategies for India.** *Med J Armed Forces India* 2020; 76:268-275 Patrikar S, Poojary D, Basannar DR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773928>
53. **Testing times in Coronavirus disease (COVID-19): A tale of two nations.** *Med J Armed Forces India* 2020; 76:243-249 Rao GG, Agarwal A, Batura D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773924>
54. **New Zealand's COVID-19 elimination strategy.** *Med. J. Aust.* 2020; Baker MG, Kvalsvig A, Verrall AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789868>
55. **Outcomes of Coronavirus Disease 2019 Drive-Through Screening at an Academic Military Medical Center.** *Open Forum Infect Dis* 2020; 7:ofaa306 Lindholm DA, Kiley JL, Jansen NK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782913>
56. **COVID-19: A tale of two pandemics across the Asia Pacific region.** *Paediatr. Respir. Rev.* 2020; Fitzgerald DA, Wong GWK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768308>
57. **The effect of staying at home due to COVID-19 outbreak on nursing students' life satisfaction and social competencies.** *Perspect. Psychiatr. Care* 2020; Yavaş Çelik M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770544>
58. **SARS-CoV-2 and the pandemic of COVID-19.** *Postgrad. Med. J.* 2020; Adil MT, Rahman R, Whitelaw D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788312>
59. **Key questions for modelling COVID-19 exit strategies.** *Proc. Biol. Sci.* 2020; 287:20201405 Thompson RN, Hollingsworth TD, Isham V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781946>
60. **Isolation until it hurts – the consequences of the corona pandemic.** *Schmerz* 2020; 34:301-302 Radbruch L, Schaible HG.
61. **Comparative infection modeling and control of COVID-19 transmission patterns in China, South Korea, Italy and Iran.** *Sci Total Environ* 2020; 747:141447 He J, Chen G, Jiang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771775>
62. **How coronavirus disease 2019 entered Africa and the Middle East: a case study from Egypt.** *Trans. R. Soc. Trop. Med. Hyg.* 2020; Khattab NM, Vermund SH, Hu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785588>
63. **Epidemiological and clinical differences of coronavirus disease 2019 patients with distinct viral exposure history.** *Virulence* 2020; 11:1015-1023 Gao Y, Ma X, Bi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787496>
64. **Effects of policies and containment measures on control of COVID-19 epidemic in Chongqing.** *World J Clin Cases* 2020; 8:2959-2976 Liang XH, Tang X, Luo YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775378>

Gastro-enterology (16 articles)

1. **Direct COVID-19 Infection of Enterocytes: The Role of Hypochlorhydria.** *Am. J. Infect. Control* 2020; Dibner JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791258>
2. **Liver transplantation and COVID-19: a case report and cross comparison between two identical twins with COVID-19.** *BMC Surg.* 2020; 20:181 Nikoupour H, Arasteh P, Gholami S, Nikeghbalian S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770973>
3. **IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less Prone to its Severe Adverse Events: True or False?** *Cell J* 2020; 22:151-154 Baradaran Ghavami SH, Shahrokh SH, Hossein-Khannazer N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779446>
4. **Systematic review on IBD patients with COVID-19: it is time to take stock.** *Clin Gastroenterol Hepatol* 2020; D'Amico F, Danese S, Peyrin-Biroulet L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777550>
5. **Drastic decrease of urgent endoscopies outside regular working hours during the Covid-19 pandemic in the paris area.** *Clin Res Hepatol Gastroenterol* 2020; Becq A, Jais B, Fron C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788129>
6. **The Episode of National Lockdown in the Pandemic: Air Traffic Restriction as the Control Strategy and Its Impact on Existing Cases and Recovery Rate of COVID-19 in Megacities of China.** *Disaster Med Public Health Prep* 2020:1-11 Li J, Wang Z, Yuan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782050>
7. **Relationship Between COVID-19 Infection and Liver Injury: A Review of Recent Data.** *Front Med (Lausanne)* 2020; 7:458 Ali N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793619>

8. **Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)*. 2020; 7:431 Boregowda U, Aloysius MM, Perisetti A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793616>
9. **What underlies the benefit of famotidine formulations used during COVID-19?** *Gastroenterology*. 2020; Singh VP, El-Kurdi B, Rood C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777281>
10. **The Impact of SARS-CoV-2 on Inflammatory Bowel Disease.** *GE Port J Gastroenterol*. 2020; 27:227-229 Estevinho MM, Magro F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775543>
11. **Hepatology in the COVID Era: Another C Virus, again Challenging the Liver.** *GE Port J Gastroenterol*. 2020; 27:230-236 Peixe P, Calinas F, Tato Marinho R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775544>
12. **Corona Virus Disease-19 pandemic: The gastroenterologists' perspective.** *Indian J. Gastroenterol.* 2020; Dhar J, Samanta J, Kochhar R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783168>
13. **Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19.** *J. Gastroenterol.* 2020; Uchida Y, Uemura H, Yamaba S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776161>
14. **Liver abnormality may develop cerebral venous sinus thrombosis in COVID-19.** *J Neurol Sci*. 2020; 417:117076 Neshin SAS, Basirjafari S, Saberi A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791424>
15. **Recommendations for the reopening and activity resumption of the neurogastroenterology units in the face of the COVID-19 pandemic. Position of the Sociedad Latinoamericana de Neurogastroenterología.** *Rev. Gastroenterol. Mex.* 2020; Remes-Troche JM, Valdovinos-Díaz MA, Viebig R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773251>
16. **Clinical characteristics of patients with COVID-19 presenting with gastrointestinal symptoms as initial symptoms: Retrospective case series.** *World J Clin Cases*. 2020; 8:2950-2958 Yang TY, Li YC, Wang SC *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775377>

Guidelines (19 articles)

1. **Neuromuscular diseases and Covid-19: Advices from scientific societies and early observations in Italy.** *Eur. J. Transl. Myol.* 2020; 30:9032 Angelini C, Siciliano G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782765>
2. **The Polish Society of Gynecologists and Obstetricians statement on surgery in gynecology during the COVID-19 pandemic.** *Ginekol. Pol.* 2020; 91:424-427 Stojko R, Staniczek J, Olejek A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779164>
3. **All India difficult airway association (AIDAA) consensus guidelines for airway management in the operating room during the COVID-19 pandemic.** *Indian J. Anaesth.* 2020; 64:S107-s115 Patwa A, Shah A, Garg R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773848>
4. **Indian Resuscitation Council (IRC) suggested guidelines for Comprehensive Cardiopulmonary Life Support (CCLS) for suspected or confirmed coronavirus disease (COVID-19) patient.** *Indian J. Anaesth.* 2020; 64:S91-s96 Singh B, Garg R, Chakra Rao SSC *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773845>
5. **Society of Onco-Anesthesia and Perioperative Care (SOAPC) advisory regarding perioperative management of onco-surgeries during COVID-19 pandemic.** *Indian J. Anaesth.* 2020; 64:S97-s102 Solanki SL, Thota RS, Garg R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773846>
6. **Guidelines for various laboratory sections in view of COVID-19: Recommendations from the Indian Association of Pathologists and Microbiologists.** *Indian J. Pathol. Microbiol.* 2020; 63:350-357 Misra V, Agrawal R, Kumar H *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769321>
7. **Structured reporting of chest CT in COVID-19 pneumonia: a consensus proposal.** *Insights Imaging* 2020; 11:92 Neri E, Coppola F, Larici AR *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785803>
8. **Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine.** *J. Aerosol Med. Pulm. Drug Deliv.* 2020; Fink JB, Ehrmann S, Li J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783675>
9. **Managing asthma in the COVID-19 pandemic and current recommendations from professional bodies: a review.** *J. Asthma* 2020; 1-8 Ong KY, Tan TL, Chan AKW *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779943>
10. **Society for Cardiovascular Magnetic Resonance (SCMR) guidance for re-activation of cardiovascular magnetic resonance practice after peak phase of the COVID-19 pandemic.** *J. Cardiovasc. Magn. Reson.* 2020; 22:58 Allen BD, Wong TC, Bucciarelli-Ducci C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772930>
11. **Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management.** *J Clin Med* 2020; 9:Weenink RP, Preckel B, Hulst AH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781614>
12. **What every Intensivist should know about COVID-19 associated acute kidney injury.** *J Crit Care* 2020; 60:91-95 Ostermann M, Lumlertgul N, Forni LG, Hoste E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777758>
13. **The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper.** *J. Glob. Infect. Dis.* 2020; 12:47-93 Stawicki SP, Jeanmonod R, Miller AC *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773996>
14. **Joint IFS-ISAR-ACE Recommendations on Resuming/Opening up Assisted Reproductive Technology Services.** *J. Hum. Reprod. Sci.* 2020; 13:82-88 Prasad S, Trivedi P, Malhotra N *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792754>
15. **Professionally responsible advocacy for women and children first during the COVID-19 pandemic: guidance from World Association of Perinatal Medicine and International Academy of Perinatal Medicine.** *J. Perinat. Med.* 2020; Chervenak FA, McCullough LB, Grünebaum A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769228>
16. **[Guiding opinion for infection protection in Ear & Nose & Throat Department during the outbreak of coronavirus disease].** *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2020; 34:196-198. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791580>
17. **Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity.** *Obes Facts*

2020:1-14Goossens GH, Dicker D, Farpour-Lambert NJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791497>

18. **SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID-19 Immune Studies and Vaccine Development.** *Vaccines (Base)* 2020; 8:Olvera A, Noguera-Julian M, Kilpelainen A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781672>
19. **Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic – Update July 2020.** *Z. Rheumatol.* 2020; Schulze-Koops H, Iking-Konert C, Leipe J *et al.*

Imaging (30 articles)

1. **Imaging findings of SARS-CoV-2 infection in pediatrics: A systematic review of coronavirus disease 2019 (COVID-19) in 850 patients.** *Acad Radiol* 2020; Katal S, Johnston SK, Johnston JH, Gholamrezanezhad A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773328>
2. **The Role of Chest Radiograph, Procalcitonin and Moxifloxacin in Diagnosis and Management of Breast Cancer Patients with COVID-19.** *Acta Med Indones* 2020; 52:163-171Rinaldi I, Muthalib A, Astowo P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778631>
3. **Pulmonary vascular enlargement on thoracic CT for diagnosis and differential diagnosis of COVID-19: a systematic review and meta-analysis.** *Ann Transl Med* 2020; 8:878Lv H, Chen T, Pan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793722>
4. **Machine learning-based CT radiomics method for predicting hospital stay in patients with pneumonia associated with SARS-CoV-2 infection: a multicenter study.** *Ann Transl Med* 2020; 8:859Yue H, Yu Q, Liu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793703>
5. **Rapid identification of COVID-19 severity in CT scans through classification of deep features.** *Biomed. Eng. Online* 2020; 19:63Yu Z, Li X, Sun H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787937>
6. **The future is in your hands - Handheld ultrasound in the emergency department.** *Cjem* 2020:1-3Thavanathan RS, Woo MY, Hall G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782061>
7. **Predictors of coronavirus disease 19 (COVID-19) pneumonitis outcome based on computed tomography (CT) imaging obtained prior to hospitalization: a retrospective study.** *Emerg Radiol* 2020; Mirza-Aghazadeh-Attari M, Zarrintan A, Nezami N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770367>
8. **A low-dose chest CT protocol for the diagnosis of COVID-19 pneumonia: a prospective study.** *Emerg Radiol* 2020; Tabatabaei SMH, Talari H, Gholamrezanezhad A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789807>
9. **Lung Ultrasound (LUS) in COVID-19 Pneumonia: Usefulness in Two Atypical Cases.** *Eur J Case Rep Intern Med* 2020; 7:001800Giugno V, Di Marzio G, Domanico A, Accogli E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789143>
10. **Effects of the COVID-19 pandemic on myocardial perfusion imaging for ischemic heart disease.** *Eur J Nucl Med Mol Imaging* 2020; Nappi C, Megna R, Acampa W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778930>
11. **Automated quantification of COVID-19 severity and progression using chest CT images.** *Eur Radiol* 2020; Pu J, Leader JK, Bandos A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789756>
12. **Structured reporting of chest CT in COVID-19 pneumonia: a consensus proposal.** *Insights Imaging* 2020; 11:92Neri E, Coppola F, Larici AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785803>
13. **Evolution of computed tomography manifestations of eleven patients with severe coronavirus disease 2019 (COVID-19) pneumonia.** *Int J Clin Pract* 2020:e13654Sun Q, Li Q, Gao F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770797>
14. **Comparison of Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) and Pneumonia Associated with Lymphoma.** *Int. J. Med. Sci.* 2020; 17:1909-1915Wang S, Zheng Y, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788869>
15. **Indications for and Findings on Transthoracic Echocardiography in COVID-19.** *J. Am. Soc. Echocardiogr.* 2020; Jain SS, Liu Q, Raikhelkar J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782131>
16. **Society for Cardiovascular Magnetic Resonance (SCMR) guidance for re-activation of cardiovascular magnetic resonance practice after peak phase of the COVID-19 pandemic.** *J. Cardiovasc. Magn. Reson.* 2020; 22:58Allen BD, Wong TC, Bucciarelli-Ducci C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772930>
17. **Clinical and Imaging Characteristics in Patients with SARS-CoV-2 Infection and Acute Intracranial Hemorrhage.** *J Clin Med* 2020; 9Nawabi J, Morotti A, Wildgruber M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781623>
18. **Optimal utilization of MSK imaging during COVID-19 pandemic.** *J Clin Orthop Trauma* 2020; 11:S428-s430Goyal N, Ghonge NP, Vaish A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774007>
19. **Longitudinal Echocardiographic Assessment of Coronary Arteries and Left Ventricular Function Following Multisystem Inflammatory Syndrome in Children (MIS-C).** *J. Pediatr.* 2020; Jhaveri S, Ahluwalia N, Kaushik S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768467>
20. **Lung Ultrasound in COVID-19 A Role Beyond the Acute Phase?** *J Ultrasound Med* 2020; Gaspardone C, Meloni C, Preda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770687>
21. **Identification of COVID-19 samples from chest X-Ray images using deep learning: A comparison of transfer learning approaches.** *J Xray Sci Technol* 2020; Rahaman MM, Li C, Yao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773400>
22. **Current Imaging Trends in COVID-19 Pneumonia.** *JNMA J. Nepal Med. Assoc.* 2020; 58:444-446Jha A, Lohani B, Ghimire RK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788768>
23. **Deep-COVID: Predicting COVID-19 from chest X-ray images using deep transfer learning.** *Med. Image Anal.* 2020; 65:101794Minaee S, Kafieh R, Sonka M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781377>
24. **18-FDG PSEUDOTUMORAL LESION WITH QUICK FLOWERING TO A TYPICAL LUNG CT COVID-19.** *Radiol Case Rep* 2020; 15:1813-1816de Barry O, Cabral D, Kahn JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788946>

25. **Incidental and simultaneous finding of pulmonary thrombus and COVID-19 pneumonia in a cancer patient derived to (18)F-FDG PET/CT. New pathophysiological insights from hybrid imaging.** *Radiol Case Rep* 2020; 15:1803-1805 Ferrando-Castagnetto F, Wakfie-Corieh CG, Garcia AMB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788944>
26. **COVID-19 in an asymptomatic patient undergoing FDG PET/CT.** *Radiol Case Rep* 2020; 15:1809-1812 Johnson LN, Vesselle H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788945>
27. **Fever and an abnormal chest X-ray during the COVID-19 pandemic.** *Respir Med Case Rep* 2020; 31:101167 Ruttens D, Van Kerrebroeck M, Vandewalle J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789106>
28. **Adaptation of prenatal care and ultrasound.** *Semin. Perinatol.* 2020:151278 Aziz A, Fuchs K, Nhan-Chang CL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792263>
29. **The "pandemic" increase in lung ultrasound use in response to Covid-19: can we complement computed tomography findings? A narrative review.** *Ultrasound J* 2020; 12:39 Vetrugno L, Baciarello M, Bignami E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785855>
30. **Correlation between Chest Computed Tomography and Lung Ultrasonography in Patients with Coronavirus Disease 2019 (COVID-19).** *Ultrasound Med. Biol.* 2020; Tung-Chen Y, Martí de Gracia M, Díez-Tascón A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771222>

Immune response (20 articles)

1. **Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19.** *Cell* 2020; Sekine T, Perez-Potti A, Rivera-Ballesteros O *et al.*
2. **Devilishly radical NETWORK in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression.** *Adv Biol Regul* 2020; 77:100741 Schönrich G, Raftery MJ, Samstag Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773102>
3. **Obesity as a contributor to immunopathology in pregnant and non-pregnant adults with COVID-19.** *Am. J. Reprod. Immunol.* 2020:e13320 McCartney SA, Kachikis A, Huebner EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779790>
4. **The absorbing filter Oxiris in severe COVID-19 patients: A case series.** *Artif. Organs* 2020; Fengmin S, Zhang H, Zhu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779737>
5. **Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study.** *Circulation* 2020; 142:611-614 Masi P, Hékimian G, Lejeune M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776849>
6. **A gendered magnifying glass on COVID-19.** *Clin. Mol. Allergy* 2020; 18:14 Salvati L, Biagioni B, Vivarelli E, Parronchi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774170>
7. **COVID-19 as a Possible Cause of Functional Exhaustion of CD4 and CD8 T-cells and Persistent Cause of Methicillin-Sensitive Staphylococcus aureus Bacteremia.** *Cureus* 2020; 12:e9000 Choudhury I, Han H, Manthani K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775080>
8. **Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the "Cytokine Release (Storm) Syndrome" Caused by SARS-CoV-2?** *Curr. Pharm. Des.* 2020; López-Iranzo FJ, López-Rodas AM, Franco L, López-Rodas G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787748>
9. **The Consequences of Coronavirus-Induced Cytokine Storm Are Associated With Neurological Diseases, Which May Be Preventable.** *Front. Neurol.* 2020; 11:745 Isacson O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793108>
10. **Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.** *Immunity* 2020; Zhou R, To KK, Wong YC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791036>
11. **Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients.** *Immunity* 2020; Zhu L, Yang P, Zhao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783921>
12. **Immune Response and COVID-19: A mirror image of Sepsis.** *Int J Biol Sci* 2020; 16:2479-2489 López-Collazo E, Avendaño-Ortiz J, Martín-Quirós A, Aguirre LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792851>
13. **Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan, China.** *Int. J. Med. Sci.* 2020; 17:2052-2062 Xu X, Yu MQ, Shen Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788884>
14. **Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?** *Int J Rheum Dis* 2020; Kabeerdoss J, Danda D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779341>
15. **Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression.** *J Med Virol* 2020; Khinda J, Janjua NZ, Cheng S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776551>
16. **Multi-System Inflammatory Syndrome in a Child Mimicking Kawasaki Disease.** *J. Trop. Pediatr.* 2020; Gupta A, Gill A, Sharma M, Garg M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778886>
17. **Epidemiological, Clinical, and Immunological Features of a Cluster of COVID-19-Contracted Hemodialysis Patients.** *Kidney Int Rep* 2020; 5:1333-1341 Ma Y, Diao B, Lv X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775837>
18. **A human circulating immune cell landscape in aging and COVID-19.** *Protein Cell* 2020:1-31 Zheng Y, Liu X, Le W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780218>
19. **Anosmia: a missing link in the neuroimmunology of coronavirus disease 2019 (COVID-19).** *Rev. Neurosci.* 2020; Yazdanpanah N, Saghadzadeh A, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776905>
20. **Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques.** *Zool Res* 2020:1-10 Song TZ, Zheng HY, Han JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772513>

Management miscellaneous diseases (90 articles)

1. **Cancer therapy and treatments during COVID-19 era.** *Adv Biol Regul* 2020; 77:100739Akula SM, Abrams SL, Steelman LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773105>
2. **The clinical impact of COVID-19 epidemic in the hematologic setting.** *Adv Biol Regul* 2020; 77:100742Finelli C, Parisi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773103>
3. **Lessons Learned at a COVID-19 designated hospital.** *Am. J. Surg.* 2020; Edwards JA, Breitman I, Kovatch I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778399>
4. **Is there an impact of COVID-19 in Vascular Surgery patient's admission to the Emergency department?** *Ann. Vasc. Surg.* 2020; Correia M, Constâncio V, Silva JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791192>
5. **Screening and Testing for COVID-19 Before Surgery.** *ANZ J Surg* 2020; Kovoor JG, Tivey DR, Williamson P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770653>
6. **Re Facial aesthetic injections in clinical practice: Pretreatment and post-treatment consensus recommendations to minimise adverse outcome Region-specific changes in line with the Covid-19 pandemic.** *Australas. J. Dermatol.* 2020; Goodman GJ, Liew S, Callan P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779184>
7. **Disease progression of cancer patients during COVID-19 pandemic: a comprehensive analytical strategy by time-dependent modelling.** *BMC Med. Res. Methodol.* 2020; 20:209Bhattacharjee A, Vishwakarma GK, Banerjee S, Shukla S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787822>
8. **Psychological impact of an epidemic/pandemic on the mental health of healthcare professionals: a rapid review.** *BMC Public Health* 2020; 20:1230Stuijzand S, Deforges C, Sandoz V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787815>
9. **Psychological distress during the COVID-19 pandemic amongst anaesthesiologists and nurses.** *Br J Anaesth* 2020; Lee MCC, Thampi S, Chan HP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792139>
10. **Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic.** *Breast Cancer Res. Treat.* 2020; Papautsky EL, Hamlisch T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772225>
11. **Development and validation of a surgical prioritization and ranking tool and navigation aid for head and neck cancer (SPARTAN-HN) in a scarce resource setting: Response to the COVID-19 pandemic.** *Cancer* 2020; de Almeida JR, Noel CW, Forner D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780426>
12. **Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics.** *Cancer Treat. Rev.* 2020; 89:102066Fares JE, El Tomb P, Khalil LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769038>
13. **Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?** *Cancers (Basel)* 2020; 12Vivarelli S, Falzone L, Grillo CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785162>
14. **[How severe is the effect of the coronavirus pandemic on the department of surgery of a university hospital? : An analysis of the first 7 weeks].** *Chirurg* 2020; von Dercks N, Seehofer D, Steinert M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793988>
15. **Incidence of surgical abdominal emergencies during SARS-CoV-2 pandemic.** *Cir Esp* 2020; Pérez-Rubio Á, Sebastián Tomás JC, Navarro-Martínez S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768138>
16. **Pediatric transplantation in Europe during the COVID-19 pandemic: early impact on activity and healthcare.** *Clin. Transplant.* 2020:e14063Doná D, Torres Canizales J, Benetti E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32786120>
17. **Adapting Policy Guidelines for Spine Surgeries During COVID-19 Pandemic in View of Evolving Evidences: An Early Experience From a Tertiary Care Teaching Hospital.** *Cureus* 2020; 12:e9147Verma V, Nagar M, Jain V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789084>
18. **Characteristic changes of traumatic dental injuries in a teaching hospital of Wuhan under transmission control measures during the COVID-19 epidemic.** *Dent. Traumatol.* 2020; Yang YT, Zhang W, Xie L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790940>
19. **Caring for Deaf and Hard of Hearing Patients in Dermatology during the COVID-19 Pandemic.** *Dermatol Ther* 2020:e14185Chang MJ, Lipner SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794243>
20. **Treatment of pemphigus patients in the COVID-19 era: a specific focus on rituximab.** *Dermatol Ther* 2020:e14188Mahmoudi H, Tavakolpour S, Nili A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794333>
21. **Dupilumab in atopic dermatitis, a protocol for SARS-COV 2 infected patients.** *Dermatol Ther* 2020:e14172Ordóñez-Rubiano MF, Campo I, Casas M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779378>
22. **Reduced emergency department utilization during the early phase of the COVID-19 pandemic: viral fear or lockdown effect?** *Disaster Med Public Health Prep* 2020:1-13Barten DG, Latten GHP, van Osch FHM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782063>
23. **Neurology practice during the COVID-19 outbreak and post-pandemic era: experiences and challenges.** *Eur. J. Neurol.* 2020; Tang Y, Xing Y, Cui L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779848>
24. **Neuromuscular diseases and Covid-19: Advices from scientific societies and early observations in Italy.** *Eur. J. Transl. Myol.* 2020; 30:9032Angelini C, Siciliano G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782765>
25. **Reconfiguring the radiology leadership team for crisis management during the COVID-19 pandemic in a large tertiary hospital in Singapore.** *Eur Radiol* 2020:1-7Tay KH, Ooi CC, Mahmood MIB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780206>
26. **Impact of Coronavirus and Covid-19 on Present and Future Anesthesiology Practices.** *Front Med (Lausanne)* 2020; 7:452Meng L, McDonagh DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793617>
27. **Emergency Response Measures for Anesthesia Nursing During the COVID-19 Pandemic: West China Hospital Experiences.** *Front Med (Lausanne)* 2020; 7:460Zheng P, Zhou R, Yin L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793621>
28. **Urological Care and COVID-19: Looking Forward.** *Front. Oncol.* 2020; 10:1313Prayer-Galetti T, Motterle G, Morlacco A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793504>
29. **Impact of Social Determinants of Health on the Emerging COVID-19 Pandemic in the United States.** *Front Public Health* 2020; 8:406Singu S, Acharya A, Challagundla K, Byraredy SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793544>

30. **The Impact of SARS-CoV-2 on Inflammatory Bowel Disease.** *GE Port J Gastroenterol* 2020; 27:227-229Estevinho MM, Magro F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775543>
31. **Hepatology in the COVID Era: Another C Virus, again Challenging the Liver.** *GE Port J Gastroenterol* 2020; 27:230-236Peixe P, Calinas F, Tato Marinho R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775544>
32. **Hand injuries treated at a hand emergency center during the COVID-19 lockdown.** *Hand Surg Rehabil* 2020; Régas I, Bellemère P, Lamou B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777488>
33. **The Perioperative Surgical Home in Pediatrics: Improve Patient Outcomes, Decrease Cancellations, Improve HealthCare Spending and Allocation of Resources during the COVID-19 Pandemic.** *Healthcare (Basel)* 2020; 8Hasan A, Zimmerman R, Gillock K, Parrish RH, 2nd. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784549>
34. **Should we screen patients with hematologic malignancies for COVID-19?** *Hematol. Oncol.* 2020; Rassy E, Khoury-Abboud RM, Ibrahim N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779823>
35. **Re-emergence of TIVA in COVID times.** *Indian J. Anaesth.* 2020; 64:S125-s131Chokshi T, Channabasappa S, Verghese DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773851>
36. **Tough times and Miles to go before we sleep- Corona warriors.** *Indian J. Anaesth.* 2020; 64:S120-s124Gupta B, Bajwa SJS, Malhotra N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773850>
37. **Railway anaesthesiologists and Indian railway COVID-19 management system.** *Indian J. Anaesth.* 2020; 64:S132-s135Patel CK, Selvam VK, Sahu DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773852>
38. **Society of Onco-Anesthesia and Perioperative Care (SOAPC) advisory regarding perioperative management of onco-surgeries during COVID-19 pandemic.** *Indian J. Anaesth.* 2020; 64:S97-s102Solanki SL, Thota RS, Garg R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773846>
39. **The Impact of COVID-19 Related Lockdown on Dental Practice in Central Italy-Outcomes of A Survey.** *Int J Environ Res Public Health* 2020; 17Sinjari B, Rexhepi I, Santilli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785056>
40. **COVID-19 and ENT SLT services, workforce and research in the UK: A discussion paper.** *Int. J. Lang. Commun. Disord.* 2020; Patterson JM, Govender R, Roe J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770652>
41. **Outpatient surgery in patients with ankle fractures minimises hospital admissions and utilisation of healthcare resources.** *Int. Orthop.* 2020; Bullock TS, Gutierrez-Naranjo JM, DelBello RG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770348>
42. **Prolonged social lockdown during COVID-19 pandemic and hip fracture epidemiology.** *Int. Orthop.* 2020; Slullitel PA, Lucero CM, Soruco ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772318>
43. **Response to "Patient preference for cellulitis treatment: at-home care is preferred to hospital-based treatment".** *J Am Acad Dermatol* 2020; Shaw KS, Karagounis TK, Yin L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777319>
44. **The impact of COVID-19 pandemic on congenital heart surgery practice: An alarming change in demographics.** *J. Card. Surg.* 2020; Korun O, Yurdakök O, Arslan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789953>
45. **Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management.** *J Clin Med* 2020; 9Weenink RP, Preckel B, Hulst AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781614>
46. **The bone prone team.** *J Clin Orthop Trauma* 2020; 11:S446-s447Kulkarni S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774010>
47. **Fracture management during COVID-19 pandemic: A systematic review.** *J Clin Orthop Trauma* 2020; 11:S431-s441Kumar Jain V, Lal H, Kumar Patralekh M, Vaishya R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774008>
48. **Conducting orthopaedic practical examination during the Covid-19 pandemic.** *J Clin Orthop Trauma* 2020; 11:S448-s455Malhotra R, Gautam D, George J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774011>
49. **Service delivery during the COVID-19 pandemic: Experience from The Oxford Bone Tumour and Soft Tissue Sarcoma service.** *J Clin Orthop Trauma* 2020; 11:S419-s422Rajasekaran RB, Whitwell D, Cosker TDA, Gibbons C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774004>
50. **Resuming arthroplasty: A well aligned and a balanced approach in the COVID-19 era.** *J Clin Orthop Trauma* 2020; 11:S423-s425Sadigale O, Bagaria V, Vaishya R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774005>
51. **Outcome of trauma and orthopaedic surgery at a UK District General Hospital during the Covid-19 pandemic.** *J Clin Orthop Trauma* 2020; 11:S442-s445Sobti A, Memon K, Bhaskar RRP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774009>
52. **Impact of the novel coronavirus disease (COVID-19) on treatment adherence and sleep duration in patients with obstructive sleep apnea treated with positive airway pressure.** *J. Clin. Sleep Med.* 2020; Batool-Anwar S, Omobomi OS, Quan SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780011>
53. **Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.** *J Dermatolog Treat* 2020;1-17Gadarowski MB, Balogh EA, Bashyam AM, Feldman SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772743>
54. **Intralesional antigen immunotherapy for warts in the era of COVID-19.** *J Dermatolog Treat* 2020;1-4Nofal A, Fawzy MM, Abdelmaksoud A, El-Hawary EE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772744>
55. **Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey.** *J Eur Acad Dermatol Venereol* 2020; Dyrberg Loft N, Halling AS, Iversen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780487>
56. **Delayed melanoma diagnosis in the COVID-19 era: Increased breslow thickness in primary melanomas seen after the COVID-19 lockdown.** *J Eur Acad Dermatol Venereol* 2020; Ricci F, Fania L, Paradisi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780876>
57. **It is not 'business as usual' for orthopaedic surgeons in May 2020- the Austrian-German-Swiss experience.** *J Exp Orthop* 2020; 7:61Liebensteiner MC, Khosravi I, Hirschmann MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770379>
58. **Suggestion of Tunisia's medical oncologist in the management of breast cancer during COVID-19 pandemic.** *J. Oncol. Pharm. Pract.* 2020;1078155220948943Yahyaoui Y, Ghodhban Z, Hamdi A *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791938>
59. **Tracheoesophageal voice prosthesis management in laryngectomy patients during the COVID-19 pandemic.** *J. Otolaryngol. Head Neck Surg.* 2020; 49:59Goldstein DP, Ralph G, de Almeida JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778168>
 60. **Cardiac surgery in North America and coronavirus disease 2019 (COVID-19): Regional variability in burden and impact.** *J. Thorac. Cardiovasc. Surg.* 2020; Ad N, Luc JGY, Nguyen TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768300>
 61. **Implementation of Telemedicine in a Laryngology Practice During the COVID-19 Pandemic: Lessons Learned, Experiences Shared.** *J. Voice* 2020; Strohl MP, Dwyer CD, Ma Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778359>
 62. **Perceived impact of the COVID-19 pandemic on orthodontic practice by orthodontists and orthodontic residents in Nigeria.** *J World Fed Orthod* 2020; Isiekwe IG, Adeyemi TE, Aikins EA, Umeh OD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768366>
 63. **Contextualizing Critical Care Medicine in the Face of Covid-19 Pandemic.** *JNMA J. Nepal Med. Assoc.* 2020; 58:447-452Neupane HC, Gauli B, Adhikari S, Shrestha N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788769>
 64. **[Guiding opinion for infection protection in Ear & Nose & Throat Department during the outbreak of coronavirus disease].** *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2020; 34:196-198. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791580>
 65. **Reopening of dental clinics during SARS-CoV-2 pandemic: an evidence-based review of literature for clinical interventions.** *Maxillofac Plast Reconstr Surg* 2020; 42:25Keyhan SO, Fallahi HR, Motamedi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793519>
 66. **Providing optimal interventional oncology procedures at one of the COVID-19 referral center in Italy.** *Med. Oncol.* 2020; 37:83Pesapane F, Ierardi AM, Arrichiello A, Carrafiello G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772185>
 67. **Virtual Parkinson's Disease Support Groups in the COVID-19 Era: Social Connection in the Time of Social Distancing.** *Mov Disord Clin Pract* 2020; 7:739-740Subramanian I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775536>
 68. **Multiple sclerosis management during the COVID-19 pandemic.** *Mult. Scler.* 2020:1352458520948231Moss BP, Mahajan KR, Bermel RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772807>
 69. **Disruption of bone densitometry practice in a Northern Italy Orthopedic Hospital during the COVID-19 pandemic.** *Osteoporos. Int.* 2020; Messina C, Buzzoni AC, Gitto S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778933>
 70. **Implementation and Evaluation of a Virtual Elective in Otolaryngology in the Time of COVID-19.** *Otolaryngol Head Neck Surg* 2020:194599820951150Steehler AJ, Pettitt-Schieber B, Studer MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779955>
 71. **Prevention of COVID-19 infection in a pediatric oncology ward in Wuhan.** *Pediatr Blood Cancer* 2020:e28424Zhang A, Hu Q, Liu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779822>
 72. **COVID-19 Could Change the Way We Respond to the Opioid Crisis-for the Better.** *Psychiatr. Serv.* 2020:appips202000226Bao Y, Williams AR, Schackman BR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781928>
 73. **Quality of life of cancer patients during coronavirus disease (COVID-19) pandemic.** *Psychooncology* 2020; Ciążyńska M, Pabianek M, Szczepaniak K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779778>
 74. **Supportive care for oral cancer survivors in COVID-19 lockdown.** *Psychooncology* 2020; Ratnasekera N, Perera I, Kandapolaarachchige P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779826>
 75. **Two months of radiation oncology in the heart of Italian "red zone" during COVID-19 pandemic: paving a safe path over thin ice.** *Radiat Oncol* 2020; 15:191Buglione M, Spiazzi L, Guerini AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778174>
 76. **Recommendations for the reopening and activity resumption of the neurogastroenterology units in the face of the COVID-19 pandemic. Position of the Sociedad Latinoamericana de Neurogastroenterología.** *Rev. Gastroenterol. Mex.* 2020; Remes-Troche JM, Valdovinos-Díaz MA, Viebig R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773251>
 77. **Dysphagia services in the era of COVID-19: Are speech-language therapists essential?** *S. Afr. J. Commun. Disord.* 2020; 67:e1-e6Coutts KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787417>
 78. **The effects of the SARS-CoV-2 pandemic on sports traumatology.** *Sports Orthopaedics and Traumatology* 2020; 36:99-102Petersen W.
 79. **Organization of thoracic surgical services during the COVID pandemic.** *Surgeon* 2020; Leow L, Ramanathan K, Kofidis T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778525>
 80. **Challenges for a Cancer Center in the Novel Coronavirus Pneumonia Epidemic.** *Technol. Cancer Res. Treat.* 2020; 19:1533033820945774Wang XS, Zeng M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783511>
 81. **Impact of COVID-19 pandemic on lung cancer treatment scheduling.** *Thorac Cancer* 2020; Fujita K, Ito T, Saito Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790028>
 82. **Deadlock of proctologic practice in Italy during COVID-19 pandemic: a national report from ProctoLock2020.** *Updates Surg* 2020; Gallo G, Sturiale A, De Simone V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770466>
 83. **Outreach and influence of surgical societies' recommendations on minimally invasive surgery during the COVID-19 pandemic - an anonymized international urologic expert inquiry.** *Urology* 2020; Boehm K, Thomas A, Bex A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781078>
 84. **Recommendations for perinatal and neonatal surgical management during the COVID-19 pandemic.** *World J Clin Cases* 2020; 8:2893-2901Ma LS, Zhao YL, Wei YD, Liu C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775372>
 85. **COVID-19 outbreak and surgical practice: The rationale for suspending non-urgent surgeries and role of testing modalities.** *World J. Gastrointest. Surg.* 2020; 12:259-268Grubic AD, Ayazi S, Zebarjadi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774764>
 86. **Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic.** *World J. Urol.* 2020; Diamand R, Ploussard G, Roumiguié M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776243>

87. **Case Volumes and Perioperative COVID-19 Incidence in Neurosurgical Patients During a Pandemic: Experiences at Two Tertiary Care Centers in Washington, DC.** *World Neurosurg* 2020; Dowlati E, Zhou T, Sarpong K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777390>
88. **In Reply to the Letter to the Editor Regarding "Impact of COVID-19 on an Academic Neurosurgery Department: The Johns Hopkins Experience".** *World Neurosurg* 2020; Khalafallah AM, Jimenez AE, Mukherjee D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781145>
89. **Economic Impact of COVID-19 on a High Volume Academic Neurosurgical Practice.** *World Neurosurg* 2020; Sivakanthan S, Pan J, Kim L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791222>
90. **Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic – Update July 2020.** *Z. Rheumatol.* 2020; Schulze-Koops H, Iking-Konert C, Leipe J *et al*

Management (76 articles)

1. **A Call for Preventive Medicine Attention for Indonesian Physicians.** *Acta Med Indones* 2020; 52:99-101 Pramono LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778622>
2. **Veno-venous extracorporeal membrane oxygenation and prone ventilation for therapeutic management of COVID-19.** *Acute Med Surg* 2020; 7:e546 Kasai T, Bunya N, Wada K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793357>
3. **Ventilators are not the answer in Africa.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3 Madzimbamuto FD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787397>
4. **Coronavirus disease 2019 in Botswana: Contributions from family physicians.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3 Motlathledi K, Bogatsu Y, Maotwe K, Tsima B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787394>
5. **Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection.** *Am. J. Med.* 2020; McCullough PA, Kelly RJ, Ruocco G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771461>
6. **Role of the renin angiotensin system in the development of severe COVID-19 in hypertensive patients.** *Am J Physiol Lung Cell Mol Physiol* 2020; Silva-Aguiar RP, Peruchetti DB, Rocco PRM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783619>
7. **Haemodynamic Monitoring and Management in COVID-19 Intensive Care Patients: An International Survey.** *Anaesth Crit Care Pain Med* 2020; Michard F, Malbrain ML, Martin GS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781167>
8. **The absorbing filter Oxiris in severe COVID-19 patients: A case series.** *Artif. Organs* 2020; Fengmin S, Zhang H, Zhu G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779737>
9. **Evaluation of coagulation status using viscoelastic testing in intensive care patients with coronavirus disease 2019 (COVID-19): An observational point prevalence cohort study.** *Aust. Crit. Care* 2020; Collett LW, Gluck S, Strickland RM, Reddi BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773357>
10. **Arginine and Endothelial Function.** *Biomedicines* 2020; 8 Gambardella J, Khondkar W, Morelli MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781796>
11. **Hazardous mismatch between pulmonary pathogens and antibiotic treatments in COVID-19 patients.** *Br J Anaesth* 2020; Coppola S, Ciabattini A, Pozzi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792137>
12. **A novel role for lidocaine in COVID-19 patients?** *Br J Anaesth* 2020; Finnerty DT, Buggy DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792138>
13. **Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19.** *Br. J. Haematol.* 2020; Chistolini A, Ruberto F, Alessandri F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779783>
14. **Weather the Cytokine Storm: A Report of Successful Management of a Colon Cancer Survivor and a Critically Ill Patient with COVID-19.** *Case Rep. Oncol.* 2020; 13:754-759 Khalid M, Dernaika T, Jacob L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774271>
15. **Challenges of Iranian Clinicians in Dealing with COVID-19: Taking Advantages of The Experiences in Wenzhou.** *Cell J* 2020; 22:155-165 Li Y, Tahamtani Y, Totonchi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779447>
16. **Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19.** *Clin Infect Dis* 2020; Nelson BC, Laracy J, Shoucri S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772069>
17. **Reducing nosocomial transmission of COVID-19: implementation of a COVID-19 triage system.** *Clin Med (Lond)* 2020; Wake RM, Morgan M, Choi J, Winn S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788160>
18. **Automated Inflating Resuscitator (AIR): Design and Development of a 3D-Printed Ventilator Prototype and Corresponding Simulation Scenario Based on the Management of a Critical COVID-19 Patient.** *Cureus* 2020; 12:e9134 Gino B, Wang Z, d'Entremont P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789074>
19. **Fluid Replacement Versus Fluid Restriction in COVID-19 Associated Hyponatremia.** *Cureus* 2020; 12:e9059 Khan AA, Ata F, Munir W, Yousaf Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782878>
20. **Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the "Cytokine Release (Storm) Syndrome" Caused by SARS-CoV-2?** *Curr. Pharm. Des.* 2020; López-Iranzo FJ, López-Rodas AM, Franco L, López-Rodas G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787748>
21. **Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab.** *Dermatol Ther* 2020:e14186 Kiss N, Lórinck K, Medvecz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794375>
22. **COVID-19 and Immunosuppressive therapy in Dermatology.** *Dermatol Ther* 2020:e14140 Schwartz RA, Pradhan S, Murrell DF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770592>
23. **Establishing a 130-bedded field intensive care unit to prepare for COVID-19 in 7 days in Bahrain Military Hospital.** *Disaster Med Public Health Prep* 2020:1-26 Louri NA, Alkhan JA, Isa HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782041>

24. **The impact of patient isolation on emergency department length of stay: a retrospective cohort study using the Registry for Emergency Care (REC-1).** *Emerg. Med. Australas.* 2020; O'Reilly GM, Mitchell RD, Mitra B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794298>
25. **Humanized care in a death for COVID-19: A case study.** *Enferm. Clin.* 2020; Allande Cussó R, Navarro Navarro C, Porcel Gálvez AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782187>
26. **Reconfiguring the radiology leadership team for crisis management during the COVID-19 pandemic in a large tertiary hospital in Singapore.** *Eur Radiol* 2020;1-7Tay KH, Ooi CC, Mahmood MIB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780206>
27. **Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.** *Faseb j* 2020; De Flora S, Balansky R, La Maestra S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780893>
28. **Safety and Efficacy of Chest Physiotherapy in Patients With COVID-19: A Critical Review.** *Front Med (Lausanne)* 2020; 7:454Abdullahi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793618>
29. **What underlies the benefit of famotidine formulations used during COVID-19?** *Gastroenterology* 2020; Singh VP, El-Kurdi B, Rood C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777281>
30. **Early de-escalation of DAPT after PCI: implications of the latest randomized trials in the COVID era.** *Indian Heart J.* 2020; 72:209-211Mahajan K, Batra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768026>
31. **Parents' Knowledge and Attitude towards COVID-19 in Children: A Jordanian Study.** *Int J Clin Pract* 2020:e13671Abuhammad S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780560>
32. **Is Exercise the Best Medicine during a COVID-19 Pandemic? Comment on Constandt, B.; Thibaut, E.; De Bosscher, V.; Scheerder, J.; Ricour, M.; Willem, A. Exercising in Times of Lockdown: An Analysis of the Impact of COVID-19 on Levels and Patterns of Exercise among Adults in Belgium.** *Int. J. Environ. Res. Public Health* 2020, 17, 4144. *Int J Environ Res Public Health* 2020; 17Hew-Butler T, Smith-Hale V, Van Sumeren M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784520>
33. **The Relationship between Health Consciousness and Home-Based Exercise in China during the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2020; 17Pu B, Zhang L, Tang Z, Qiu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781751>
34. **Probiotics and Covid-19.** *Int. J. Food Sci. Nutr.* 2020:1-7Bottari B, Castellone V, Neviani E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787470>
35. **Is Colombia an example of successful containment of the COVID-19 2020 pandemic? A critical analysis of the epidemiological data. March to July 2020.** *Int J Infect Dis* 2020; la Hoz-Restrepo F, Alvis-Zakzuk NJ, la Hoz-Gomez JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791206>
36. **Factors Affecting Perceived Effectiveness of COVID-19 Prevention Measures among Filipino during Enhanced Community Quarantine in Luzon, Philippines: Integrating Protection Motivation Theory and Extended Theory of Planned Behavior.** *Int J Infect Dis* 2020; Prasetyo YT, Castillo AM, Salonga LJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768695>
37. **The COVID-19 epidemic and reorganisation of triage, an observational study.** *Intern Emerg Med* 2020; Turcato G, Zaboli A, Pfeifer N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772281>
38. **Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19.** *J Am Coll Cardiol* 2020; 76:122-124Paranjpe I, Fuster V, Lala A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32387623>
39. **Staffing Levels and COVID-19 Cases and Outbreaks in US Nursing Homes.** *J Am Geriatr Soc* 2020; Gorges RJ, Konetzka RT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770832>
40. **Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19.** *J Clin Med* 2020; 9Bruce E, Barlow-Pay F, Short R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785086>
41. **Key Aspects in Nutritional Management of COVID-19 Patients.** *J Clin Med* 2020; 9Fernández-Quintela A, Milton-Laskibar I, Trepiana J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785121>
42. **What every Intensivist should know about COVID-19 associated acute kidney injury.** *J Crit Care* 2020; 60:91-95Ostermann M, Lumlertgul N, Forni LG, Hoste E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777758>
43. **Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan.** *J Formos Med Assoc* 2020; Tsai CC, Wang YC, Chiang TT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773262>
44. **The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper.** *J. Glob. Infect. Dis.* 2020; 12:47-93Stawicki SP, Jeanmonod R, Miller AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773996>
45. **COVID-19 and AIDS: outcomes from the co-existence of two global pandemics and the importance of chronic antiretroviral therapy.** *J Med Virol* 2020; Patel RH, Acharya A, Mohan M, Byrareddy SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779740>
46. **Containing SARS-CoV-2 in hospitals facing finite PPE, limited testing, and physical space variability: Navigating resource constrained enhanced traffic control bundling.** *J Microbiol Immunol Infect* 2020; De Georgeo MR, De Georgeo JM, Egan TM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773286>
47. **The influence of experiences of involvement in the COVID-19 rescue task on the professional identity among Chinese nurses: A qualitative study.** *J. Nurs. Manag.* 2020; Sheng Q, Zhang X, Wang X, Cai C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770772>
48. **A medicalized hotel as a public health resource for the containment of Covid-19: more than a place for quarantining.** *J Public Health (Oxf)* 2020; Ramírez-Cervantes KL, Romero-Pardo V, Pérez-Tovar C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776147>
49. **Crisis Standards of Care in the USA: A Systematic Review and Implications for Equity Amidst COVID-19.** *J Racial Ethn Health Disparities* 2020; Cleveland Manchanda EC, Sanky C, Appel JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789816>
50. **Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.** *J. Thromb. Thrombolysis* 2020; Mattioli M, Benfaremo D, Mancini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794132>
51. **Instructive Messages and Lessons From Chinese Countermarching Nurses of Caring for COVID-19 Patients: A Qualitative Study.** *J. Transcult. Nurs.* 2020:1043659620950447He Q, Li T, Su Y, Luan Y.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783500>
52. **A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review.** *Life (Basel)* 2020; 10:Monari C, Gentile V, Camaioni C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784922>
 53. **Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection.** *Med Clin (Barc)* 2020; Martínez-Del Río J, Piqueras-Flores J, Nieto-Sandoval Martín de la Sierra P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782110>
 54. **The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients.** *Med. Hypotheses* 2020; 144:110140Hamed MGM, Hagag RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768893>
 55. **“Hybrid tracheostomy”: a low risk procedure for tracheostomy in COVID-19 patients.** *Medizinische Klinik - Intensivmedizin und Notfallmedizin* 2020; Nibbe L, Jungehülsing M, Röber S *et al.*
 56. **European Aeromedical Evacuation Transports with SARS-COV 2 positive Patients.** *Notarzt* 2020; Sammito S, Post J, Ritter DM *et al.*
 57. **Algorithm for flexible decision-making in the intra-hospital management of patients with the changing requirements of the SARS-CoV-2 pandemic.** *Notfall und Rettungsmedizin* 2020; 23:356-363Waydhas C, Hosbach I, Bockelmann-Jung S *et al.*
 58. **Relevant Nutrition Therapy in COVID-19 and the Constraints On Its Delivery by a Unique Disease Process.** *Nutr. Clin. Pract.* 2020; Patel JJ, Martindale RG, McClave SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32786117>
 59. **Early Nutritional Interventions with Zinc, Selenium and Vitamin D for Raising Anti-Viral Resistance Against Progressive COVID-19.** *Nutrients* 2020; 12:Alexander J, Tinkov A, Strand TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784601>
 60. **A Five-Ingredient Nutritional Supplement and Home-Based Resistance Exercise Improve Lean Mass and Strength in Free-Living Elderly.** *Nutrients* 2020; 12:Nilsson MI, Mikhail A, Lan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785021>
 61. **Out of Sight but Not Out of Mind: Caring for Patients Receiving OPAT During the SARS-CoV-2 Pandemic.** *Open Forum Infect Dis* 2020; 7:ofaa309Rivera CG, Mahoney MV, Stevens RW, Abu Saleh O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782914>
 62. **The Face of COVID-19: Facial Pressure Wounds Related to Prone Positioning in Patients Undergoing Ventilation in the Intensive Care Unit.** *Otolaryngol Head Neck Surg* 2020:194599820951470Jiang ST, Fang CH, Chen JT, Smith RV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779961>
 63. **COVID-19: A tale of two pandemics across the Asia Pacific region.** *Paediatr. Respir. Rev.* 2020; Fitzgerald DA, Wong GWK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768308>
 64. **Hanshiyi Formula, an approved medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study.** *Pharmacol. Res.* 2020:105127Tian J, Yan S, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791263>
 65. **The Role of Hospital and Community Pharmacists in the Management of COVID-19: Towards an Expanded Definition of the Roles, Responsibilities, and Duties of the Pharmacist.** *Pharmacy (Basel)* 2020; 8:Bragazzi NL, Mansour M, Bonsignore A, Ciliberti R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784696>
 66. **Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression.** *Physiology (Bethesda)* 2020; 35:288-301Bohn MK, Hall A, Sepiashvili L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783610>
 67. **Clinical course and physiotherapy intervention in 9 patients with COVID-19.** *Physiotherapy* 2020; 109:1-3Lee AJY, Chung CLH, Young BE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791333>
 68. **Explaining the homogeneous diffusion of COVID-19 nonpharmaceutical interventions across heterogeneous countries.** *Proc Natl Acad Sci U S A* 2020; Sebhatu A, Wennberg K, Arora-Jonsson S, Lindberg SI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788356>
 69. **Drive-thru pharmacy services: A way forward to combat COVID-19 pandemic.** *Res Social Adm Pharm* 2020; Hussain R, Dawoud DM, Babar ZU. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792322>
 70. **The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice.** *Rheumatology (Oxford)* 2020; Liew JW, Bhana S, Costello W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789449>
 71. **Pharmacists roles and responsibilities during epidemics and pandemics in Saudi Arabia: An opinion paper from the Saudi Society of clinical pharmacy.** *Saudi Pharm J* 2020; 28:1030-1034Badreldin HA, Raslan S, Almudaiheem H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788836>
 72. **COVID-19: Clinical aspects and therapeutics responses.** *Saudi Pharm J* 2020; 28:1004-1008Khan S, Ali A, Shi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788835>
 73. **Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study.** *Thromb Res* 2020; 194:209-215Stessel B, Vanvuchelen C, Bruckers L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788120>
 74. **COVID-19: Implications, Reactions and Future Directions.** *Turk Arch Otorhinolaryngol* 2020; 58:122-126Dhanani R, Wasif M, Pasha HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783040>
 75. **Melatonin potentials against viral infections including COVID-19: current evidence and new findings.** *Virus Res.* 2020:198108Juybari KB, Pourhanifeh MH, Hosseinzadeh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768490>
 76. **[COVID-19: new challenges for medical science and practical health].** *Vopr. Pitan.* 2020; 89:6-13Tutelyan VA, Nikityuk DB, Burlyayeva EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790253>

Mental – public health (70 articles)

1. **Mass Panic Disaster Management in COVID-19 Pandemic.** *Acta Med Indones* 2020; 52:179-184Shatri H, Faisal E, Putranto R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778634>
2. **The effects of coronavirus disease 2019 pandemic on the South African health system: A call to maintain essential health services.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e5Nyasulu J, Pandya H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787396>

3. **Recommendations for a national Coronavirus disease 2019 response guideline for the care of older persons in Nigeria during and post-pandemic: A family physician's perspective.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3Olagundoye O, Enema O, Adebowale A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787399>
4. **Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future.** *Alzheimers Dement* 2020; Mok VCT, Pendlebury S, Wong A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789951>
5. **Public Awareness Toward Coronavirus Disease-2019.** *Asia Pac. J. Public Health* 2020;1010539520949421Bdair IA, Alshloul MN, Maribbay GL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787582>
6. **Flattening the curve of COVID-19 for medical education in psychiatry and addiction medicine.** *Australas Psychiatry* 2020;1039856220946647Looi JC, Bonner D, Maguire P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772702>
7. **COVID-19 and the mental well-being of Australian medical students: impact, concerns and coping strategies used.** *Australas Psychiatry* 2020;1039856220947945Lyons Z, Wilcox H, Leung L, Dearsley O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772729>
8. **COVID-19: Reduced Lung Function and Increased Psycho-emotional Stress.** *Bioinformatics* 2020; 16:293-296Wu D, Ellis D, Datta S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773987>
9. **Psychological Therapies and Psychoeducational Recommendations for Bipolar Disorder Treatment During COVID-19 Pandemic."** *Bipolar Disord* 2020; de Siqueira Rotenberg L, Nascimento C, Cohab Khafif T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780503>
10. **Opioids and the COVID-19 pandemic: does chronic opioid use or misuse increase clinical vulnerability?** *Br J Anaesth* 2020; Lambert DG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768181>
11. **COVID-19: Concerns and behaviours in Croatia.** *Br. J. Health Psychol.* 2020; Lauri Korajlija A, Jokic-Begic N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779816>
12. **Multiple COVID-19 Risk Factors Increase the Likelihood of Experiencing Anxiety Symptoms in Canada.** *Can. J. Psychiatry* 2020;706743720949356Elton-Marshall T, Wells S, Jankowicz D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787572>
13. **Pediatric neuropsychological evaluation via telehealth: Novel models of care.** *Clin. Neuropsychol.* 2020;1-13Pritchard AE, Sweeney K, Salorio CF, Jacobson LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787508>
14. **Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients.** *Crit Care* 2020; 24:491Helms J, Kremer S, Merdji H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771053>
15. **Anxiety, pandemic-related stress and resilience among physicians during the COVID-19 pandemic.** *Depress. Anxiety* 2020; Mosheva M, Hertz-Palmor N, Dorman Ilan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789945>
16. **Public health lessons learned from biases in coronavirus mortality overestimation.** *Disaster Med Public Health Prep* 2020;1-24Brown RB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782048>
17. **[Comment] The challenges of planetary mental health in the COVID-19 era.** *Exp. Ther. Med.* 2020; 20:1843-1844Tsamakis K, Dimitrakakis G, Stefanadi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782492>
18. **What Happened to Patients With Obsessive Compulsive Disorder During the COVID-19 Pandemic? A Multicentre Report From Tertiary Clinics in Northern Italy.** *Front Psychiatry* 2020; 11:720Benatti B, Albert U, Maina G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793008>
19. **Mental Health Status of Paediatric Medical Workers in China During the COVID-19 Outbreak.** *Front Psychiatry* 2020; 11:702Liu Y, Wang L, Chen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792998>
20. **Association Between Current Physical Activity and Current Perceived Anxiety and Mood in the Initial Phase of COVID-19 Confinement.** *Front Psychiatry* 2020; 11:729López-Bueno R, Calatayud J, Ezzatvar Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793013>
21. **Life History Orientation Predicts COVID-19 Precautions and Projected Behaviors.** *Front. Psychol.* 2020; 11:1857Corpuz R, D'Alessandro S, Adeyemo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793087>
22. **COVID-19: Growing Health Disparity Gaps and an Opportunity for Health Behavior Discovery?** *Health Equity* 2020; 4:316-319Farmer N, Wallen GR, Baumer Y, Powell-Wiley TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775940>
23. **Picking Up the Pieces: Healthcare Quality in a Post-COVID-19 World.** *Health Secur* 2020; Vinoya-Chung CR, Jalon HS, Cho HJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780582>
24. **Attitude, practice, behavior, and mental health impact of COVID-19 on doctors.** *Indian J. Psychiatry* 2020; 62:257-265Chatterjee SS, Bhattacharyya R, Bhattacharyya S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773868>
25. **Psychological impact of COVID-19 on medical care workers in China.** *Infect Dis Poverty* 2020; 9:113Si MY, Su XY, Jiang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787929>
26. **Risk Perception and Depression in Public Health Crises: Evidence from the COVID-19 Crisis in China.** *Int J Environ Res Public Health* 2020; 17Ding Y, Xu J, Huang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784792>
27. **Children's Anxiety and Factors Related to the COVID-19 Pandemic: An Exploratory Study Using the Children's Anxiety Questionnaire and the Numerical Rating Scale.** *Int J Environ Res Public Health* 2020; 17Garcia de Avila MA, Hamamoto Filho PT, Jacob F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784898>
28. **The Quality of Life, Psychological Health, and Occupational Calling of Korean Workers: Differences by the New Classes of Occupation Emerging Amid the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2020; 17Kim YJ, Kang SW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781702>
29. **Isolation of patients in psychiatric hospitals in the context of the COVID-19 pandemic: An ethical, legal, and practical challenge.** *Int. J. Law Psychiatry* 2020; 71:101572Brown C, Ruck Keene A, Hooper CR, O'Brien A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768110>
30. **Forensic mental telehealth assessment (FMFTA) in the context of COVID-19.** *Int. J. Law Psychiatry* 2020; 71:101595Drogin EY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768117>
31. **Mental health and capacity laws in Northern Ireland and the COVID-19 pandemic: Examining powers, procedures and protections under emergency legislation.** *Int. J. Law Psychiatry* 2020; 71:101602Farrell AM, Hann P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768125>

32. **Domestic violence against women and the COVID-19 pandemic: What is the role of psychiatry?** *Int. J. Law Psychiatry* 2020; 71:101594 Gulati G, Kelly BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768101>
33. **The impact of the Covid-19 pandemic in the precipitation of intimate partner violence.** *Int. J. Law Psychiatry* 2020; 71:101606 Moreira DN, Pinto da Costa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768122>
34. **COVID-19 and forced alcohol abstinence in India: The dilemmas around ethics and rights.** *Int. J. Law Psychiatry* 2020; 71:101579 Nadkarni A, Kapoor A, Pathare S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768113>
35. **Scottish mental health and capacity law: The normal, pandemic and 'new normal'.** *Int. J. Law Psychiatry* 2020; 71:101593 Stavert J, McKay C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768103>
36. **The psychological impact of COVID-19 on 'hidden' frontline healthcare workers.** *Int J Soc Psychiatry* 2020:20764020950772 Teo WZY, Soo YE, Yip C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779498>
37. **Behavioral Health and Service Usage During the Coronavirus Disease 2019 Pandemic Among Emerging Adults Currently or Recently Experiencing Homelessness.** *J. Adolesc. Health* 2020; Tucker JS, D'Amico EJ, Pedersen ER *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792255>
38. **Elevated depression and anxiety symptoms among pregnant individuals during the COVID-19 pandemic.** *J. Affect. Disord.* 2020; 277:5-13 Lebel C, MacKinnon A, Bagshawe M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777604>
39. **Editorial Perspective: COVID-19 pandemic-related psychopathology in children and adolescents with mental illness.** *J. Child Psychol. Psychiatry* 2020; Jefsen OH, Rohde C, Nørremark B, Østergaard SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779748>
40. **Psychological impact of COVID-19 outbreak on frontline nurses: A cross-sectional survey study.** *J. Clin. Nurs.* 2020; Nie A, Su X, Zhang S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32786150>
41. **Community psychology and the crisis of care.** *J. Community Psychol.* 2020; Malherbe N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789911>
42. **The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients.** *J Cyst Fibros* 2020; Havermans T, Houben J, Vermeulen F *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768311>
43. **Psychological teleconsultations in patients suffering from chronic skin diseases during the COVID-19 era: a service to improve patients' quality of life.** *J Dermatolog Treat* 2020:1-7 Marasca C, De Rosa A, Fabrocini G *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783664>
44. **Factors related to preventive COVID-19 infection behaviors among people with mental illness.** *J Formos Med Assoc* 2020; Chang KC, Strong C, Pakpour AH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773260>
45. **The impact of sheltering-in-place during the COVID-19 pandemic on older adults' social and mental well-being.** *J. Gerontol. B Psychol. Sci. Soc. Sci.* 2020; Krendl AC, Perry BL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778899>
46. **Modern Sencicide in the Face of a Pandemic: An Examination of Public Discourse and Sentiment about Older Adults and COVID-19 Using Machine Learning.** *J. Gerontol. B Psychol. Sci. Soc. Sci.* 2020; Xiang X, Lu X, Halavanau A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785620>
47. **The status and high risk factors of severe psychological distress in migraine patients during nCOVID-2019 outbreak in Southwest China: a cross-sectional study.** *J. Headache Pain* 2020; 21:100 Ma M, Fang J, Li C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787771>
48. **COVID-19 anxiety among frontline nurses: predictive role of organisational support, personal resilience and social support.** *J. Nurs. Manag.* 2020; Labrague LJ, de Los Santos J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770780>
49. **The influence of experiences of involvement in the COVID-19 rescue task on the professional identity among Chinese nurses: A qualitative study.** *J. Nurs. Manag.* 2020; Sheng Q, Zhang X, Wang X, Cai C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770772>
50. **The psychological impact on an orthopaedic outpatient setting in the early phase of the COVID-19 pandemic: a cross-sectional study.** *J. Orthop. Surg. Res.* 2020; 15:322 Wong KC, Han XA, Tay KS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787965>
51. **Stress and the Surgical Resident in the COVID-19 Pandemic.** *J Surg Educ* 2020; Collins C, Mahuron K, Bongiovanni T *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792326>
52. **The Behaviour Changes in Response to COVID-19 Pandemic within Malaysia.** *Malays. J. Med. Sci.* 2020; 27:45-50 Koh Boon Yau E, Pang Tze Ping N, Shoesmith WD *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788840>
53. **Ultra Brief Psychological Interventions for COVID-19 Pandemic: Introduction of a Locally-Adapted Brief Intervention for Mental Health and Psychosocial Support Service.** *Malays. J. Med. Sci.* 2020; 27:51-56 Ping NPT, Shoesmith WD, James S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788841>
54. **The Impact of COVID-19 on Health Behavior, Stress, Financial and Food Security among Middle to High Income Canadian Families with Young Children.** *Nutrients* 2020; 12:Carroll N, Sadowski A, Laila A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784530>
55. **Psychological effects caused by the COVID-19 pandemic in health professionals: A systematic review with meta-analysis.** *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2020:110062da Silva FCT, Neto MLR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771337>
56. **Psychiatric symptomatology associated with depression, anxiety, distress, and insomnia in health professionals working in patients affected by COVID-19: A systematic review with meta-analysis.** *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2020:110057da Silva FCT, Neto MLR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777327>
57. **Impact of COVID-19 pandemic on mental health.** *Psychiatr. Pol.* 2020; 54:187-198 Heitzman J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772053>
58. **The Behavioral Health System and Its Response to COVID-19: A Snapshot Perspective.** *Psychiatr. Serv.* 2020:appips202000264 Pinals DA, Hepburn B, Parks J, Stephenson AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781926>
59. **Social Participation, Inclusion and Mental Well-Being following SARS-CoV-2 Related Restrictions on Going Out: A Follow-up Study from Germany.** *Psychiatr. Prax.* 2020; Schützwohl M, Mergel E.

60. **Psychological effects of the COVID 19 pandemic on healthcare workers globally: A systematic review.** *Psychiatry Res* 2020; 292:113360Sheraton M, Deo N, Dutt T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771837>
61. **What about social determinants of health against xenophobia?** *Public Health* 2020; Adja KYC, Wu E, Golinelli D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782163>
62. **Who is lonely in lockdown? Cross-cohort analyses of predictors of loneliness before and during the COVID-19 pandemic.** *Public Health* 2020; 186:31-34Bu F, Steptoe A, Fancourt D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768621>
63. **COVID-19 lockdown in people with severe mental disorders in Spain: Do they have a specific psychological reaction compared with other mental disorders and healthy controls?** *Schizophr Res* 2020; González-Blanco L, Dal Santo F, García-Álvarez L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771308>
64. **Isolation until it hurts – the consequences of the corona pandemic.** *Schmerz* 2020; 34:301-302Radbruch L, Schaible HG.
65. **Prevalence and associated factors of poor sleep quality among Chinese returning workers during the COVID-19 pandemic.** *Sleep Med.* 2020; 73:47-52Yang Y, Zhu JF, Yang SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771927>
66. **Risk factors for anxiety of otolaryngology healthcare workers in Hubei province fighting coronavirus disease 2019 (COVID-19).** *Soc. Psychiatry Psychiatr. Epidemiol.* 2020; Yang X, Zhang Y, Li S, Chen X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785756>
67. **Contact Tracing: An Opportunity for Social Work to Lead.** *Soc Work Public Health* 2020:1-13Ross AM, Zerden LS, Ruth BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781912>
68. **Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic (Sleep COVID-19): structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:704Elder GJ, Alfonso-Miller P, Atkinson WCM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771068>
69. **COVID-19 related anxiety in people living with HIV: An online cross-sectional study.** *Turk J Med Sci* 2020; Kuman TunÇel Ö, PullukÇu H, Erdem HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777899>
70. **[COVID-19: new challenges for medical science and practical health].** *Vopr. Pitan.* 2020; 89:6-13Tutelyan VA, Nikityuk DB, Burlyaeva EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790253>

Meta-analyses - systematic reviews (13 articles)

1. **Pulmonary vascular enlargement on thoracic CT for diagnosis and differential diagnosis of COVID-19: a systematic review and meta-analysis.** *Ann Transl Med* 2020; 8:878Lv H, Chen T, Pan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793722>
2. **Psychological impact of an epidemic/pandemic on the mental health of healthcare professionals: a rapid review.** *BMC Public Health* 2020; 20:1230Stuijzand S, Deforges C, Sandoz V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787815>
3. **Impact of COVID-19 on the Mental Health of Healthcare Professionals in Pakistan.** *Cureus* 2020; 12:e8974Sandesh R, Shahid W, Dev K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775056>
4. **Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:431Boregowda U, Aloysius MM, Perisetti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793616>
5. **COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:459Nasiri MJ, Haddadi S, Tahvildari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793620>
6. **Is neutrophilia associated with mortality in COVID-19 patients? A meta-analysis and meta-regression.** *Int. J. Lab. Hematol.* 2020; Shi L, Wang Y, Liang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779881>
7. **Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis.** *J Integr Med* 2020; Fan AY, Gu S, Alemi SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792254>
8. **Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression.** *J Med Virol* 2020; Khinda J, Janjua NZ, Cheng S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776551>
9. **Epidemiology of COVID-19: A Systematic Review and Meta-analysis of Clinical Characteristics, Risk factors and Outcomes.** *J Med Virol* 2020; Li J, Huang DQ, Zou B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790106>
10. **Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis.** *J Med Virol* 2020; Sarkar S, Soni KD, Khanna P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776573>
11. **Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis.** *J. Neurol.* 2020; Patel U, Malik P, Shah D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770412>
12. **Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis.** *Kidney Int Rep* 2020; 5:1149-1160Robbins-Juarez SY, Qian L, King KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775814>
13. **Psychological effects caused by the COVID-19 pandemic in health professionals: A systematic review with meta-analysis.** *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2020:110062da Silva FCT, Neto MLR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771337>

Mortality (15 articles)

1. **Association of Frailty with Mortality in Older Inpatients with Covid-19: A Cohort Study.** *Age Ageing* 2020; Aw D, Woodrow L, Ogliaari G, Harwood R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778870>

2. **COVID-19 mortality in Lombardy: the vulnerability of the oldest old and the resilience of male centenarians.** *Aging (Albany NY)* 2020; 12Marcon G, Tettamanti M, Capacci G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788424>
3. **Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients.** *Crit Care* 2020; 24:495Rommelink M, De Mendonça R, D'Haene N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787909>
4. **Preliminary Post-Mortem COVID-19 Evidence of Endothelial Injury and Factor VIII Hyperexpression.** *Diagnostics (Basel)* 2020; 10Cipolloni L, Sessa F, Bertozzi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784826>
5. **Humanized care in a death for COVID-19: A case study.** *Enferm. Clin.* 2020; Allande Cussó R, Navarro Navarro C, Porcel Gálvez AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782187>
6. **A case study in model failure? COVID-19 daily deaths and ICU bed utilisation predictions in New York state.** *Eur. J. Epidemiol.* 2020:1-10Chin V, Samia NI, Marchant R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780189>
7. **Death tolls of COVID-19: Where come the fallacies and ways to make them more accurate.** *Glob Public Health* 2020:1-6Lin TPH, Wan KH, Huang SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787510>
8. **Impact of myocardial injury on mortality in patients with COVID-19: a meta-analysis.** *Hellenic J. Cardiol.* 2020; Sanz-Sánchez J, Vrachatis DA, Reimers B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781301>
9. **Simultaneous circulation of COVID-19 and flu in Italy: potential combined effects on the risk of death?** *Int J Infect Dis* 2020; Capone A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768696>
10. **Is neutrophilia associated with mortality in COVID-19 patients? A meta-analysis and meta-regression.** *Int. J. Lab. Hematol.* 2020; Shi L, Wang Y, Liang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779881>
11. **Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression.** *J Med Virol* 2020; Khinda J, Janjua NZ, Cheng S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776551>
12. **Effects of Particulate Matter Exposure on the Transmissibility and Case Fatality Rate of COVID-19: A Nationwide Ecological Study in China.** *J Travel Med* 2020; Ran J, Zhao S, Han L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779721>
13. **Defining heart disease risk for death in COVID-19 infection.** *QJM* 2020; Li J, Guo T, Dong D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790836>
14. **History of Stroke Is Independently Associated With In-Hospital Death in Patients With COVID-19.** *Stroke* 2020:Strokeaha120030685Kummer BR, Klang E, Stein LK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772679>
15. **The clash between palliative care and COVID-19.** *Support. Care Cancer* 2020; Mercadante S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793999>

Online – IT – Apps (25 articles)

1. **Reply to: An Expanded COVID-19 Telemedicine Intermediate Care Model Utilizing Repurposed Hotel Rooms.** *Am J Respir Crit Care Med* 2020; Bruni T, Lalvani A, Richeldi L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790518>
2. **An Expanded COVID-19 Telemedicine Intermediate Care Model Utilizing Repurposed Hotel Rooms.** *Am J Respir Crit Care Med* 2020; Fenton ME, Wasko K, Behl V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790480>
3. **Tele-yoga for stress management: Need of the hour during the COVID-19 pandemic and beyond?** *Asian J Psychiatr* 2020; 54:102334Jasti N, Bhargav H, George S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777755>
4. **Experience with online lectures about endoscopic sinus surgery using an video conferencing app.** *Auris Nasus Larynx* 2020; Maeda Y, Takeda K, Hayama M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792117>
5. **Pediatric neuropsychological evaluation via telehealth: Novel models of care.** *Clin. Neuropsychol.* 2020:1-13Pritchard AE, Sweeney K, Salorio CF, Jacobson LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787508>
6. **Automated Inflating Resuscitator (AIR): Design and Development of a 3D-Printed Ventilator Prototype and Corresponding Simulation Scenario Based on the Management of a Critical COVID-19 Patient.** *Cureus* 2020; 12:e9134Gino B, Wang Z, d'Entremont P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789074>
7. **Internet public opinion evolution in the COVID-19 event and coping strategies.** *Disaster Med Public Health Prep* 2020:1-23Zhong Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782053>
8. **Medical populism and the COVID-19 pandemic.** *Glob Public Health* 2020:1-13Lasco G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780635>
9. **Death tolls of COVID-19: Where come the fallacies and ways to make them more accurate.** *Glob Public Health* 2020:1-6Lin TPH, Wan KH, Huang SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787510>
10. **Telemedicine for chronic pain management during COVID-19 pandemic.** *Indian J. Anaesth.* 2020; 64:456-462Ghai B, Malhotra N, Bajwa SJS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792708>
11. **COVID-19 on TikTok: harnessing an emerging social media platform to convey important public health messages.** *Int. J. Adolesc. Med. Health* 2020; Basch CH, Hillyer GC, Jaime C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776899>
12. **Big Data Analysis of Media Reports Related to COVID-19.** *Int J Environ Res Public Health* 2020; 17Jung JH, Shin JI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781727>
13. **Telemedicine and the battle for health equity: Translating temporary regulatory orders into sustained policy change.** *J Am Acad Dermatol* 2020; Kassamali B, Haddadi NS, Rashighi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781185>
14. **Telemedicine during COVID-19 pandemic.** *J Arrhythm* 2020; 36:804-805Menardi E, Ballari GP, Racca E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778850>

15. **Psychological teleconsultations in patients suffering from chronic skin diseases during the COVID-19 era: a service to improve patients' quality of life.** *J Dermatolog Treat* 2020;1-7Marasca C, De Rosa A, Fabbrocini G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783664>
16. **The use of data from electronic health records in times of a pandemic-a legal and ethical assessment.** *J Law Biosci* 2020; 7:lsaa041Stoeger K, Schmidhuber M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793374>
17. **A Systematic Review of Smartphone Applications Available for Corona Virus Disease 2019 (COVID19) and the Assessment of their Quality Using the Mobile Application Rating Scale (MARS).** *J Med Syst* 2020; 44:164Davalbhakta S, Advani S, Kumar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779002>
18. **Mitigating Bias in Virtual Interviews for Applicants Who are Underrepresented in Medicine.** *J. Natl. Med. Assoc.* 2020; Nwora C, Allred DB, Verduzco-Gutierrez M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768242>
19. **Implementation of Telemedicine in a Laryngology Practice During the COVID-19 Pandemic: Lessons Learned, Experiences Shared.** *J. Voice* 2020; Strohl MP, Dwyer CD, Ma Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778359>
20. **Rapid Deployment of a Free, Privacy-Assured COVID-19 Symptom Tracker for Public Safety During Reopening: System Development and Feasibility Study.** *JMIR Public Health Surveill* 2020; 6:e19399Kassaye SG, Spence AB, Lau E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788148>
21. **The infodemics of COVID-19 amongst healthcare professionals in India.** *Med J Armed Forces India* 2020; 76:276-283Datta R, Yadav AK, Singh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773929>
22. **Pandemic printing: a novel 3D-printed swab for detecting SARS-CoV-2.** *Med. J. Aust.* 2020; Williams E, Bond K, Isles N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772375>
23. **Virtual Parkinson's Disease Support Groups in the COVID-19 Era: Social Connection in the Time of Social Distancing.** *Mov Disord Clin Pract* 2020; 7:739-740Subramanian I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775536>
24. **Grappling with the 'human' problem hiding behind the technology: Telehealth during and beyond COVID-19.** *Psychooncology* 2020; Sansom-Daly UM, Bradford N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779776>
25. **An Observational Study of the Impact of COVID-19 and the Transition to Telehealth on Community Mental Health Center Providers.** *Res Sq* 2020; Sklar M, Reeder K, Carandang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793893>

Other – Miscellaneous (28 articles)

1. **Prohibiting alcohol sales during the coronavirus disease 2019 pandemic has positive effects on health services in South Africa.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e4Reuter H, Jenkins LS, De Jong M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787395>
2. **COVID-19 clinical implications: the significance of nanomedicine.** *Bioimpacts* 2020; 10:137-138Barar J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793434>
3. **Construction time, cost and testing data of a prefabricated isolation medical unit for COVID-19.** *Data Brief* 2020; 32:106068Zhou Y, Zhang Z, Wang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775578>
4. **Vacation in times of corona: Rights and duties of pharmacy employees.** *Deutsche Apotheker Zeitung* 2020; 160van den Heuvel M.
5. **The Episode of National Lockdown in the Pandemic: Air Traffic Restriction as the Control Strategy and Its Impact on Existing Cases and Recovery Rate of COVID-19 in Megacities of China.** *Disaster Med Public Health Prep* 2020:1-11Li J, Wang Z, Yuan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782050>
6. **Region-specific air pollutants and meteorological parameters influence COVID-19: A study from mainland China.** *Ecotoxicol. Environ. Saf.* 2020; 204:111035Lin S, Wei D, Sun Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768746>
7. **Medical populism and the COVID-19 pandemic.** *Glob Public Health* 2020:1-13Lasco G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780635>
8. **Sick leave accessibility in junior doctors at an Australian health service.** *Infect Dis Health* 2020; Mitchell L, Coatsworth N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792298>
9. **"Stay at Home, Protect the National Health Service, Save Lives": a cost benefit analysis of the lockdown in the United Kingdom.** *Int J Clin Pract* 2020:e13674Miles D, Stedman M, Heald AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790942>
10. **The Impact of COVID-19 on the Insurance Industry.** *Int J Environ Res Public Health* 2020; 17Babuna P, Yang X, Gyiilbag A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784978>
11. **Impacts of COVID-19 on Trade and Economic Aspects of Food Security: Evidence from 45 Developing Countries.** *Int J Environ Res Public Health* 2020; 17Erokhin V, Gao T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785155>
12. **Denial and Distraction: How the Populist Radical Right Responds to COVID-19 Comment on "A Scoping Review of PRR Parties' Influence on Welfare Policy and its Implication for Population Health in Europe".** *Int J Health Policy Manag* 2020; Falkenbach M, Greer SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772011>
13. **Views on Workplace Policies and its Impact on Health-Related Quality of Life During Coronavirus Disease (COVID-19) Pandemic: Cross-Sectional Survey of Employees.** *Int J Health Policy Manag* 2020; Wong EL, Ho KF, Wong SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772010>
14. **How perceived threat of Covid-19 causes turnover intention among Pakistani nurses: A moderation and mediation analysis.** *Int. J. Ment. Health Nurs.* 2020; Irshad M, Khattak SA, Hassan MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779356>
15. **A cross-sectional study of Persian medicine and the COVID-19 pandemic in Iran: Rumors and recommendations.** *Integr Med Res* 2020; 9:100482Molavi Vardanjani H, Heydari ST, Dowran B, Pasalar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789107>
16. **The role of Korean Medicine in the post-COVID-19 era: an online panel discussion part 2 - basic research and education.** *Integr Med Res* 2020; 9:100488Park S, Hahm DH, Joo M *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789108>
17. **Impact of COVID-19 on global hepatitis C elimination efforts.** *J Hepatol* 2020; Blach S, Kondili LA, Aghemo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777322>
 18. **Response to Rabelo-da-Ponte.** *J Infect Dis* 2020; Zeng QL, Yu ZJ, Ji F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777045>
 19. **The use of data from electronic health records in times of a pandemic-a legal and ethical assessment.** *J Law Biosci* 2020; 7:lsaa041Stoeger K, Schmidhuber M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793374>
 20. **Panic buying or good adherence? Increased pharmacy purchases of drugs from wholesalers in the last week prior to Covid-19 lockdown.** *J. Psychiatr. Res.* 2020; 130:19-21Kostev K, Lauterbach S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768709>
 21. **Crisis as opportunity: how COVID-19 can reshape the Australian health system.** *Med. J. Aust.* 2020; Blecher GE, Blashki GA, Judkins S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776335>
 22. **Shedding light on the restart.** *Phys. Med.* 2020; 77:18-20Fusi F, Romano G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768916>
 23. **Key questions for modelling COVID-19 exit strategies.** *Proc. Biol. Sci.* 2020; 287:20201405Thompson RN, Hollingsworth TD, Isham V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781946>
 24. **The Role of Law and Ethics in Recent Preparedness and Response for Vaccine-Preventable Illness.** *Public Health Rep.* 2020:33354920949532Silverman RD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791033>
 25. **[Is SARS-CoV-2 also attacking the French language?].** *Rev. Med. Interne* 2020; Andrès E, Pessaux P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768268>
 26. **Significant decrease of lightning activities during COVID-19 lockdown period over Kolkata megacity in India.** *Sci Total Environ* 2020; 747:141321Chowdhuri I, Pal SC, Saha A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771791>
 27. **Air quality development during the COVID-19 pandemic over a medium-sized urban area in Thailand.** *Sci Total Environ* 2020; 746:141320Stratoulas D, Nuthammachot N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768789>
 28. **Impacts of the COVID-19 responses on traffic-related air pollution in a Northwestern US city.** *Sci Total Environ* 2020; 747:141325Xiang J, Austin E, Gould T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771792>

Pathology (7 articles)

1. **Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients.** *Crit Care* 2020; 24:495Rommelink M, De Mendonça R, D'Haene N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787909>
2. **Preliminary Post-Mortem COVID-19 Evidence of Endothelial Injury and Factor VIII Hyperexpression.** *Diagnosics (Basel)* 2020; 10Cipolloni L, Sessa F, Bertozzi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784826>
3. **COVID-19: An up-to-date review - from morphology to pathogenesis.** *Indian J. Pathol. Microbiol.* 2020; 63:358-366Bal A, Agrawal R, Vaideeswar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769322>
4. **Guidelines for various laboratory sections in view of COVID-19: Recommendations from the Indian Association of Pathologists and Microbiologists.** *Indian J. Pathol. Microbiol.* 2020; 63:350-357Misra V, Agrawal R, Kumar H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769321>
5. **What can we learn from a COVID-19 lung biopsy?** *Int J Infect Dis* 2020; Wu J, Yu J, Zhou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768699>
6. **Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?** *Int J Rheum Dis* 2020; Kabeerdoss J, Danda D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779341>
7. **A Japanese case of COVID-19: An autopsy report.** *Pathol. Int.* 2020; Okudela K, Hayashi H, Yoshimura Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794245>

Protection (47 articles)

1. **COVID-19 and a novel initiative to improve safety by 3D printing personal protective equipment parts from computed tomography.** *3D Print Med* 2020; 6:20Coté JJ, Haggstrom J, Vivekanandan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785811>
2. **SARS-CoV-2: The Increasing Importance of Water Filtration against Highly Pathogenic Microbes.** *ACS Chem Neurosci* 2020; Siddiqui R, Khamis M, Ibrahim T, Khan NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790273>
3. **Homo sapiens versus SARS-CoV-2.** *ACS Chem Neurosci* 2020; Siddiqui R, Khan NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32786329>
4. **Health Issues Among Healthcare Workers During COVID-19 Pandemic: a Psychosomatic Approach.** *Acta Med Indones* 2020; 52:172-176Widjaja FF, Shatri H, Putranto R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778632>
5. **The nose lid for the endoscopic endonasal procedures during COVID-19 era: technical note.** *Acta Neurochir. (Wien.)* 2020; Solari D, Bove I, Esposito F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779028>
6. **Specific risk factors for SARS-CoV-2 transmission among health care workers in a university hospital.** *Am. J. Infect. Control* 2020; Çelebi G, Pişkin N, Bekleviç A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771498>
7. **A Care Escalation Framework to Address Lapses in Donning and Doffing of Personal Protective Equipment During the COVID-19 Pandemic.** *Am. J. Infect. Control* 2020; Goulding AM, Wu PE, Gold WL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771497>
8. **3D-printed protected face shields for healthcare workers in Covid-19 pandemic.** *Am. J. Infect. Control* 2020; Lemarteleur V, Fouquet V, Goff SL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791260>

9. **Lesson Learned from China Regarding Use of Personal Protective Equipment.** *Am. J. Infect. Control* 2020; Zhan M, Anders RL, Lin B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791259>
10. **A cross-sectional study of immune seroconversion to SARS-CoV-2 in frontline maternity health professionals.** *Anaesthesia* 2020; Bampoe S, Lucas DN, Neall G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777861>
11. **Aerosol-generating procedures in thoracic surgery in the COVID-19 era in Malaysia.** *Asian Cardiovasc. Thorac. Ann.* 2020;218492320950898Sathiamurthy N, Balasubbiah N, Dharmaraj B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787442>
12. **[Investigation of protective exposure risk events in nurses against corona virus disease 2019 in Wuhan].** *Beijing Da Xue Xue Bao Yi Xue Ban* 2020; 52:711-714Wang Q, Guo JY, Sun H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773807>
13. **Use of a high-flow extractor to reduce aerosol exposure in tracheal intubation.** *Br J Anaesth* 2020; Matava C, Collard V, Siegel J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792136>
14. **Use of HEPA filters to reduce the risk of nosocomial spread of SARS-CoV-2 via operating theatre ventilation systems.** *Br J Anaesth* 2020; Yeo S, Hosein I, McGregor-Davies L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773218>
15. **When infections don't reflect infectiousness: interpreting contact investigation data with care.** *Clin Infect Dis* 2020; Kendall EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770232>
16. **Guidance on hand jewelry for prevention of COVID-19 transmission in healthcare settings.** *Dermatol Ther* 2020; Conway J, Wu AG, Lipner SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785937>
17. **Hydrogel patches alleviate skin injuries to the cheeks and nasal bridge caused by continuous N95 mask use.** *Dermatol Ther* 2020; Zhou N, Yang L, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785973>
18. **Disinfectants and antiseptics facing coronavirus: synthesis of evidence and recommendations.** *Enferm. Clin.* 2020; León Molina J, Abad-Corpa E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778501>
19. **Biosafety threats of the rapidly established labs for SARS-CoV-2 tests in China.** *Environ Int* 2020; 143:105964Yuan D, Gao W, Liang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768807>
20. **Can a health care worker have sex in the time of COVID-19?** *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2020; Naik BS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778481>
21. **Can surgery follow the dictates of the pandemic "keep your distance"? Requirements with COVID-19 for hygiene, resources and the team.** *GMS Hyg Infect Control* 2020; 15:Doc19Krüger CM, Kramer A, Türler A, Riediger H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782898>
22. **Cardiological society of India document on safety measure during echo evaluation of cardiovascular disease in the time of COVID-19.** *Indian Heart J.* 2020; 72:145-150Gupta R, Das MK, Mohanan PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768012>
23. **Guidelines for various laboratory sections in view of COVID-19: Recommendations from the Indian Association of Pathologists and Microbiologists.** *Indian J. Pathol. Microbiol.* 2020; 63:350-357Misra V, Agrawal R, Kumar H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769321>
24. **Suction mitigation of airborne particulate generated during sinonasal drilling and cautery.** *Int Forum Allergy Rhinol* 2020; Workman AD, Xiao R, Feng A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779883>
25. **Criticality of physical/social distancing, handwashing, respiratory hygiene, and face-masking during the COVID-19 pandemic and beyond.** *Int J Clin Pract* 2020:e13656Rahimi F, Talebi Bezzmin Abadi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772412>
26. **Care during COVID-19: Drug use, harm reduction, and intimacy during a global pandemic.** *Int. J. Drug Policy* 2020:102896Schlosser A, Harris S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768156>
27. **Alternative Methods of Sterilization in Dental Practices Against COVID-19.** *Int J Environ Res Public Health* 2020; 17Cumbo E, Gallina G, Messina P, Scardina GA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784414>
28. **Analysis of Gender-Dependent Personal Protective Behaviors in a National Sample: Polish Adolescents' COVID-19 Experience (PLACE-19) Study.** *Int J Environ Res Public Health* 2020; 17Guzek D, Skolmowska D, Głabska D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785004>
29. **Forensic mental telehealth assessment (FMFTA) in the context of COVID-19.** *Int. J. Law Psychiatry* 2020; 71:101595Drogin EY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768117>
30. **Cross-continental comparison of safety and protection measures amongst urologists during COVID-19.** *Int. J. Urol.* 2020; de la Rosette J, Laguna P, Álvarez-Maestro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772434>
31. **Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine.** *J. Aerosol Med. Pulm. Drug Deliv.* 2020; Fink JB, Ehrmann S, Li J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783675>
32. **Managing yourself and keeping your family safe: An experience of a COVID positive surgeon.** *J Clin Orthop Trauma* 2020; 11:S426-s427Pandey R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774006>
33. **Seborrheic dermatitis and masks.** *J Cosmet Dermatol* 2020; Veraldi S, Angileri L, Barbareschi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790897>
34. **SARS-CoV-2 infection: Advocacy for training and social distancing in healthcare settings.** *J Hosp Infect* 2020; Gagneux-Brunon A, Pelissier C, Gagnaire J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781200>
35. **Containment of COVID-19 amongst ancillary healthcare workers: an integral component of infection control.** *J Hosp Infect* 2020; Wee LE, Ying Sim JX, Conceicao EP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781199>
36. **Powered Air Purifying Respirator (PAPR) restores the N95 face mask induced cerebral hemodynamic alterations among Healthcare Workers during COVID-19 Outbreak.** *J Neurol Sci* 2020; 417:117078Bharatendu C, Ong JJY, Goh Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768718>
37. **Survey on the use of personal protective equipment and COVID-19 testing of pregnant women in Japan.** *J. Obstet. Gynaecol. Res.* 2020; Umazume T, Miyagi E, Haruyama Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779285>
38. **Isolation through rubber dam to prevent COVID-19 exposure during flapless trans-crestal sinus lift procedures.** *J. Oral Implantol.* 2020; Checchi V, Generali L, Generali P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780815>

39. **Rapid Deployment of a Free, Privacy-Assured COVID-19 Symptom Tracker for Public Safety During Reopening: System Development and Feasibility Study.** *JMIR Public Health Surveill* 2020; 6:e19399Kassaye SG, Spence AB, Lau E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788148>
40. **The Behaviour Changes in Response to COVID-19 Pandemic within Malaysia.** *Malays. J. Med. Sci.* 2020; 27:45-50Koh Boon Yau E, Pang Tze Ping N, Shoesmith WD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788840>
41. **"Hybrid tracheostomy": a low risk procedure for tracheostomy in COVID-19 patients.** *Medizinische Klinik - Intensivmedizin und Notfallmedizin* 2020; Nibbe L, Jungehülsing M, Röber S *et al.*
42. **Use of a Novel Negative-Pressure Tent During Bedside Tracheostomy in COVID-19 Patients.** *Neurocrit. Care* 2020; Rajajee V, Williamson CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770341>
43. **European Aeromedical Evacuation Transports with SARS-COV 2 positive Patients.** *Notarzt* 2020; Sammito S, Post J, Ritter DM *et al.*
44. **Droplet and Aerosol Generation With Endonasal Surgery: Methods to Mitigate Risk During the COVID-19 Pandemic.** *Otolaryngol Head Neck Surg* 2020:194599820949802Dharmarajan H, Freiser ME, Sim E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779964>
45. **Mitigation of Aerosols Generated During Rhinologic Surgery: A Pandemic-Era Cadaveric Simulation.** *Otolaryngol Head Neck Surg* 2020:194599820951169Sharma D, Ye MJ, Campiti VJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779974>
46. **Two months of radiation oncology in the heart of Italian "red zone" during COVID-19 pandemic: paving a safe path over thin ice.** *Radiat Oncol* 2020; 15:191Buglione M, Spiazzi L, Guerini AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778174>
47. **COVID-19: the need to redesign head coverings of personal protective equipment for manual stethoscopes.** *Trans. R. Soc. Trop. Med. Hyg.* 2020; Ogoina D, James H, Ominabo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780833>

Pulmonary disease (11 articles)

1. **COVID-19: Reduced Lung Function and Increased Psycho-emotional Stress.** *Bioinformatics* 2020; 16:293-296Wu D, Ellis D, Datta S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773987>
2. **Analysis of cardiopulmonary findings in COVID-19 fatalities: High incidence of pulmonary artery thrombi and acute suppurative bronchopneumonia.** *Cardiovasc. Pathol.* 2020; 49:107263Grosse C, Grosse A, Salzer HJF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784110>
3. **A physiological approach to understand the role of respiratory effort in the progression of lung injury in SARS-CoV-2 infection.** *Crit Care* 2020; 24:494Cruces P, Retamal J, Hurtado DE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778136>
4. **COVID-19 Complicated by Spontaneous Pneumothorax.** *Cureus* 2020; 12:e9104Mallik T, Dinesh A, Engdahl R, Sabado M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789049>
5. **COVID-19: A Pneumological Point of View - Long-Term Sequelae of COVID-19 - Implications For Follow-up In Respiratory Medicine.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:1086-1092Leo F, Wormanns D, Grohé C.
6. **COVID-19 Associated Pneumonia and Pleural Effusion Masquerading as Heart Failure in Rheumatic Heart Disease.** *Eur J Case Rep Intern Med* 2020; 7:001842Malik J, Javed N, Naeem H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789145>
7. **What can we learn from a COVID-19 lung biopsy?** *Int J Infect Dis* 2020; Wu J, Yu J, Zhou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768699>
8. **Managing asthma in the COVID-19 pandemic and current recommendations from professional bodies: a review.** *J. Asthma* 2020:1-8Ong KY, Tan TL, Chan AKW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779943>
9. **Bronchoscopic procedures during COVID-19 pandemic: Experiences in Turkey.** *J. Surg. Oncol.* 2020; Ozturk A, Sener MU, Yılmaz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783207>
10. **A Japanese case of COVID-19: An autopsy report.** *Pathol. Int.* 2020; Okudela K, Hayashi H, Yoshimura Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794245>
11. **The course of COVID-19 in a 55-year-old patient diagnosed with severe idiopathic pulmonary arterial hypertension.** *Pulm Circ* 2020; 10:2045894020936659Mandler D, Lichtblau M, Ulrich S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782784>

Renal disease (13 articles)

1. **COVID-19 Outbreak in a Hemodialysis Center: A Retrospective Monocentric Case Series.** *Can J Kidney Health Dis* 2020; 7:2054358120944298Mazzoleni L, Ghafari C, Mestrez F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782814>
2. **COVID-19 in Patients With Renal Cell Carcinoma in the Russian Federation.** *Clin. Genitourin. Cancer* 2020; Tsimafeyeu I, Alekseeva G, Berkut M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792300>
3. **COVID-19 and the Kidneys: An Update.** *Front Med (Lausanne)* 2020; 7:423Benedetti C, Waldman M, Zaza G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793615>
4. **A family cluster of diagnosed coronavirus disease 2019 (COVID-19) kidney transplant recipient in Thailand.** *Immun Inflamm Dis* 2020; Sakulkonkij P, Bruminhent J, Pankongngam C, Chalermphunchai N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770646>
5. **Authors' Reply.** *J Am Soc Nephrol* 2020; Farkash EA, Wilson AM, Jentzen JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792369>
6. **What every Intensivist should know about COVID-19 associated acute kidney injury.** *J Crit Care* 2020; 60:91-95Ostermann M, Lumlertgul N, Forni LG, Hoste E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777758>
7. **COVID-19 in Renal Transplant Patient Presenting With Active Typical Symptoms and Resolved Atypical Symptoms.** *J Investig Med High Impact Case Rep* 2020; 8:2324709620949307Adapa S, Konala VM, Naramala S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779481>

8. **SARS-CoV-2 Causes a Specific Dysfunction of the Kidney Proximal Tubule.** *Kidney Int* 2020; Werion A, Belkhir L, Perrot M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791255>
9. **Epidemiological, Clinical, and Immunological Features of a Cluster of COVID-19-Contracted Hemodialysis Patients.** *Kidney Int Rep* 2020; 5:1333-1341Ma Y, Diao B, Lv X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775837>
10. **Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis.** *Kidney Int Rep* 2020; 5:1149-1160Robbins-Juarez SY, Qian L, King KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775814>
11. **COVID-19 Infection in Kidney Transplant Recipients: A Single-Center Case Series of 22 Cases From Belgium.** *Kidney Med* 2020; 2:459-466Devresse A, Belkhir L, Vo B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775986>
12. **COVID-19-Associated Collapsing Focal Segmental Glomerulosclerosis: A Report of 2 Cases.** *Kidney Med* 2020; 2:493-497Sharma Y, Nasr SH, Larsen CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775990>
13. **Kidney transplantation during the COVID-19 pandemic: Potential long-term consequences of an early post-transplant infection.** *Transpl Infect Dis* 2020:e13446Del Bello A, Marion O, Sallusto F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790932>

Reviews (47 articles)

1. **Imaging findings of SARS-CoV-2 infection in pediatrics: A systematic review of coronavirus disease 2019 (COVID-19) in 850 patients.** *Acad Radiol* 2020; Katal S, Johnston SK, Johnston JH, Gholamrezanezhad A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773328>
2. **SARS-CoV-2 pandemic: An overview.** *Adv Biol Regul* 2020; 77:100736Acuti Martellucci C, Flacco ME, Cappadona R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773099>
3. **Where are we with understanding of COVID-19?** *Adv Biol Regul* 2020; 77:100745Akula SM, McCubrey JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773101>
4. **COVID-19 and pregnancy: A review of clinical characteristics, obstetric outcomes and vertical transmission.** *Aust N Z J Obstet Gynaecol* 2020; Pettiroso E, Giles M, Cole S, Rees M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779193>
5. **A comprehensive review of COVID-19 characteristics.** *Biol. Proced. Online* 2020; 22:19Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774178>
6. **Comprehensive review of coronavirus disease 2019 (COVID-19).** *Biomed J* 2020; Chauhan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788071>
7. **Coronavirus Spectrum Infections (COVID-19, MERS, SARS) in Cancer Patients: A Systematic Review of the Literature.** *Cancer Invest.* 2020:1-23Knisely A, Wu J, Kaplan SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787597>
8. **Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics.** *Cancer Treat. Rev.* 2020; 89:102066Fares JE, El Tomb P, Khalil LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769038>
9. **Is COVID-19 to Blame?** *Cell J* 2020; 22:166-168Asgari A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779448>
10. **Systematic review on IBD patients with COVID-19: it is time to take stock.** *Clin Gastroenterol Hepatol* 2020; D'Amico F, Danese S, Peyrin-Biroulet L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777550>
11. **Dermatological Manifestations in Patients With SARS-CoV-2: A Systematic Review.** *Cureus* 2020; 12:e9446Almutairi A, Alfaleh M, Alasheikh M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775112>
12. **COVID-19: An Update Regarding the Quest for Finding an Effective Cure.** *Cureus* 2020; 12:e9010Bangash FS, Saeed G, Shahab P, Waheed A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775090>
13. **Cardiovascular Considerations of Experimental Hydroxychloroquine Therapy on Patients Diagnosed With COVID-19: A Case Series Review.** *Cureus* 2020; 12:e9151Patel J, Patel R, Rodriguez LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789088>
14. **Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.** *Curr Atheroscler Rep* 2020; 22:48Moriarty PM, Gorby LK, Stroes ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710255>
15. **The Plausible role of Indian Traditional Medicine in combating Corona Virus (SARS-CoV 2): a mini-review.** *Curr. Pharm. Biotechnol.* 2020; Adithya J, Nair B, Aishwarya S, Nath LR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32767920>
16. **COVID-19: Questions and answers from infectiology.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:1051-1056Khatamzas E, Rothe C, Kroidl I.
17. **COVID-19: A Pneumological Point of View - Long-Term Sequelae of COVID-19 - Implications For Follow-up In Respiratory Medicine.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:1086-1092Leo F, Wormanns D, Grohé C.
18. **COVID-19: a cardiological point-of-view.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:1063-1067Weckbach LT, Kellnar A, Stremmel C *et al.*
19. **Holistic Analysis of Coronavirus Literature: A Scientometric Study of the Global Publications Relevant to SARS-CoV-2 (COVID-19), MERS-CoV (MERS) and SARS-CoV (SARS).** *Disaster Med Public Health Prep* 2020:1-15Şenel E, Topal FE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787980>
20. **"Tomorrow Never Dies": Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies.** *Diseases* 2020; 8Laskar P, Yallapu MM, Chauhan SC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781617>
21. **Viruses and viral epidemics in the metabolic theory of evolution.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Jankowski R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773332>
22. **COVID-19: A review of the proposed pharmacological treatments.** *Eur. J. Pharmacol.* 2020:173451Lam S, Lombardi A, Ouanounou A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768505>
23. **Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020.** *Excli j* 2020; 19:992-1016Nabil A, Uto K, Elshemy MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788913>

24. **Repurposing current therapeutic regimens against SARS-CoV-2 (Review).** *Exp. Ther. Med.* 2020; 20:1845-1855 KK, I PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782493>
25. **Safety and Efficacy of Chest Physiotherapy in Patients With COVID-19: A Critical Review.** *Front Med (Lausanne)* 2020; 7:454Abdullahi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793618>
26. **Relationship Between COVID-19 Infection and Liver Injury: A Review of Recent Data.** *Front Med (Lausanne)* 2020; 7:458Ali N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793619>
27. **COVID-19 and the Kidneys: An Update.** *Front Med (Lausanne)* 2020; 7:423Benedetti C, Waldman M, Zaza G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793615>
28. **Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective.** *Hum. Cell* 2020;1-12Gupta A, Kashte S, Gupta M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780299>
29. **COVID-19: An up-to-date review - from morphology to pathogenesis.** *Indian J. Pathol. Microbiol.* 2020; 63:358-366Bal A, Agrawal R, Vaideeswar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769322>
30. **Cluster infections play important roles in the rapid evolution of COVID-19 transmission: a systematic review.** *Int J Infect Dis* 2020; Liu T, Gong D, Xiao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768702>
31. **COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases.** *J Am Acad Dermatol* 2020; Kasperkiewicz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781181>
32. **Updated information on new coronavirus disease 2019 occurrence, drugs, and prediction of a potential receptor.** *J. Biochem. Mol. Toxicol.* 2020:e22594Khadai F, Ahsan A, Chamanifard M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770858>
33. **Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.** *J Dermatolog Treat* 2020;1-17Gadrowski MB, Balogh EA, Bashyam AM, Feldman SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772743>
34. **The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.** *J Infect Public Health* 2020; Bchetnia M, Girard C, Duchaine C, Laprise C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778421>
35. **Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.** *J Infect Public Health* 2020; Jomah S, Asdaq SMB, Al-Yamani MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773212>
36. **A Systematic Review of Smartphone Applications Available for Corona Virus Disease 2019 (COVID19) and the Assessment of their Quality Using the Mobile Application Rating Scale (MARS).** *J Med Syst* 2020; 44:164Davalbhakta S, Advani S, Kumar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779002>
37. **Crisis Standards of Care in the USA: A Systematic Review and Implications for Equity Amidst COVID-19.** *J Racial Ethn Health Disparities* 2020; Cleveland Manchanda EC, Sanky C, Appel JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789816>
38. **A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review.** *Life (Basel)* 2020; 10Monari C, Gentile V, Camaioni C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784922>
39. **Possible Targets and Therapies of SARS-CoV-2 Infection.** *Mini Rev. Med. Chem.* 2020; Sarkar K, Sil PC, Nabavi SF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32767936>
40. **Ten key points about COVID-19 in children: the shadows on the wall.** *Pediatr Pulmonol* 2020; Escosa-García L, Aguilera-Alonso D, Calvo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790245>
41. **Psychological effects of the COVID 19 pandemic on healthcare workers globally: A systematic review.** *Psychiatry Res* 2020; 292:113360Sheraton M, Deo N, Dutt T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771837>
42. **The renin angiotensin aldosterone system and COVID-19.** *Saudi Pharm J* 2020; 28:977-984Alsufyani HA, Docherty JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788834>
43. **The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management.** *Thromb Res* 2020; 194:101-115Abou-Ismael MY, Diamond A, Kapoor S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788101>
44. **A Scoping Review of Registered Clinical Trials of Convalescent Plasma for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence (FAST Evidence).** *Transfus Med Rev* 2020; Zheng K, Liao G, Lalu MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771272>
45. **COVID-19: Implications, Reactions and Future Directions.** *Turk Arch Otorhinolaryngol* 2020; 58:122-126Dhanani R, Wasif M, Pasha HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783040>
46. **The "pandemic" increase in lung ultrasound use in response to Covid-19: can we complement computed tomography findings? A narrative review.** *Ultrasound J* 2020; 12:39Vetrugno L, Baciarello M, Bignami E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785855>
47. **Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies.** *Vaccines (Basel)* 2020; 8Mahmood Z, Alrefai H, Hetta HF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781571>

Risk factors (50 articles)

1. **An HIV-infected patient with coronavirus disease 2019 has a favourable prognosis: a case report.** *Ann Palliat Med* 2020; Tian C, Tang L, Wu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787379>
2. **Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population.** *Arch. Gerontol. Geriatr.* 2020; 91:104204Mostaza JM, García-Iglesias F, González-Alegre T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771883>
3. **Is there a smoker's paradox in COVID-19?** *BMJ Evid Based Med* 2020; Usman MS, Siddiqi TJ, Khan MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788164>
4. **Impact of sex and age on respiratory support and length of hospital stay among 1792 patients with COVID-19 in Wuhan, China.** *Br J Anaesth* 2020; Zheng H, Tan J, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773217>
5. **Multiple COVID-19 Risk Factors Increase the Likelihood of Experiencing Anxiety Symptoms in Canada.** *Can. J. Psychiatry* 2020:706743720949356Elton-Marshall T, Wells S, Jankowicz D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787572>

6. **Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-Cov-2 infection: a multicenter cohort study (PREDI-CO study).** *Clin Microbiol Infect* 2020; Bartoletti M, Giannella M, Scudeller L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781244>
7. **Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.** *Curr Atheroscler Rep* 2020; 22:48Moriarty PM, Gorby LK, Stroes ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710255>
8. **Angiotensin-converting Enzyme 2 roles in the Pathogenesis of COVID-19.** *Curr Hypertens. Rev.* 2020; Kenarkoohi A, Maleki M, Safari T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778033>
9. **Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection.** *Diabetes Metab Syndr* 2020; 14:1463-1465Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771919>
10. **SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.** *EBioMedicine* 2020; 58:102907Chung MK, Karnik S, Saef J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771682>
11. **Predictors of coronavirus disease 19 (COVID-19) pneumonitis outcome based on computed tomography (CT) imaging obtained prior to hospitalization: a retrospective study.** *Emerg Radiol* 2020; Mirza-Aghazadeh-Attari M, Zarrintan A, Nezami N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770367>
12. **Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review.** *Endocrine* 2020; Lisco G, De Tullio A, Giagulli VA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779091>
13. **Automated quantification of COVID-19 severity and progression using chest CT images.** *Eur Radiol* 2020; Pu J, Leader JK, Bandos A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789756>
14. **Sympathetic activation: a potential link between comorbidities and COVID-19.** *Febs j* 2020; Porzionato A, Emmi A, Barbon S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779891>
15. **Nicotine and the nicotinic cholinergic system in COVID-19.** *Febs j* 2020; Tizabi Y, Getachew B, Copeland RL, Aschner M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790936>
16. **Association Between ABO Blood Group System and COVID-19 Susceptibility in Wuhan.** *Front Cell Infect Microbiol* 2020; 10:404Fan Q, Zhang W, Li B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793517>
17. **Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:431Boregowda U, Aloysius MM, Perisetti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793616>
18. **COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:459Nasiri MJ, Haddadi S, Tahvildari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793620>
19. **Frequency and type of red flags in patients with Covid-19 and headache: a series of 104 hospitalized patients.** *Headache* 2020; García-Azorín D, Trigo J, Talavera B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790215>
20. **Associations Between Chronic Health Conditions and COVID-19 Preventive Behaviors Among a Nationally Representative Sample of U.S. Adults: An Analysis of the COVID Impact Survey.** *Health Equity* 2020; 4:336-344Camacho-Rivera M, Islam JY, Vidot DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783017>
21. **Impact of myocardial injury on mortality in patients with COVID-19: a meta-analysis.** *Hellenic J. Cardiol.* 2020; Sanz-Sánchez J, Vrachatis DA, Reimers B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781301>
22. **ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.** *Hypertension* 2020; 76:651-661Sharma RK, Stevens BR, Obukhov AG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783758>
23. **Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.** *Immunity* 2020; Atyeo C, Fischinger S, Zohar T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783920>
24. **Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection.** *Infect Genet Evol* 2020;104498Klaassen K, Stankovic B, Zucic B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771700>
25. **Gender differences in the battle against COVID-19: impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes.** *Int J Clin Pract* 2020:e13666Stoian AP, Toth PP, Kempler P, Rizzo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770758>
26. **Comparison of COVID-19 Health Risks With Other Viral Occupational Hazards.** *Int J Health Serv* 2020;20731420946590Unger JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772627>
27. **Vitamin D3 and K2 and their potential contribution to reducing the COVID-19 mortality rate.** *Int J Infect Dis* 2020; Goddek S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768697>
28. **Increased Complement Receptor-3 levels in monocytes and granulocytes distinguish COVID-19 patients with pneumonia from those with mild symptoms.** *Int J Infect Dis* 2020; Gupta R, Gant VA, Williams B, Enver T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771640>
29. **Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review.** *Int. J. Lab. Hematol.* 2020; Wagner J, DuPont A, Larson S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779838>
30. **Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan, China.** *Int. J. Med. Sci.* 2020; 17:2052-2062Xu X, Yu MQ, Shen Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788884>
31. **The association between cardiac injury and outcomes in hospitalized patients with COVID-19.** *Intern Emerg Med* 2020; Karbalai Saleh S, Oraii A, Soleimani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772283>
32. **COVID-19 severity associates with pulmonary redistribution of CD1c+ DC and inflammatory transitional and nonclassical monocytes.** *J. Clin. Invest.* 2020; Sánchez-Cerrillo I, Landete P, Aldave B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784290>
33. **Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19.** *J. Endocrinol. Invest.* 2020; Carpagnano GE, Di Lecce V, Quaranta VN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772324>

34. **Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan.** *J Formos Med Assoc* 2020; Tsai CC, Wang YC, Chiang TT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773262>
35. **COVID-19 and comorbidities: Deleterious impact on infected patients.** *J Infect Public Health* 2020; Ejaz H, Alsrhani A, Zafar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788073>
36. **Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression.** *J Med Virol* 2020; Khinda J, Janjua NZ, Cheng S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776551>
37. **Epidemiology of COVID-19: A Systematic Review and Meta-analysis of Clinical Characteristics, Risk factors and Outcomes.** *J Med Virol* 2020; Li J, Huang DQ, Zou B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790106>
38. **Analysis of the application value of serum antibody detection for staging of COVID-19 infection.** *J Med Virol* 2020; Zheng Y, Yan M, Wang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779744>
39. **Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis.** *J. Neurol.* 2020; Patel U, Malik P, Shah D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770412>
40. **Prevalence of Comorbidities and Risks Associated with COVID-19 Among Black and Hispanic Populations in New York City: an Examination of the 2018 New York City Community Health Survey.** *J Racial Ethn Health Disparities* 2020; Arasteh K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794024>
41. **Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression.** *Physiology (Bethesda)* 2020; 35:288-301 Bohn MK, Hall A, Sepiashvili L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783610>
42. **High affinity interaction of Solanum tuberosum and Brassica juncea residue smoke water compounds with proteins involved in coronavirus infection.** *Phytother. Res.* 2020; Dave GS, Rakholiya KD, Kaneria MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779305>
43. **Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom.** *Proc Natl Acad Sci U S A* 2020; Hamer M, Gale CR, Kivimäki M, Batty GD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788355>
44. **Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.** *Rheumatol. Int.* 2020; Montero F, Martínez-Barrio J, Serrano-Benavente B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794113>
45. **Abnormal liver-related biomarkers in COVID-19 patients and the role of prealbumin.** *Saudi J. Gastroenterol.* 2020; Li T, Guo Y, Zhuang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769260>
46. **The renin angiotensin aldosterone system and COVID-19.** *Saudi Pharm J* 2020; 28:977-984 Alsufyani HA, Docherty JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32788834>
47. **Early spring near-surface ozone in Europe during the COVID-19 shutdown: Meteorological effects outweigh emission changes.** *Sci Total Environ* 2020; 747:141322 Ordóñez C, Garrido-Perez JM, García-Herrera R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781318>
48. **Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry.** *Stroke* 2020:Strokeaha120031208 Ntaios G, Michel P, Georgiopoulos G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787707>
49. **A model to predict SARS-CoV-2 infection based on the first three-month surveillance data in Brazil.** *Trop Med Int Health* 2020; Diaz-Quijano FA, da Silva JMN, Ganem F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790891>
50. **Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques.** *Zool Res* 2020:1-10 Song TZ, Zheng HY, Han JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772513>

Safety (10 articles)

1. **Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19.** *Clin Infect Dis* 2020; Nelson BC, Laracy J, Shoucri S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772069>
2. **Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.** *Crit Care* 2020; 24:497 Hifumi T, Isokawa S, Otani N, Ishimatsu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787901>
3. **Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.** *Eur. J. Clin. Pharmacol.* 2020:1-12 Chen C, Pan K, Wu B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780229>
4. **Chloroquine and COVID-19: Should We Care about Ototoxicity?** *Int Arch Otorhinolaryngol* 2020; 24:e359-e363 Monteiro EMR, Nascimento MFL, Brito TRC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774508>
5. **Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports.** *J Artif Organs* 2020; Bidar F, Hékimian G, Martin-Toutain I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789604>
6. **Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy.** *J Clin Med* 2020; 9:AI Rihani SB, Smith MK, Bikmetov R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785135>
7. **QTc prolongation during antiviral therapy in two COVID-19 patients.** *J. Clin. Pharm. Ther.* 2020; Zhu S, Wang J, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779770>
8. **Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.** *J Dermatolog Treat* 2020:1-17 Gadarowski MB, Balogh EA, Bashyam AM, Feldman SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772743>
9. **Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.** *J. Thromb. Thrombolysis* 2020; Mattioli M, Benfaremo D, Mancini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794132>
10. **COVID-19: A tale of two pandemics across the Asia Pacific region.** *Paediatr. Respir. Rev.* 2020; Fitzgerald DA, Wong GWK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768308>

Treatment options (67 articles)

1. **NK cells: A double edge sword against SARS-CoV-2.** *Adv Biol Regul* 2020; 77:100737Masselli E, Vaccarezza M, Carubbi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773100>
2. **Principles and treatment strategies for the use of Chinese herbal medicine in patients at different stages of coronavirus infection.** *Am. J. Cancer Res.* 2020; 10:2010-2031Huang ST, Lai HC, Lin YC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774998>
3. **Tocilizumab exerts anti-inflammatory activity in six critically ill COVID-19 patients: a retrospective analysis.** *Ann Transl Med* 2020; 8:881Qian S, An J, Qi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793725>
4. **Computational-based drug repurposing methods in COVID-19.** *Bioimpacts* 2020; 10:205-206Masoudi-Sobhanzadeh Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793443>
5. **Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis.** *Bioinformation* 2020; 16:301-306Hakmi M, Bouricha EM, Kandoussi I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773989>
6. **Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment.** *Biomed. Pharmacother.* 2020; 129:110500Xin S, Cheng X, Zhu B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768975>
7. **Anti-inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H(2) S-donors in COVID-19 therapy.** *Br. J. Pharmacol.* 2020; Citi V, Martelli A, Brancaleone V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783196>
8. **Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.** *Clin Immunol* 2020:108555Laurence J, Mulvey JJ, Seshadri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771488>
9. **AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.** *Clin Infect Dis* 2020; Ivashchenko AA, Dmitriev KA, Vostokova NV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770240>
10. **Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.** *Comput. Biol. Chem.* 2020; 88:107351Meyer-Almes FJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769050>
11. **Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.** *Crit Care* 2020; 24:497Hifumi T, Isokawa S, Otani N, Ishimatsu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787901>
12. **COVID-19: An Update Regarding the Quest for Finding an Effective Cure.** *Cureus* 2020; 12:e9010Bangash FS, Saeed G, Shahab P, Waheed A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775090>
13. **Cardiovascular Considerations of Experimental Hydroxychloroquine Therapy on Patients Diagnosed With COVID-19: A Case Series Review.** *Cureus* 2020; 12:e9151Patel J, Patel R, Rodriguez LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789088>
14. **Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.** *Curr Atheroscler Rep* 2020; 22:48Moriarty PM, Gorby LK, Stroes ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32710255>
15. **The Plausible role of Indian Traditional Medicine in combating Corona Virus (SARS-CoV 2): a mini-review.** *Curr. Pharm. Biotechnol.* 2020; Adithya J, Nair B, Aishwarya S, Nath LR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32767920>
16. **Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the "Cytokine Release (Storm) Syndrome" Caused by SARS-CoV-2?** *Curr. Pharm. Des.* 2020; López-Iranzo FJ, López-Rodas AM, Franco L, López-Rodas G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787748>
17. **Androgen sensitivity in COVID-19 and antiandrogens: prospective data are still needed.** *Dermatol Ther* 2020:e14166lanhez M, Ramos PM, Goren A, Miot HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772478>
18. **The (hydroxy)chloroquine earthquake: Withdrawn publications shake the confidence in science to the core.** *Deutsche Apotheker Zeitung* 2020; 160.
19. **Volatile molecules for COVID-19: A possible pharmacological strategy?** *Drug Dev Res* 2020; Colalto C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779824>
20. **Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.** *Eur. J. Clin. Pharmacol.* 2020:1-12Chen C, Pan K, Wu B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780229>
21. **In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2.** *Eur. J. Pharmacol.* 2020:173448Vijayakumar BG, Ramesh D, Joji A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768503>
22. **Repurposing current therapeutic regimens against SARS-CoV-2 (Review).** *Exp. Ther. Med.* 2020; 20:1845-1855S KK, I PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32782493>
23. **Host-directed therapies: a potential solution to combat COVID-19.** *Expert Opin Biol Ther* 2020:1-4Baindara P, Agrawal S, Mandal SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783643>
24. **Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.** *Faseb j* 2020; De Flora S, Balansky R, La Maestra S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780893>
25. **Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.** *Front. Immunol.* 2020; 11:1841Benani A, Ben Mkaddem S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793246>
26. **Global multi-omics and systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules against COVID-19: An in silico approach.** *Genomics* 2020; Muthuramalingam P, Jeyasri R, Valliammai A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771622>
27. **Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective.** *Hum. Cell* 2020:1-12Gupta A, Kashte S, Gupta M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780299>
28. **Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19.** *Infect Dis Ther* 2020; Meletiadijs J, Tsiodras S, Tsirigotis P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789663>

29. **Chloroquine and COVID-19: Should We Care about Ototoxicity?** *Int Arch Otorhinolaryngol* 2020; 24:e359-e363Monteiro EMR, Nascimento MFL, Brito TRC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774508>
30. **Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results.** *Int J Antimicrob Agents* 2020;106136Lopez A, Duclos G, Pastene B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777263>
31. **Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab.** *Int J Infect Dis* 2020; Langer-Gould A, Smith JB, Gonzales EG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768693>
32. **Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation.** *Int J Infect Dis* 2020; Potere N, Di Nisio M, Rizzo G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768701>
33. **SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells.** *Int J Mol Sci* 2020; 21Cannalire R, Stefanelli I, Cerchia C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784899>
34. **Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports.** *J Artif Organs* 2020; Bidar F, Hékimian G, Martin-Toutain I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789604>
35. **Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study.** *J Biomol Struct Dyn* 2020:1-13Mukherjee S, Dasgupta S, Adhikary T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772895>
36. **IL-18 and infections: Is there a role for targeted therapies?** *J. Cell. Physiol.* 2020; Vecchié A, Bonaventura A, Toldo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32794180>
37. **Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy.** *J Clin Med* 2020; 9Al Rihani SB, Smith MK, Bikmetov R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785135>
38. **QTc prolongation during antiviral therapy in two COVID-19 patients.** *J. Clin. Pharm. Ther.* 2020; Zhu S, Wang J, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779770>
39. **Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations.** *J. Clin. Pharmacol.* 2020; Ji P, Chen J, Golding A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779201>
40. **Tannins inhibit SARS-CoV-2 through binding with catalytic dyad residues of 3CL(pro) : An in silico approach with 19 structural different hydrolysable tannins.** *J. Food Biochem.* 2020:e13432Khalifa I, Zhu W, Mohammed HHH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783247>
41. **Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis.** *J Integr Med* 2020; Fan AY, Gu S, Alemi SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792254>
42. **Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study.** *J Med Virol* 2020; Giacomelli A, Pagani G, Ridolfo AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776534>
43. **Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis.** *J Med Virol* 2020; Sarkar S, Soni KD, Khanna P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776573>
44. **Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China.** *J Med Virol* 2020; Xue H, Liu Y, Luo P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779755>
45. **Clinical trial to test the efficacy of melatonin in COVID-19.** *J. Pineal Res.* 2020:e12683Acuña-Castroviejo D, Escames G, Figueira JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770854>
46. **Interaction of Drug Candidates with Various SARS-CoV-2 Receptors: An in Silico Study to Combat COVID-19.** *J. Proteome Res.* 2020; Barros RO, Junior F, Pereira WS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32786890>
47. **A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review.** *Life (Basel)* 2020; 10Monari C, Gentile V, Camaioni C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784922>
48. **Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.** *Life Sci* 2020:118205Hosseini FS, Amanlou M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777300>
49. **Antiviral Activity of Nanomaterials against Coronaviruses.** *Macromol. Biosci.* 2020:e2000196Muhammad W, Zhai Z, Gao C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783352>
50. **Recent Discovery for Inhibitors Targeting in SARS-CoV-2 and Developed anti-NCP.** *Mini Rev. Med. Chem.* 2020; Faheem M, Singh VK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32767940>
51. **Possible Targets and Therapies of SARS-CoV-2 Infection.** *Mini Rev. Med. Chem.* 2020; Sarkar K, Sil PC, Nabavi SF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32767936>
52. **Old drugs in new shoes. Substances that are (not) used against COVID-19.** *Monatsschr. Kinderheilkd.* 2020; Kerbl R.
53. **Anthraquinone Derivatives as an Immune Booster and their Therapeutic Option Against COVID-19.** *Nat Prod Bioprospect* 2020; Khanal P, Patil BM, Chand J, Naaz Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772313>
54. **Rapid determination and optimisation of berberine from Himalayan Berberis lycium by soxhlet apparatus using CCD-RSM and its quality control as a potential candidate for COVID-19.** *Nat Prod Res* 2020:1-6Katara AK, Singh B, Shukla P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787584>
55. **Repurposing of Kinase Inhibitors for Treatment of COVID-19.** *Pharm. Res.* 2020; 37:167Weisberg E, Parent A, Yang PL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32778962>
56. **Emerging Therapeutic Modalities against COVID-19.** *Pharmaceuticals (Basel)* 2020; 13Malik S, Gupta A, Zhong X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784499>
57. **Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial.** *Pharmacol. Res.* 2020:105126Xiao M, Tian J, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781283>
58. **Potential influence of Nagella sativa (Black cumin) in reinforcing immune system: A hope to decelerate the COVID-19 pandemic.** *Phytomedicine* 2020:153277Kulyar MF, Li R, Mehmood K *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32773257>
59. **Physicians' knowledge of potential covid-19 drug-drug interactions: An online survey in turkey.** *Postgrad. Med.* 2020; Sürmelioğlu N, Yalçın N, Kuşçu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780961>
 60. **Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons Learned from 1918 Spanish Flu and Other Previous Pandemics.** *Stem Cell Rev Rep* 2020; Park YJ, Farooq J, Cho J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789802>
 61. **The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.** *Stem Cells Transl Med* 2020; Can A, Coskun H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779878>
 62. **A Scoping Review of Registered Clinical Trials of Convalescent Plasma for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence (FAST Evidence).** *Transfus Med Rev* 2020; Zheng K, Liao G, Lalu MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771272>
 63. **Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:702Akram J, Azhar S, Shahzad M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771032>
 64. **Nigella sativa supplementation to treat symptomatic mild COVID-19: A structured summary of a protocol for a randomised, controlled, clinical trial.** *Trials* 2020; 21:703Koshak AE, Koshak EA, Mobeireek AF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771034>
 65. **Melatonin, Aging and COVID-19: Could melatonin be beneficial for COVID-19 treatment in elderly?** *Turk J Med Sci* 2020; Öztürk G, Akbulut KG, Güney Ş. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777902>
 66. **Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies.** *Vaccines (Basel)* 2020; 8Mahmood Z, Alrefai H, Hetta HF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781571>
 67. **Melatonin potentials against viral infections including COVID-19: Current evidence and new findings.** *Virus Res.* 2020; 287:198108Bahrapour Juybari K, Pourhanifeh MH, Hosseinzadeh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32768490>

Trials (15 articles)

1. **Tocilizumab exerts anti-inflammatory activity in six critically ill COVID-19 patients: a retrospective analysis.** *Ann Transl Med* 2020; 8:881Qian S, An J, Qi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793725>
2. **Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19).** *Biomed J* 2020; Verma HK, Merchant N, Verma MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792167>
3. **Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-Cov-2 infection: a multicenter cohort study (PREDI-CO study).** *Clin Microbiol Infect* 2020; Bartoletti M, Giannella M, Scudeller L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781244>
4. **Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.** *Eur. J. Clin. Pharmacol.* 2020:1-12Chen C, Pan K, Wu B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32780229>
5. **Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results.** *Int J Antimicrob Agents* 2020:106136Lopez A, Duclos G, Pastene B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32777263>
6. **The COVID-19 epidemic and reorganisation of triage, an observational study.** *Intern Emerg Med* 2020; Turcato G, Zaboli A, Pfeifer N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772281>
7. **International study on impact of COVID-19 on cardiac and thoracic aortic aneurysm surgery.** *J. Card. Surg.* 2020; Idhrees M, Bashir M, Mousavizadeh M, Hosseini S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789915>
8. **Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study.** *J Med Virol* 2020; Giacomelli A, Pagani G, Ridolfo AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776534>
9. **Clinical trial to test the efficacy of melatonin in COVID-19.** *J. Pineal Res.* 2020:e12683Acuña-Castroviejo D, Escames G, Figueira JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770854>
10. **Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial.** *Pharmacol. Res.* 2020:105126Xiao M, Tian J, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781283>
11. **An Observational Study of the Impact of COVID-19 and the Transition to Telehealth on Community Mental Health Center Providers.** *Res Sq* 2020; Sklar M, Reeder K, Carandang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32793893>
12. **The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice.** *Rheumatology (Oxford)* 2020; Liew JW, Bhana S, Costello W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32789449>
13. **Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry.** *Stroke* 2020:Strokeaha120031208Ntaios G, Michel P, Georgiopoulos G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32787707>
14. **Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:702Akram J, Azhar S, Shahzad M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32771032>
15. **Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic (Sleep COVID-19): structured summary of a study protocol for a randomised controlled**

Vaccines (9 articles)

1. **A Rational Design of a Multi-Epitope Vaccine Against SARS-CoV-2 Which Accounts for the Glycan Shield of the Spike Glycoprotein.** *ChemRxiv* 2020; Martin WR, Cheng F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32793875>
2. **Vaccine hesitancy: the next challenge in the fight against COVID-19.** *Eur. J. Epidemiol.* 2020; Dror AA, Eisenbach N, Taiber S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32785815>
3. **Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes.** *Genome Med.* 2020; 12:70Poran A, Harjanto D, Malloy M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32791978>
4. **A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.** *Immunity* 2020; Laczko D, Hogan MJ, Toulmin SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783919>
5. **Structural Basis for Designing Multi-epitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation.** *JMIR Bioinform Biotech* 2020; 1:e19371Srivastava S, Verma S, Kamthania M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776022>
6. **Amplifying RNA Vaccine Development.** *N Engl J Med* 2020; 382:2469-2471 Fuller DH, Berglund P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32558474>
7. **Influenza immunization and COVID-19.** *Vaccine* 2020; Maltezou HC, Theodoridou K, Poland G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32773245>
8. **SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development.** *Vaccines (Base)* 2020; 8Olvera A, Noguera-Julian M, Kilpelainen A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32781672>
9. **Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?** *Viruses* 2020; 12Al-Kassmy J, Pedersen J, Kobinger G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32784685>

Women – pregnancy (27 articles)

1. **Maternal outcome of pregnant women admitted to Intensive Care Units for Covid-19.** *Am J Obstet Gynecol* 2020; Hee Kim CN, Hutcheon J, van Schalkwyk J, Marquette G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32771379>
2. **Obesity as a contributor to immunopathology in pregnant and non-pregnant adults with COVID-19.** *Am. J. Reprod. Immunol.* 2020:e13320McCartney SA, Kachikis A, Huebner EM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32779790>
3. **COVID-19 in pregnancy: Placental and neonatal involvement.** *Am. J. Reprod. Immunol.* 2020:e13306Prochaska E, Jang M, Burd I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779810>
4. **A cross-sectional study of immune seroconversion to SARS-CoV-2 in frontline maternity health professionals.** *Anaesthesia* 2020; Bampoe S, Lucas DN, Neall G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32777861>
5. **Impact of COVID-19 and other viruses on reproductive health.** *Andrologia* 2020:e13791Batiha O, Al-Deeb T, Al-Zoubi E, Alsharu E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790205>
6. **COVID-19 and pregnancy: A review of clinical characteristics, obstetric outcomes and vertical transmission.** *Aust N Z J Obstet Gynaecol* 2020; Pettiroso E, Giles M, Cole S, Rees M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32779193>
7. **A gendered magnifying glass on COVID-19.** *Clin. Mol. Allergy* 2020; 18:14Salvati L, Biagioni B, Vivarelli E, Parronchi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774170>
8. **Intervention Delivery Matters: What Mothers at High Risk for Type 2 Diabetes Want in a Diabetes Prevention Program-Results from a Comparative Effectiveness Trial.** *Diabetes Ther.* 2020; Palmer KNB, Garr Barry VE, Marrero DG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770443>
9. **A multicenter study on epidemiological and clinical characteristics of 125 newborns born to women infected with COVID-19 by Turkish Neonatal Society.** *Eur. J. Pediatr.* 2020; Oncel MY, Akin IM, Kanburoglu MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32776309>
10. **COVID-19 during pregnancy, delivery and postpartum period based on EBM.** *Ginekol. Pol.* 2020; 91:417-423Stanczyk P, Jachymski T, Sieroszewski P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779163>
11. **The Polish Society of Gynecologists and Obstetricians statement on surgery in gynecology during the COVID-19 pandemic.** *Ginekol. Pol.* 2020; 91:424-427Stojko R, Staniczek J, Olejek A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32779164>
12. **Anaesthetic management of a COVID-19 parturient for caesarean section - Case report and lessons learnt.** *Indian J. Anaesth.* 2020; 64:S141-s143Chhabra A, Rao TN, Kumar M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32773854>
13. **Breastfeeding mothers with COVID-19 infection: a case series.** *Int Breastfeed J* 2020; 15:69Pereira A, Cruz-Melguizo S, Adrien M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770999>
14. **Gender differences in the battle against COVID-19: impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes.** *Int J Clin Pract* 2020:e13666Stoian AP, Toth PP, Kempler P, Rizzo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32770758>
15. **Possible intrauterine infection: Positive nucleic acid testing results and consecutive positive SARS-CoV-2-specific antibody levels within 50 days after birth.** *Int J Infect Dis* 2020; Gao J, Hu X, Sun X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32771637>
16. **Elevated depression and anxiety symptoms among pregnant individuals during the COVID-19 pandemic.** *J. Affect. Disord.* 2020; 277:5-13Lebel C, MacKinnon A, Bagshawe M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32777604>
17. **Joint IFS-ISAR-ACE Recommendations on Resuming/Opening up Assisted Reproductive Technology Services.** *J. Hum. Reprod. Sci.* 2020; 13:82-88Prasad S, Trivedi P, Malhotra N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32792754>

18. **Spectrum of neonatal COVID-19 in Iran: 19 infants with SARS-CoV-2 perinatal infections with varying test results, clinical findings and outcomes.** *J Matern Fetal Neonatal Med* 2020;1-10Schwartz DA, Mohagheghi P, Beigi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32783494>
19. **Potential effects of SARS-CoV-2 infection during pregnancy on fetuses and newborns are worthy of attention.** *J. Obstet. Gynaecol. Res.* 2020; Dang D, Wang L, Zhang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779309>
20. **Covid-19 pandemic and pregnancy.** *J. Obstet. Gynaecol. Res.* 2020; Hayakawa S, Komine-Aizawa S, Mor GG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779342>
21. **Survey on the use of personal protective equipment and COVID-19 testing of pregnant women in Japan.** *J. Obstet. Gynaecol. Res.* 2020; Umazume T, Miyagi E, Haruyama Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32779285>
22. **Professionally responsible advocacy for women and children first during the COVID-19 pandemic: guidance from World Association of Perinatal Medicine and International Academy of Perinatal Medicine.** *J. Perinat. Med.* 2020; Chervenak FA, McCullough LB, Grünebaum A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32769228>
23. **Addressing the Disproportionate Impacts of the COVID-19 Pandemic on Sexual and Gender Minority Populations in the United States: Actions Toward Equity.** *LGBT Health* 2020; Phillips G, 2nd, Felt D, Ruprecht MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32790495>
24. **Caesarean delivery of first prediagnosed COVID-19 pregnancy in Nigeria.** *Pan Afr. Med. J.* 2020; 36:100Makwe CC, Okunade KS, Rotimi MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32774659>
25. **Adaptation of prenatal care and ultrasound.** *Semin. Perinatol.* 2020:151278Aziz A, Fuchs K, Nhan-Chang CL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32792263>
26. **Bleeding during the pandemic: the politics of menstruation.** *Sex Reprod Health Matters* 2020; 28:1801001Jahan N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32772837>
27. **Recommendations for perinatal and neonatal surgical management during the COVID-19 pandemic.** *World J Clin Cases* 2020; 8:2893-2901Ma LS, Zhao YL, Wei YD, Liu C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32775372>

to subscribe click [here](#)
